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ABSTRACT 
The work presented here represents three separate research projects. Each explores 
different approaches to the same problem: how can artificial macromolecules be used to 
target specific intracellular sites in living organisms, and how may that technology be 
exploited to treat different disease states? Here, the copolymers based on pHPMA [poly N-
(2-hydroxypropyl)methacrylamide)] were used to demonstrate cellular and subcellular 
targeting in a cancer model. Used as carriers for low molecular weight drugs, pHPMA 
copolymers may possess great potential for increasing the efficacy of drugs, while also 
decreasing side effects resulting from drug exposure to healthy tissues and cells.  
In the first project, antibody Fab’ fragments were dimerized using a 
multifunctionalized PEG (poly(ethylene glycol)) crosslinker to create a targeting module 
for pHPMA/drug carriers. The linker was semitrifunctional, able to crosslink 2 Fab’ 
antibody fragments, which could then be attached to an HPMA-doxorubicin anticancer 
drug carrier. Monoclonal antibody Fab’ fragments were chosen that target ovarian 
carcinoma cells. Using this strategy, the conjugates are selectively uptaken by cancer cells, 
whereby free doxorubicin is released. 
In the second project, HPMA copolymers were created with a terminal 
mitochondriotropic chemical moiety, TPP (triphenylphosphonium). Lipophilic cations are 
used to traffic low molecular weight drugs to mitochondria. Studies had reported that 
terminal TPP can also traffic high molecular weight, uncharged, linear macromolecules 
 iv 
into mitochondria, and enable delivery to the cytosol via direct transduction through the 
plasma membrane. Semitelechelic TPP-HPMA copolymers were synthesized to determine 
if this effect could be applied to HPMA copolymer drug conjugates. 
In the third project, the flexibility of HPMA polymerization chemistry was 
exploited to create a large “library” or array of different HPMA copolymers with a wide 
range of chemical properties. Copolymers were made incorporating a variety of cationic, 
anionic, and hydrophobic sidechains. This array of copolymers was incubated and 
microinjected directly into the cytoplasm of living cells. The resulting uptake and/or 
intracellular distribution was observed using time-lapse confocal microscopy and flow 
cytometry. Using HPMA copolymers as a model, this work functioned as a general survey 
for cellular uptake, and the intracellular distribution/trafficking that can be expected when 
artificial macromolecules are internalized into living cells. 
This work was dedicated to Jill. 
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1.1 Engineered Materials in Medicine 
The role of biomaterials in medicine has expanded greatly over the past century. 
Our ability to replace, replicate or augment biological functions using engineered materials 
has grown in line with our greater understanding of biological systems and the 
requirements necessary to make materials biocompatible and functional in living systems. 
In all complex organisms, a fundamental obstacle to engineered materials is the myriad of 
biological recognition systems in place to detect the presence of foreign or altered 
materials, i.e., the recognition of self from nonself. These include the many familiar 
pathways involved in the immune, complement, and blood coagulation systems. These 
responses have evolved to detect physical damage or to help defend living things from 
toxins, intrusions, parasites, or biological invaders. However, these same systems represent 
the fundamental barrier restricting the application of synthetic or engineered materials for 
medicinal uses. 
Understanding what makes a material or chemical compound biocompatible has 
been a slow process of trial and error and innovation, evolving over many decades. This 
has required a deep understanding of biological systems or how they respond to a variety 




cardiovascular, or dental applications are representative of the type of progress that has 
been made possible by the refinement of biomaterials. A great deal has also been 
accomplished via biotechnology, which is essentially the production of natural proteins 
and nucleic acids through the artificial manipulation of biological systems. In the emerging 
fields of nanotechnology and nanomedicines, synthetic materials have been shown to be 
increasingly useful for biological applications. 
 
1.1.1 Natural vs. Synthetic Polymers 
 
Proteins, polysaccharides and nucleic acids play central roles in all organisms, and 
are basic building blocks of all living systems. The use of artificial polymers in medicine 
has been spurred by the possibility of expanding our ability to create engineered materials 
that are not restricted by the chemical and physical limitations of naturally occurring 
chemicals and polymers. Engineered natural polymers face an array of natural biological 
hurdles when used as medicines, such as the array of enzymes and endogenous physical 
conditions, such as low pH, that may degrade their physical structures and break them 
down. Further, the immune system is specifically adapted to detect natural polymers and 
possesses a myriad of responses that recognize, neutralize, remove, or degrade natural 
polymers. Part of the utility of synthetic polymers is the ability to overcome many of these 
barriers. 
The research described in this document is focused on what are now termed 
“nanomedicines”, engineered macromolecules introduced (typically via the vasculature) 
into organisms for therapeutic applications. As this technology advances, they can be 




further able to form a myriad of possible aggregates and other superstructures, and possess 
nearly limitless potential functions. Overall, however, the type of constructs to be discussed 
here are engineered “nanoparticles” that function in many of the same roles of as natural, 
free circulating proteins, analogous to blood plasma proteins. 
 
1.1.2 Synthetic Polymers in Medicine 
The root of polymeric nanomedicines can be traced back to the first medical 
applications of wholly synthetic polymers. Early examples were demonstrated by polymers 
used as blood plasma expanders during World War II. To maintain osmotic pressure after 
trauma, the synthetic polymer PVP [poly(2-vinylpyrrolidone)] was used as a blood plasma 
expander after traumatic blood loss (1). This essentially replaced the function of albumin, 
the most prevalent protein in blood, thereby maintaining osmotic pressure within the 
vasculature. It was found that PVP, HPMA (N-(2-hydroxypropyl)methacrylamide) and 
other hydrophilic polymers used as plasma expanders were nonimmunogenic, and high 
molecular weight polymers could be retained in circulation for periods of time much longer 
compared to most endogenous plasma proteins (2). 
Polymers that form hydrogels were the basis of the first gas-permeable contact lens. 
Notably, hydrogels made from copolymers of HEMA (2-hydroxyethyl methacrylate) and 
EDMA (ethylene dimethacrylate) were one of the first materials used (3, 4). These 
materials were not only useful due to their optical properties, hydrogel polymers were 
noted early on for their long-term biocompatibility, specifically the lack of inflammation 





These homopolymers maintain a structural free random coil structure and most 
have a large hydrodynamic volume disproportionate to their molecular weight as compared 
to proteins. Albumin has a molecular weight of 66 kDa and represents the upper limit for 
glomeruli filtration, a pore size of about 7 nm. Synthetic polymers with a hydrodynamic 
radius below the renal threshold of 3.8 nm are rapidly cleared from circulation. However, 
polymers and other nanoparticles above 7 nm are maintained in circulation until removed 
via complement and the RES (reticuloendothelium system), also known as the 
mononuclear phagocytic system. They can also be removed by the phagocytic Kuffer cells 
in the liver (5). 
 
1.1.3 Polymer Conjugates 
The most successful uses of water-soluble, synthetic polymers to date has been to 
create simple conjugates to modify the properties of therapeutically active compounds, 
proteins, or nucleic acids. The flexibility inherent in polymer synthesis has been proven to 
be useful when combined with other types of biological agents. These hybrid constructs 
have included polymer-drug conjugates, polymer-protein conjugates, polymeric micelles, 
and polymer-nucleic acid polyplexes. In each of these cases, polymers are employed to 
greatly enhance the existing biological activities and/or the transport characteristics of the 
given therapeutic agent and have been used to greatly enhance the biocompatibility (6), 
pharmacokinetics (7, 8), nonimmunogenicity (9), and cell targetability (9-11) of these 







The invisibility of many synthetic polymers from biological systems has been the 
rationale for the creation of some of the most useful polymer-based conjugates. PEG 
(poly(ethylene glycol)) has long been used for its “stealth” properties and its ability to 
confer these properties when they are conjugated to proteins and other materials. 
“PEGylated” proteins are produced by the covalent attachment of functionalized polymers, 
where one end of the polymer chain possesses a reactive functional group that can react 
with a specific amino acid side chain on a protein. Compared to the unaltered protein, the 
polymer conjugate is typically more soluble and stable, and possesses a longer 
intravascular half- life after injection. This approach was first demonstrated in the 1970s 
when Abuchowski et al. PEGylated bovine serum albumin and bovine liver catalase. It was 
found that the PEGylated proteins possessed improved stability, greatly increased 
circulation time, and a sharply reduced immunological response compared to the 
unmodified proteins (12, 13). 
The hydrodynamic volume of PEG is disproportionately large for a given molecular 
weight, and the increased volume of the protein conjugate can be used to exclude it from 
filtration and removal from circulation by the glomulerus. As a surface polymer, it protects 
the protein from proteolytic degradation in plasma or tissue interstitium and inhibits 
removal from circulation by the RES. The immunogenicity of the protein is also reduced 
by protecting the protein from interaction with various components of the immune system, 
such as antibodies that would recognize unmodified proteins. 
PEGylated proteins represent the most common and successful medicinal 




approved by the FDA for clinical use. Included are:  PEG–asparaginase (Oncaspar®) for 
the treatment of acute lymphoblastic leukemia (14, 15), PEG–adenosine deaminase 
(Adagen®) for severe combined immunodeficiency disease (SCID)(16), PEG–interferon 
α2a (Pegasys®) for renal cell carcinoma and hepatitis C,(17, 18) PEG–interferon α2b 
(PEG–Intron®) for hepatitis C, several types of cancer, multiple sclerosis, and 
HIV/AIDS,(19) PEG–granulocyte-colony stimulating factor (Pegfilgrastim, Neulasta®) for 
neutropenia during chemotherapy (20), PEG-interferon β1a (Plegridy®) for multiple 
sclerosis (21), mPEG-epoetin β (Mircera®) for anemia due to chonic kidney disease (22), 
PEG-uricase (Krystexxa) for gout (23), PEG-antihemophilic factor VIII (Adynovate®) for 
hemophilia A (24), and PEG–growth hormone receptor antagonist (Pegvisomant, 
Somavert®) for the treatment of acromegaly (25). 
The appeal of PEG has traditionally been drawn from its simplicity, low cost of 
synthesis, and its presumed lack of biorecognition and immunogenicity. More recent 
studies, however, have shown PEG is not as biologically inert as originally thought. Under 
certain conditions PEG and PEG conjugates can generate several types of immune 
responses. Some conjugates have been found to cause complement activation in certain 
circumstances (21, 26-29). Rapid clearance of PEGylated liposomes can occur after 
repeated injections due to immune recognition (30). PEG can also be chemically altered by 
peroxidation, which has been shown to cause several negative effects in biological systems 
(31-33). 
The limitations of PEG as a component of nanomedicine conjugates has driven 
renewed interest into research in other synthetic alternatives.(34, 35) HPMA copolymers, 




of copolymer synthesis with a variety of other monomers. One of the reasons HPMA was 
initially selected was due to the hydrolytic stability of the amide bond connecting the 2-
hydroxlypropyl sidechain (36). Copolymers of HPMA are also easier to synthesize with 
the use of other methacrlyates and methacryamide monomers. The composition of the 
resulting copolymers is relatively easy to predict and multiple types of comonomer can be 
incorporated in the same copolymer. 
 
1.2 Polymer-Drug Conjugates for the Treatment of Cancer 
An example of a more direct approach to using synthetic polymers to create 
therapeutics has been the development of polymer-drug conjugates. Here, polymer 
conjugates are created with traditional chemotherapy drugs covalently attached to them via 
degradable spacers. The use of the polymeric carrier introduces many advantages for the 
treatment of disease. 
The current standard of care for the treatment of most types of cancer usually 
includes the use of chemotherapy agents. These cytotoxic drugs are traditionally low 
molecular weight hydrophobic compounds that induce apoptosis by the inhibition of DNA 
replication or microtubule spindle functions in mitotic cells. They selectively destroy tumor 
cells by triggering apoptosis in rapidly dividing cells in a dose-dependent manner. Dosages 
used therapeutically, however, are limited by their toxicity to rapidly dividing normal cells. 
These include bone marrow cells, and the epithelial cells of the kidney and gastrointestinal 
tract. The effectiveness of chemotherapy drugs is also limited due to their susceptibility to 





To overcome these limitations, chemotherapy drugs have been conjugated to high 
molecular weight, hydrophilic polymer carriers. Carriers used have included natural 
polymers such as dextran (6), and albumin (37); and synthetic polymers including: 
poly(ethylene glycol) (PEG) (38), styrene-maleic anhydride copolymer (SMA) (9), and N-
(2-hydroxypropyl)methacrylamide (HPMA) copolymer (8, 10). Water-soluble 
macromolecular drug conjugates have been demonstrated to possess a greater intravascular 
half-life, a lower specific toxicity, able to avoid traditional multidrug resistance 
mechanisms, and possess the potential to be more precise and effective than free antitumor 
drugs. 
 
1.2.1 The EPR Effect and Passive Tumor Tissue Targeting 
Cancer was a natural subject for some of the first polymer-drug conjugates due to 
the “EPR (enhanced permeability and retention) effect” (1). Early research with soluble 
polymers showed that circulating macromolecules passively concentrated in tumor tissues 
over time. For intravenous applications, extravasion through the endothelium is a barrier 
that typically limits all macromolecules (biological or nonbiological) greater than ~50 kDa 
from escaping the vasculature. The accumulation of macromolecules was attributed to the 
higher rates of macromolecular extravasation that occur in the neovasculature typically 
produced by solid tumors. Because lymphatic drainage is also often impaired, the EPR 
effect allows long-circulating macromolecules to be concentrated in the local interstitium 
surrounding tumors (9).  
For these reasons, macromolecular drug carriers were capable of passive targeting 




limited by the fact that the active component remains covalently attached to the polymeric 
carrier. Most LMW drugs require internalization by the cancer cells and, typically, 
subcellular localization to the active site in the nucleus or mitochondria. This spurred the 
development of polymer-drug conjugates where the drug was attached via a degradable 
bond hydrolyzed selectively after reaching the tumor cell, whereby the drug would enter 
cells by simple diffusion. 
Much of the recent history of polymer-drug conjugate development has been 
devoted to the design of better methods to deliver high enough concentrations of drugs to 
an active site within cells to produce their therapeutic effect. This effort has entailed 
methods to actively target the cells, and strategies to better concentrate the bioactive 
ingredient to the required subcellular target. 
 
1.3 Macromolecular Drug Carriers and Barriers to Cell Entry 
To improve the cellular uptake and specificity of drugs possible by diffusion, 
numerous approaches have been developed to use polymeric carriers for cell uptake. 
Macromolecules are naturally excluded from the outer plasma and various subcellular 
membranes. Notable membrane-excluded intracellular organelles include endosomes, 
lysosomes, the nucleus, and mitochondria. Therefore, two general approaches have been 
used to overcome these barriers: 1) direct membrane transduction, or 2) co-opting of the 
active endocytotic pathways, enzyme activities, and subcellular trafficking mechanisms of 
the cell. Figure 1.1. summarizes some of the targets of drug delivery in the cell and the 





1.3.1 Lysosomotropic Drug Carriers and Cell Targeting 
Many polymer-drug conjugates developed are lysosomotropic, that is, conjugates 
designed to be internalized by cells via endocytosis and trafficked to the lysosomal 
compartment (8). There, the lowered pH and/or presence of lysosome-specific enzymes 
would cleave the bond used to attach the drug to the conjugate. The LMW drug would then 
be free to diffuse out of the lysosome and reach its active site within the cell.  
This paradigm of the targetable lysosomotropic HPMA copolymer-drug conjugates 
is represented in Figure 1.2. The basic structural features are of a hydrophilic polymer 
“decorated” with low molecular weight drug. These are attached by covalent linkers which 
are selectively degradable at the target site. These are typically hydrolysable bonds that are 
cleaved due to lowered pH or specific redox conditions, or are enzyme-specific peptide 
bonds. Also attached is a targeting moiety or other selective binding construct that is 
designed to specifically bind to surface receptors on target cells. The objective in this model 
is to deliver high concentrations of drug with a long biological half-life to specific cell 
types, without significant toxicity to normal cells (39). The HPMA backbone and pendant 
linkers are hydrolytically and enzymatically stable in the vasculature and the interstitium,  
 that have been shown to retain most of their biological activity (40). Subcellular 
localization of intact polymer-drug conjugates raises the possibility of trafficking and 








1.3.2 Macromolecular Delivery to the Cytoplasm 
More recent work has been devoted to the development of methods to deliver intact 
macromolecules to the cytoplasm of living cells that avoid trafficking to the lysosomal 
compartment. These can be divided into two categories, peptidic and nonpeptidic factors. 
In each of these pathways, a compound is internalized into the cell by either endocytosis, 
or by nonendocytotic, direct transduction into the cytosol. The transduction factor then 
destabilizes the internalizing vesicle by some method that allows the release of the 
compound into the cytoplasm.  Peptide transduction domains (PTDs) or cell penetrating 
peptides (CPPs) were originally thought to directly penetrate the plasma membrane by a 
nonenergetic physical mechanism. However, more recent work has disputed this 
hypothesis and they are now thought to be rapidly internalized by fluid-phase lipid raft-
dependent macropinocytosis, a specialized form of endocytosis (41). The peptide then 
destabilizes the vesicle to release their contents into the cytoplasm. Subcellular targeting 
represents another potential layer of control in targeted drug delivery. 
Quantum dots are semiconductor nanoparticles that have been successfully used as 
stable fluorescent particles for labeling and tracking subcellular structures in live cells. For 
targeting the cytosol, quantum dots up to 30 nm in diameter and coated with PEG-grafted 
PEI were shown to be rapidly endocytosed, and then slowly released in the cytoplasm of 
live Hela cells (42). Alternately, quantum dots coated with PEG and conjugated to NLS or 
MLS peptides have been shown to efficiently localize to the mitochondria or nuclei, 
respectively, of live 3T3 fibroblast cells after electroporation or transfection agents (43). 
For peptidic factors, the homeotic transcription factor ANTP peptide 




HIV-1 virus are prototypical CPPs. In initial studies to modulate the uptake of 
macromolecules, TAT peptide was chemically added to several proteins such as 
horseradish peroxidase and beta-galactosidase to mediate delivery (44).  Since then, TAT 
peptide has been used to enhance the uptake of a variety of proteins, nucleic acids, 
polymers, and nanoparticles (45-49). More recently, TAT peptide was combined with the 
pH-sensitive fusogenic peptide HA2 to create an internalization module that greatly 
enhanced the uptake, endosomal release and cytoplasmic delivery of macromolecules. 
Using this, escape from macropinosomes was dramatically enhanced for a transducible 
TAT-Cre recombinase reporter assay on live cells (50). 
Alternately, polymeric and dendritic carriers with weakly cationic charges may be 
transduced into the cytoplasm via the so-called “proton sponge effect,” whereby lysis of 
endosomes can be induced before fusion with lysosomes (51). By this hypothesis, lowering 
of the pH in endosomes causes the polymer to build up H+ ions. The ions raise the 
membrane potential of the vesicle causing the concentration of Cl- ions to increase also. 
The combination increases the osmotic pressure in the endosome until it bursts, releasing 
its contents into the cytosol (52). For example, polyethylenimine (PEI) has been used 
extensively as a nonviral vector for nucleic acid transfections, in vitro and in vivo (53, 54). 
By this method polyanionic DNA or RNA is condensed with PEI to form a stable polyplex 
that is endosomolytic. The polyplex is then uptaken by endocytosis, but avoids degradation 







1.3.4 Gene Therapy and Direct Cytoplasmic Delivery   
To place the role of drug delivery with macromolecular carriers in perspective, 
many of the issues related to the development of therapeutic macromolecules have been 
illustrated in the field of gene therapy. There are many aspects to this field. However, the 
most typical goal of this work is to develop methods whereby a nucleic acid encoding an 
entire gene (or RNAi) is internalized by targeted cells. Transfecting genomic DNA with a 
new gene can be thought of as macromolecular drug transport problem where the ideal 
vector: 1) delivers an intact nucleic acid to a targeted organ, tissue, or cell type; 2) permits 
the binding and uptake by cells in a way that avoids degradation in the lysosomal 
compartment; 3) allows subcellular transit through the cytoplasm and/or uptake into the 
nucleus. 
From this perspective, the virus is a nanodevice, able to reprogram a cell with a 
payload of genes, and can efficiently perform several functions at the same time, including 
protecting nucleic acid from enzymatic degradation during transport through the organism, 
biorecognition and binding to a target cell, direct transduction of nucleic acids through the 
plasma membrane, and directing the intracellular trafficking of the nucleic acid to the 
targeted subcellular compartment. The development of man-made materials as drug 
carriers can be interpreted as the initial stage of development of a nanotechnology that 








1.4 Antibodies for Cellular Targeting 
Antibodies are globular proteins produced in blood plasma and are the body’s 
mainline defense against pathological foreign organisms. They are divided into 5 main 
specialized classes: IgG, IgA, IgM, IgD and IgE, with IgG the most abundant. IgGs consist 
of 4 protein components, 2 50kDa heavy chains and 2 25kDa lights chains, which form a 
tetrameric quaternary structure. The heavy chains consist of 3 constant domains (CH1, CH2, 
CH3) and a variable domain (VH). The light chains have 1 constant domain (CL) and a 
variable domain (VL). The heavy chains are connected to each other and the light chains 
are connected to the heavy chains via disulfide bonds and form the protein into a general 
Y-shape. The connector point in the middle is referred to as the hinge region. The “trunk” 
of the antibody is the C-terminal domain of the heavy chains and is referred to as the Fc 
region for “fragment crystallizable”. The N-terminal “arms” of the antibody each contain 
an antigen binding region and are referred to as the Fab fragments for “fragments antigen 
binding” (Figure 1.3.). 
To chemically isolate the Fab from the IgG proteins, there are two general 
approaches using proteolytic enzymes. If IgG1 is digested with papain, the open hinge 
region of the antibody is completely digested leaving Fab’ fragments containing a single 
interchain disulfide bond. If IgG1 is digested with pepsin, however, the hinge region can 
be partially digested leaving a (Fab’)2 fragment, where the two Fab’ fragments remain 
connected by a portion of the hinge region. If the cysteine bonds of the (Fab’)2 fragment 
are then selectively reduced to disassociate the fragments, the Fab arms with the remaining 
pieces of the hinge region are referred to as Fab’ fragments. (Figure 1.4.) The active thiol 




conjugation chemistries (55). 
There are small differences in structure between the subtypes of IgG antibodies 
(56). (Figure 1.3.) In experiments described in Chapter 2, the U1C2 hybridoma for anti-P-
glycoprotein (anti-P-gp) was used to produce Fab’ for conjugate chemistries. However, the 
U1C2 antibody is of the IgG2a subtype, which has a slightly different structure from IgG1, 
particularly with respect to the hinge region and the number of interchain disulfide bonds. 
Digestion of IgG2a antibodies was found to produce a heterogeneous mixture of fragments, 
so a new protocol was developed using lysyl endopeptide as the protease. This protocol 
development is described in detail in Fowers et al. (2001) (57). 
 
1.4.1 Bispecific Antibodies and Cell Targeting 
The development of bispecific antibodies (BiAbs) and other bispecific targeting 
constructs is a rapidly expanding field with numerous applications for drug development, 
diagnosis, and imaging (58-62). Many strategies have been developed using BiAbs. These 
include, redirection of lymphatic cells, dual targeting and pretargeting strategies, 
intravasculature half-life extension, and delivery through biological barriers, such as the 
blood-brain barrier (63-65). Bispecific antibodies are used for a variety of diseases, 
including cancer, chronic inflammatory diseases, autoimmune, neurodegeneration, 
bleeding disorders, and infections (66-69). 
Bispecific monoclonal antibodies (BsAbs) and multivalent Fab’ (or Fv’) conjugates 
have been explored more recently to further expand the capabilities of immunotherapy. 
These constructs have been developed to bring together disparate cell and/or molecular 




recruitment of cytotoxic T cells to tumor cells is one of the most promising approaches for 
the treatment of a variety of cancers (70, 71). 
Many methods have been developed for bispecific or multispecific targeting using 
the antigen-binding domains of antibodies.  These include hybridoma fusion lines (triomas 
or quadromas), a wide array of genetically engineered constructs (such minibodies and 
diabodies), and chemical conjugation (72-78). Quadromas and genetic constructs are 
efficient sources of bispecific targeting agents once they are isolated. However, both 
require a great deal of time, money and expertise to initially produce. Further, their 
effectiveness can’t be easily predicted before they are constructed, synthesized and 
purified. Chemical conjugation allows any existing pair of mAbs to be used to screen their 
feasibility for bispecific targeting. Chemical conjugation of antibody proteins would 
logically be the most straightforward method to rapidly test bispecific targeting constructs, 
but this approach was long limited for several reasons. Purified antibodies and antibody 
fragments are often instable in solution, particularly when undergoing chemical 
modification reactions. The disulfide bridges in the proteins are particularly prone to 
breaking or swapping. Low molecular weight chemical crosslinking agents were hard to 
target and were inefficient due to steric factors. Separation and purification of the antibody 
products was difficult, requiring multiple steps. All these factors resulted in low yields. 
 
1.4.2 Early Approaches to Fab’ Chemical Conjugates 
In most early synthetic procedures, purified IgG was first digested in the hinge 
region with the enzyme pepsin to obtain the (Fab’)2 fragment. This was especially 




degraded into small fragments which were easily removed by gel filtration. (Fab’)2 is then 
reduced to yield two Fab’ fragments. The free thiol groups are then used to site-specifically 
crosslink fragments for two different antigens. (Figure 1.4.) 
Two types of reactions initially used to conjugate Fab’ fragments that produced 
useful bispecific products were:  1) thiol activation and exchange and 2) maleimide 
crosslinking. 
The thiol exchange method was demonstrated via activation with 5,5'-
disulfanediylbis(2-nitrobenzoic acid) (DBNT–Ellman’s reagent) (79) and 4,4’-dipyridyl 
disulfide (Figure 1.5. A) (80). For both, one Fab’ is activated and the unreacted activator 
is then removed by gel filtration. The second Fab’ is then allowed to react with the activated 
conjugate which is thereby coupled by simple disulfide bonds. Yields of BsAb up to 50% 
were reported. The reagent succinimidyl-3(2-pyridyl-dithiol)-propionate (SPDP) had also 
been described. However, it produced random crosslinks and the resulting products were 
too heterogeneous for further characterization (Figure 1.5. A) (81). 
Low molecular weight bismaleimide conjugates were later developed to improve 
synthetic yields. Quadri et al. assessed three bismaleimide linkers to stabilize a 
homospecific antiferritin (Fab’)2 fragment in vivo (Figure 1.5. B): bis-maleimidomethyl 
ether (BMME), N,N’ p-phenylene dimaleimide (p-PDM), and N,N’ bismaleimidohexane 
(BMH) (82). The small size of these linkers was putatively intended to reduce possibility 
of linker derived immune recognition of the conjugate. All three conjugates here were 
found to be nonimmunogenic and to remain in circulation longer than unmodified (Fab’)2. 
Other chemically linked BsAbs cited in the literature during this time often used σ-PDM 




the hydrolytic stability of chemically conjugated Fab’ fragments, Quadri et al. used solid 
phase synthesis of BsAbs to simplify synthesis and showed that low yields are largely the 
result of inefficient coupling of the second Fab’ fragment to the Fab’-PDM conjugate (87). 
This was likely due to steric hindrance.  
A larger bismaleimide crosslinker, N,N’-bis(3-maleimidopropionyl)-2-hydroxyl-
1,3-propanediamine (BMP), was used to create chimeric Fab’/Fc conjugates (% yields not 
reported). Bispecific minibodies have been synthesized using peptide linkers capped with 
Nε-maleimidocaproyl amino acids to conjugate scFv’ fragments (Figure 1.5. B.) (88). 
Maleimide and polyoxime-based linkers were custom-synthesized by several 
research groups to produce trivalent and tetravalant Fab’ conjugates (89, 90). These linkers 
require several reactions to produce and do not lend themselves to the production of multi-
specific conjugates. Yields using these linkers were reported to range from 4 to 18%. 
 
1.5 PEG-Dimerized Fab’ Fragments for Targeting  
Ovarian Carcinoma Cells 
Chapter 2 describes the development of PEG-crosslinked Fab’ fragments as 
targeting modules for HPMA copolymer drug conjugates. This work explored use of short 
PEG polymers that possessed two thiol-specific terminal functional groups to dimerize 
Fab’ fragments isolated from monoclonal antibodies. Antibodies chosen were specific for 
surface antigens commonly expressed on ovarian, and many other, carcinoma cells. 
Previously, polymer-drug conjugates had been developed that employed a single 
monoclonal antibody, a single Fab’ fragment, or used multiple Fab’ fragments in a 




by cultured carcinoma cells. However, the resulting drug conjugate did not demonstrate 
significantly higher chemotherapeutic effectiveness compared to nontargeted conjugates. 
The work here explores the use of well-defined targeting modules consisting of dimerized 
Fab’ fragments created with PEG linkers. The goal of this approach was to develop an 
efficient and well-defined synthetic method to couple antibody fragments in a manner that 
would also provide for the bispecific targeting of carcinoma cells. 
The basic structure of the proposed targeting moiety would consist of two Fab’ 
fragments derived from monoclonal antibodies specific for epitopes on two different 
antigens found on ovarian carcinoma cells, each bound to an end of a branched PEG linker 
(Figure 1.6.). The Fab’ fragments have a relatively low affinity to their corresponding 
receptor proteins but since the Fab’ fragments are covalently linked, it was hypothesized 
that the binding of one would result in the cooperative binding of the other. The length of 
the linker would be large enough to span the average distance between two membrane 
proteins on a cell, but small enough to present the membrane surface to both fragments at 
the same time. Ideally, binding to a nontarget cell with only one target epitope would be 
reversible and would release the conjugate before it is endocytosed into the cell. It was 
proposed that the binding kinetics to cells that present both target epitopes would uptake 
conjugate via receptor-mediated endocytosis in concentrations orders of magnitude higher 
than cells that possessed only one surface epitope. 
The use of two affinity moieties connected by a flexible linker was intended to 
achieve several effects at once. First, the availability of two antigen proteins presents many 
possible combinations for targets on cancer cells. Second, bispecific targeting doesn’t 




since most carcinoma cells are phenotypically diverse and the presence of a unique and 
universal oncoprotein or other antigen on the cells would be unusual. Third, the use of long 
flexible PEG linkers to tether the antibody fragments would theoretically increase the 
affinity of the conjugate to cells as well as decrease the time required to diffuse to the cell. 
This would result from reduced steric hindrance of the antigen binding site from the rest of 
the conjugate and from increased translational and rotational mobility of the fragments. 
Antibody/antigen interactions require a specific orientation for binding, and increased 
freedom of movement would, hypothetically, increase conjugate binding kinetics to 
targeted cells  
 
 
1.6 Mitochondrial Targeting of HPMA Copolymers 
1.6.1 Rationale 
Chapter 3 describes the synthesis and characterization of HPMA copolymers 
designed to target mitochondria. Mitochondria possess a variety of factors desirable for 
drug targeting. The organelles have been increasingly recognized to have important roles 
in functions aside from glycolysis and ATP production for the cell, and are a logical focus 
for anticancer treatments as they are crucial for execution of apoptosis (programmed cells 
death). In addition, mitochondria dysfunction has been shown to contribute to a growing 
number of disease states, including cancer, neuronal degeneration, obesity, diabetes and 
ischemia-reperfusion injury (97, 98). Most of these diseases are associated with excess 
oxidative damage resulting from mitochondrial dysfunction. For this reason, the 
development of mitochondriotropic antioxidants has been a focus for drug discovery. 




as pivotal events in the development of cancer. For example, BCL-2 family proteins have 
become active targets for the design of anticancer drugs (99). These proteins are integral 
regulators of apoptotic cell death located at the mitochondrial outer membrane. Numerous 
mitochondriotropic compounds are in development and clinical testing as cancer 
treatments. These include antisense agents to knock out protein expression (100), and 
several small molecule antagonists (101). 
 
1.6.2 Mitochondria Targeting Peptides 
Precursor proteins that are trafficked to mitochondria depend on an MLS 
(mitochondrial localization sequence) or MTS (mitochondrial-targeting sequence) peptide 
region located on their N-termini. These peptides control the active import of the 
mitochondrial protein code in the cells’ genomic DNA. They are recognized by the 
cytoplasmic molecular chaperone, MSF, and then by Tom70 and Tom20 of the 
mitochondrial outer membrane receptor complex. For intramitochondrial localization, 
MLS’s possess a multirole sorting sequence that specifically interact with various 
components of the mitochondrial protein import pathway. 
MLS sequences have been successfully conjugated with various proteins, polymers 
and other macromolecules to render them mitochondriotropic (as noted for quantum dots, 
previously). For this purpose, MLS peptide leader sequences 
MSVLTPLLLRGLTGSARRLPVPRAKIH (27 aa) from cytochrome-c oxidase VIII 
(COX-8) subunit (102) and MLSALARPVGAALRRSFSTSAQNN (24 aa) mitochondrial 
malate dehydrogenase (mMDH) (103) have both been used. For example, a mMDH 




mitochondria in several cells types (104). 
 
1.6.3 Lipophilic Cations 
Nonpeptidic cationic functional groups have also been used as targeting moieties 
to traffic conjugates to the mitochondrial compartment. Most small molecule 
mitochondriotropic compounds are lipophilic cations and include rhodamine-123(105, 
106), oligoguanidinium (107, 108), triarylmethane (109-111), and triphenylphosphonium 
(TPP)(112-114). Each of these consists of cationic charges that are highly delocalized in a 
multiple aromatic ring structure. These moieties possess a net positive charge that is 
shielded in a “cage” of hydrophobic rings that prevent the approach of counter ions. 
Mitochondrial localization is thereby generated by the attraction of the delocalized cation 
for the negative transmembrane electrostatic potential (∆psi) in mitochondria created 
during respiration during oxidative phosphorylation (115, 116). The mix of cationic and 
hydrophobic properties of the cations also greatly enhances their diffusion across lipid 
bilayers. In this model, the cations have a high affinity for the surface anionic charge of 
biological membranes, which enhances the initial adsorption to the bilayer. In the outer 
plasma membrane and mitochondrial membrane, the transmembrane potential creates a 
driving force to pull the cation across the bilayer while the net hydrophobicity of the moiety 
structure minimizes the energy barrier that would normally block the diffusion of cations. 
Lipophilic cations have also been incorporated into the bipolar lipid dequalinium 
that have been used to form mitochondriotropic vesicles or “DQAsomes” (117, 118). 
DQAsomes have been used as vectors for drug and nucleic acids to the mitochondria of 




anionic lipid membranes but release their payload after trafficking and adsorption with the 
cardiolipin-rich mitochondrial membrane. DQAsomes loaded with MLS-plasmid 
conjugates were shown to colocalize intact DNA with mitochondria in living cells in 
contrast with MLS-plasmid alone (119, 120). 
 
1.6.3.1 Triphenylphosphonium (TPP) 
TPP has been used to create an entire class of low molecular weight mitochondria 
localizing drugs, largely through the work of Michael Murphy now at the MRC Dunn 
Human Nutrition Unit, Cambridge, UK. For instance, TPP has been used to make 
antioxidants mitochondriotropic in conjugation with vitamin E (“Mito Vit E”), ebselen 
(“MitoPeroxidase”) and ubiquinol (“MitoQ”) to enhance the ability of the compound to 
protect cells from oxidative damage (121-125). Cells incubated with micromolar 
concentrations of Mito Vit E were found to have levels of the drug in their mitochondria 
80-fold higher compared to those incubated with unmodified vitamin E (121). 
MitoQ compounds were synthesized by attaching TPP to ubiquinone using an alkyl 
spacer.  In isolated cells, it was found that the compounds were localized to mitochondria 
in concentrations several hundred-fold higher than that expected with ubiquinone.  
Furthermore, when the length of the alkyl spacer was altered between C3 and C15, the 
degree of association with the inner mitochondrial membrane could be regulated, as 
determined by a lipid peroxidation assay (126). In vivo, rats fed MitoQ showed improved 
heart function compared to control animals after ischemic injury to their heart tissue (97). 
MitoPeroxidase was developed as an antioxidant to prevent degradation of phospholipids 




RBL-2H3 rats, basophilic leukemia cells stressed using 2-deoxyglucose or H2O2, both 
MitoPeroxidase and ebselen were found to decrease caspase 3 activity and the likelihood 
of apoptosis (122). TPP has also been used to create mitochondriotropic compounds for 
other purposes.  Thiobutyltriphenylphosphonium bromide was successfully used to 
specifically label thiol proteins in mitochondria via Western blotting using an anti-TPP 
monoclonal antibody as a probe. An mtDNA-specific alkylating agent was created 
incorporating TPP in the compound [4-((11aS)-7-methoxy-1,2,3,11a-tetrahydro-5H-
pyrrolo[2,1-c][1,4]benzodiazepin-5-on-8-oxy)butyl]-triphenylphosphonium iodide to 
derivatize guanidine bases. However, this compound failed to alter the mtDNA in living 
cells (127). 
 
1.6.3.2  TPP: Membrane Transduction and Trafficking of Macromolecules 
TPP caught the attention of those working on polymeric drug carriers when, in 
2001, it was successfully used to target macromolecules to mitochondria. Murphy et al. 
found that terminally functionalized TPP targeted antisense PNAs (peptide nucleic acids) 
localized within isolated mitochondria and co-localized in the mitochondria of whole cells 
in vitro (116). Furthermore, it was reported that TPP-PNA conjugates as large as 4 kDa 
incubated with live cells were directly transduced through the plasma membrane, trafficked 
through the cytosol, and passed through the inner and outer membranes of mitochondria in 
high concentrations. It was hypothesized that the terminal TPP cation destabilized the 
structure of lipid bilayers sufficiently to allow a large, linear, uncharged macromolecule to 
be inserted into and pulled through the plasma membrane and mitochondrial membrane 




In the initial paper, TPP-PNA conjugates were created that contained an antisense 
sequence specific for the point mutation in mtDNA that causes the 'myoclonic epilepsy and 
ragged red fibres' (MERRF) phenotype in cultured cells.  Mitochondrial localization was 
confirmed in living cells using a TPP-specific electrode, anti-TPP immunoblotting after 
subcellular fractionation, confocal microscopy, immunogold SEM, and by crosslinking to 
mitochondrial matrix proteins. Although PCR probing of mRNA expression indicated 
antisense activity in cell-free systems, the conjugate failed to block the expression of the 
mutated gene. Direct plasma membrane penetration was further supported using TPP-
PNAs where the TPP moiety was attached using a linker containing a disulfide bond.  The 
compound was designed to allow the TPP moiety to be released upon transduction to the 
cytosol after reduction by the glutathione activity found in cytoplasm. Cytosol-specific 
delivery was demonstrated in mouse P388 cells incubated with conjugates containing 
antisense PNAs for the Pax2 protein. It was found that the expression of the Pax2 protein 
decreased by 85-90% (115). 
 
1.6.4 Mitochondriotropic Semitelechelic TPP-HPMA Copolymers 
Like PNAs, HPMA homopolymers are also linear, uncharged, hydrophilic 
macromolecular polymers. Indeed, the balance of hydrophilicity/hydrophobicity of PNA 
and pHPMA is very similar (128). It was therefore hypothesized that pHPMA polymer 
chains with a single terminal TPP cation end-group would possess the same membrane 
transduction and mitochondriotropic properties observed using TPP-PNA. Since either one 
of these properties could be exploited for variety of possible drug carrier applications, a 




membrane transduction and mitochondria-localization properties. 
The TPP-HPMA copolymers synthesized were semitelechelic HPMA copolymers 
possessing a single TPP end group on one terminus. Polymerizing semitelechelic TPP-
HPMA polymers was performed in single step via the use of a thiol chain transfer agent 
containing TPP, thereby creating low-molecular weight polymer chains each possessing 
single cation fixed on one terminus of the final polymer (Figure 1.7.). The use of a chain 
transfer agent also allowed for more control over the molecular weight of the resulting 
polymers, yielding lower molecular weight with low polydispersity. 
For trafficking experiments, semitelechelic TPP-HPMA copolymers were created 
using methacroylylated monomers containing either fluorescein or BODIPY® FL (4,4-
difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene) to act as drug models and to allow 
for microscopic visualization of the polymers in vitro and in vivo (128). Since it was 
unknown how sensitive the activity of TPP cation’s function would be to the single 
carboxylate negative charge on fluorescein, uncharged fluorescent marker BODIPY® FL 
was included to ensure that the resulting copolymers attached to TPP were electrically 
neutral. Mitochondrial localization was characterized incubating cultured ovarian 
carcinoma cells in media containing the copolymers, by measuring copolymer binding to 
isolated mitochondria from mouse liver, and by microinjection of TPP-HPMA copolymer 
solutions into live cells. Cell uptake and intracellular trafficking of the copolymers was 
characterized by confocal microscopy using cultured carcinoma cells. 
This study represented an initial feasibility study on the use of the lipophilic cation 
TPP to targeted HPMA copolymers to mitochondria in living cells. It was also an 




diseases could hypothetically be treated using mitochondriotropic drug carriers. Further, 
proof of direct transduction through the cell’s plasma membrane would represent an 
entirely new method carrying drugs to the cytosol that didn’t rely on active uptake by 
endocytosis pathways. 
 
1.7 A Large Polymer Array – a Synthetic Polymer Library 
Since the development of simple polymer conjugates, many new polymers for drug 
delivery have been developed that employ a huge array of functions that control 
biodistribution, bioavailability, biodegradability, cell targeting, and subcellular trafficking. 
Polymers of different types are incorporated into these nanocarriers that include micelles, 
polymersomes, dendrimers, nanohydrogels, nanoparticles and nanotubules (129). 
However, these innovations are still in their infancy and basic knowledge of how these 
materials interact with living organisms, and how to control the various biological 
functions of these materials remains lacking. The motivation of the work described in 
Chapter 4 was to gain a systematic understanding of how cells can interact with a variety 
of synthetic materials. 
A review of contemporary literature revealed that there are large gaps in our 
understanding of how synthetic macromolecules interact with living cells. Experiments 
designed to directly transduce HPMA copolymers into the cytoplasm of living cells was 
difficult to evaluate since little is known about how basic physio-chemical characteristics 
of synthetic materials affect the distribution and transport of nanoparticles within cells. 
Basic information, such as the diffusivity of synthetic polymers through cytoplasm, was 




known regarding how charge, molecular weight, and relative hydrophilicity affect binding 
to cell membranes, cell uptake, intracellular trafficking, membrane transduction, cell 
toxicity, intracellular distribution and fate. 
 
1.7.1 An HPMA Copolymer Array 
HPMA copolymers are extremely versatile for incorporating monomers containing 
various other chemical moieties and functional groups. In contrast with PEG, the 
incorporation of methacryloylated comonomers is straightforward and the contents of the 
resulting copolymers is predictable based on the ratios of the feed monomers. Given this 
flexibility, a large array of HPMA copolymers was created that possessed a very wide range 
of different charges, charge densities and hydrophilicities (Figure 1.8.). The comonomers 
used included weak and strong acids, weak and strong bases, and methacryoylated (MA) 
peptide monomers with varying numbers of hydrophobic amino acids. The general reaction 
scheme is shown in Figure 1.9. Each polymer was fractionated based on molecular weight 
using identical size-exclusion chromatography protocols to create parallel “ladders” of 
copolymer molecular weight standards. 
This work represents a systematic approach to characterizing how the physio-
chemical features of water soluble polymers interact with the cell. In one experimental 
series, each of the polymers was microinjected in live cultured cells and the distribution of 
the cells over time was monitored in detail using time-lapse confocal microscopy (130). In 
the other experimental series, live cells were incubated in media containing each copolymer 
and the differences in cell uptake and trafficking were observed by flow cytometry and by 




copolymer in this array were studied by Liu et al., and are summarized in Chapter 5 (131). 
 
1.7.2 Nuclear Entry 
Special interest was devoted to the rates of entry into the nucleus. Initial 
microinjection experiments using array copolymers revealed significant differences in the 
rates of polymer diffusion into the nuclei. Cytoplasmic macromolecules are typically 
excluded from entering membrane-limited organelles, such as mitochondria, lysosomes, 
the ER, in a nonspecific manner.  The exception to this is the nucleus whose membrane 
possesses channels that allow the passive uptake of intermediate-sized macromolecules.  
The NPC (nuclear pore complex) of the nuclear envelope is composed of about 30 different 
nucleoporin proteins and is the conduit for both nuclear import and export of 
macromolecules, such as proteins and nucleic acids.  In active transport, cargos as large as 
40 nm possessing NLS (nuclear localization sequence) or NES (nuclear export sequence) 
signaling peptides are guided through the channel after binding to NTR (nuclear transport 
receptor) proteins (132). For smaller macromolecules below 10 nm, however, NPCs have 
been shown to act as nonspecific pores that allow exchange between the nucleus and 
cytoplasm by diffusion (133). As a conduit for nonbiological macromolecules, the NPCs 
have been shown to transmit PEG-coated gold colloid particles 4-7 nm in diameter (134).  
In contrast, 27 nm and 39 nm PEG-gold particles and 25 nm quantum dot particles 
conjugated with NLS peptide sequences have been shown to require the active nuclear 
import mechanism for uptake by the nucleus (132, 134, 135). 
Dynamic structural modeling of several of the nucleoporins in the core of the NPC 




selection. The structure of several nucleoporins notably contains natively unfolded 
domains containing hydrophobic FG (phenylalanine-glycine) domains, consisting of FG, 
GFLG, and FXFG peptide repeats. Several different models are currently under debate to 
account for the dynamics of NPC transport. Ribbeck et al. (136, 137) proposed that the FG 
domains form a polymer brush conformation in the NPC channel that excludes larger 
solutes by entropic hydrophobic repulsion. Frey et al. suggested that nucleoporins form an 
unstructured hydrogel mesh in the core of the NPC channel through reversible crosslinks 
of FG peptide repeats that they possess (138). Nuclear transport receptors have been shown 
to possess a number of hydrophobic regions that specifically bind to nucleoporins in their 
FG repeat regions and have been proposed to disassociate interchain crosslinks. The pore 
proteins, thereby, form a 3-dimensional mesh with a simple molecular weight permeability 
cut-off when crosslinked. In this model of active transport, NTRs are able to open the 
nucleoporin mesh by “melting” the hydrogel structure and guide large macromolecules in 
or out of the nuclear compartment (139). Alternately, Melčák et al. proposed an interface 
between the α-helical regions of nucleoporins that selectively slide circumferentially to 
dilate the NPC pore opening after NTR binding (140). 
Since this work was done, many models have been proposed for the structure and 
function of the NPC. However, the subject currently remains an active area of contention 
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Figure 1.2. Schematic model of targetable polymer drug conjugates with degradable 
drug linkers 
Figure 1.1. Summary of the cell surface and intracellular targets for drug carriers and 






Figure 1.3. Depictions of the basic structure of the IgG protein. Lower half illustrates 















Figure 1.5. Structures of thiol crosslinkers used in early protein conjugation studies. 







Figure 1.6. General method to dimerize bispecific Fab’ fragments using a 









methacryloylated monomer with 
















Figure 1.10. Representation of the chemical characteristics of the HPMA copolymers in the 






PEG-DIMERIZED Fab’ CONJUGATES FOR THE TARGETING OF 
 HPMA COPOLYMER-DRUG CONJUGATES 
 
2.1 Introduction 
Monoclonal antibodies and Fab’ antibody fragments previously have been 
incorporated into drug-polymer conjugates to selectively target drug delivery to cancer 
cells(1-3). Antibodies bind very specifically and avidly to cell surface antigens, but their 
high-molecular weight and interactions between lymphocytes and the Fc of the whole 
antibody often limits their usefulness for conjugate targeting. To avoid these issues, 
isolated Fab’ fragments have been used. However, they possess much lower binding 
affinities and yield less effective cell uptake rates as a result. When antibodies or 
antibody fragments are attached to polymers via nonspecific conjugation reactions, it has 
been shown that there is often significant loss of antibody affinity to the corresponding 
epitope. This loss of affinity can be attributed to several sources, including chemical 
alteration of the antibody antigen binding site, reduction in the translational and rotational 
diffusivity of the polymer-coupled antibody, and steric hindrance of the antigen binding 
site by the polymer backbone. 
In this chapter, chemically dimerized Fab’ fragments were investigated as 
possible targeting modules for polymer-drug conjugates. These modules were created by 
 53 
the site-specific attachment of Fab’ fragments using extended PEG linkers possessing 
two terminal thiol-specific moieties. It was hypothesized that these modules would be 
ideal for targeting cancer cells and would enhance cellular uptake of conjugates. PEG 
was used, as opposed to low molecular weight crosslinkers, to improve synthetic yields, 
and to possibly increase yields for a subsequent site-directed attachment of the PEG 
linker to HPMA-drug conjugates. Expected higher synthetic yields were hypothesized to 
result from the high degrees of freedom imparted to the functionalized termini of the PEG 
linker, and due to the lack of steric interference between the crosslinked protein 
fragments (4, 5). In addition, the fragments would not require a specific orientation 
towards each for crosslinking to occur.  
An efficient chemical crosslinking method for antibody fragments was sought to 
create a direct and efficient method to create bispecific (Fab’)2 constructs (6). By this 
theoretical approach, existing monoclonal antibodies could be “mixed and matched” in 
any bispecific combination, thereby creating a method to quickly screen the effectiveness 
of bispecific approaches, and avoid the time-consuming trial and error process required 
for genetically engineered constructs, such as diabodies. 
 
2.1.1 Bispecific Targeting for Cancer Cells 
Although many surface features have been identified that can be used to target 
tumor cells, a general difficulty in developing targeted conjugates is the identification of 
antigens that are specific for tumor cells. Specific surface features of tumors cells may 
include the translational products of specific oncogenes and other proteins expressed on 
many tumor cells, such as the products of the MDR1 gene, P-glycoprotein (1). These 
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products, however, are usually not unique to tumor cells, but are rather overexpressed in 
comparison to normal cells. With targeted binding using monospecific, high-avidity 
antibodies, a large majority of the drug-conjugates may bind to nontumor cells with low 
densities of the target epitope since the number of these cells is typically much greater 
than tumor cells (and correspondingly, the total number of potential binding sites). 
The cell surface antigens that tumor cells typically present are not only often non-
specific, they are also highly variable due to the genomic and phenotypic instability of 
most cancer cells (7, 8). In general, most receptor proteins that tumor cells present are 
characteristic of the type of tissue to which oncogenesis first occurred. As the cancer 
progresses, however, these receptor proteins can change as the cells become more poorly 
differentiated. Changes in cell phenotype can also occur in response to environmental 
conditions, such as the selective response to various chemotherapy drugs. The design of 
targeted conjugates for the treatment of cancer requires not only that different targeting 
moieties be used for different types of cancer, but that the targets are critical to the 
proliferation of the cancer cells. Bispecific targeting allows the targeting of cancer cell 
surface antigens that are not only overexpressed, but presented in combined pairs that 
aren’t typically found on any normal cells in the body. 
 
2.2.2 Research Plan 
The conjugates described here are based on targeted HPMA conjugates previously 
described for use against tumor cells derived from human ovarian epithelial cells. These 
conjugates consisted of a HPMA backbone with a fraction of sidechains substituted with 
either a drug (doxorubicin or mesochlorin e6) or an antibody-derived targeting moiety. 
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The substituted chemicals are covalently bound to the backbone with a gly-phe-leu-gly 
tetrapeptide linker. This linker has been shown to be specifically cleaved from the 
conjugate by cathepsin B and to only release the conjugated drug in the lysosomal 
compartment (9). 
Rather than use a targeting moiety based on a single monoclonal antibody, 
however, the goal of this research was to investigate the possibility of the use of a bi- or 
multispecific targeting moiety. The basic structure of the proposed targeting moiety 
would consist of two Fab’ fragments derived from monoclonal antibodies specific for 
epitopes on two different proteins found on the tumor cell, connected to each end of a 
branched PEG linker. Single Fab’ fragments have a relatively low affinity to their 
corresponding receptor proteins, but it was hypothesized that a bifunctional Fab’ 
construct connected with an extended polymer linker would have a high affinity for 
targeted tumor cells. Since the antibody fragments are covalently linked, the binding of 
one should result in the cooperative binding to cell surface receptors. It was proposed that 
the polymeric linker possessing many degrees of conformational freedom would be long 
enough to span the average distance between two membrane proteins on the cell, but 
small enough to present the membrane surface to both fragments at the same time. It was 
also suggested that binding to a nontarget cell with only one target epitope would be 
reversible and would release the conjugate before it is endocytosed into the cell. Only 
cells that present both target epitopes would result in the binding of the conjugate to 
allow receptor-mediated endocytosis to take place and, therefore, greatly increase the 
uptake of the polymer-drug conjugate. 
For this research, several hybridoma cell lines were obtained that produce 
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monoclonal IgG antibodies that specifically bind cell surface proteins known to be 
expressed on ovarian carcinoma cells, including P-glycoprotein, CD44/OA3, HER-2, and 
EGFR. Using in vitro bioreactors, hybridomas were grown at scales large enough to 
produce antibodies in amounts suitable for laboratory-scale synthetic chemistry. 
Antibodies were purified and concentrated using preparative–scale affinity 
chromatography. (Fab’)2 antibody fragments were obtained by partial enzymatic 
digestion of the protein in their relative open hinge regions (Figure 2.1. and Figure 2.2.). 
Fab’ fragments were produced for site-specific attachment to polymers via free cysteine 
thiol groups in their hinge region (Figure 2.3.).  
For proof of concept, commercially available bifunctional PEG crosslinkers were 
used to dimerize antibody fragments via site-specific attachment to the free thiol in the 
hinge region of Fab’. PEG linkers possessing maleimide or vinyl sulfone terminal 
moieties were used to create PEG crosslinked Fab’ fragments (Figure 2.4.). Both 
monospecific and bispecific Fab’ dimers were created (Figure 2.5. and Figure 2.6.). The 
effect of the PEG crosslinking on binding kinetics and uptake of the constructs by 
cultured ovarian carcinoma cells were compared to that of unmodified IgG antibodies. 
Hemitrifunctional bismaleimide-PEG crosslinkers were synthesized to dimerize 
Fab’ fragments via a linker that could subsequently be selectively attached to HPMA 
copolymer-drug conjugates. This was accomplished by coupling two heterobifunctional 
PEGs possessing terminal amine-specific succinimide and thiol-specific maleimide 
moieties (Figure 2.7.). This created a bifunctional maleimide PEG linker possessing a 
central carboxylate that could be subsequently functionalized with a hydrazide moiety for 
site-specific attachment to HPMA-doxorubicin copolymer-drug conjugate containing side 
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chains functionalized with a reactive p-nitrophenyl ester group (Figure 2.8.). The end 
goal of this work was to, in effect, create engineered bispecific antibodies with an “Fc 
fragment” removed and replaced with a polymer-drug conjugate, while also replacing the 
hinge region with a synthetic, extended PEG polymer. Different Fab’ fragments were 
used to create bispecific (Fab’)2 constructs linked by PEG hinges and the biological 
activity of the coupled antibody fragments was investigated.  
 
2.2.3 Monoclonal Antibodies 
For this work, four types of monoclonal antibodies were produced for targeting 
ovarian carcinoma cell lines: OV-TL16, which produces an IgG1 subclass antibody 
against the CD44/OA3 tumor marker; anti-EGFR (anti-epithelial growth factor receptor); 
anti-HER2 (anti- human epidermal growth factor receptor 2); and UIC2, an IgG2a 
subclass antibody against p-glycoprotein (anti-P-gp), the product of the MDR1 gene 
(multidrug resistance) that is frequently over-expressed in drug-resistant cancer cell lines. 
 
2.2.4 (Fab’)2 Production-IgG2a Subclass Antibodies 
Since the enzymatic cleavage methods that produce Fab’ fragments from IgG1 
type antibodies is not optimizable for IgG2a antibodies, a new method to produce Fab’ 
from IgG2a antibodies was required to obtain Fab’ fragments from the U1C2 anti-P-gp 
monoclonal antibody. Extensive work was required to develop and optimize a simplified 
method using the enzyme lysyl endopeptidase (LE) to create IgG2a Fab’ fragments (10). 
When preparing (Fab’)2 fragments, the IgG subclass is important in the choice of 
digestive enzyme (11, 12). Pepsin, lysyl endopeptidase (LE), clostripain, and 
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mercuripapain, among others, have been investigated to optimize preparation of (Fab’)2 
from the mouse IgG2a subclass (12-14). LE cleavage of IgG2a has been shown to 
provide stable (Fab’)2 and Fc fragments (12). Lysyl endopeptidase has an optimal activity 
pH range between 8.5 and 10.7 (15), but it does retain sufficient enzymatic activity at 
physiological pH. Pepsin also produces stable (Fab’)2 fragments from IgG2a, although 
pepsin cleavage may result in a heterogeneous product due to broader substrate 
specificity (16-18).  
A simple and efficient method for preparation of Fab’ fragments from murine 
IgG2a was developed that would allow conjugation to an N-(2-
hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugate for targeting the P-
glycoprotein-expressing cell line, A2780/AD. Due to the difficulties encountered with 
preparation of Fab’ fragments from murine IgG2a, purification of the (Fab’)2 fragment 
was carried out to prevent LE cleavage in the hinge region above the two remaining 
disulfide bonds. Previous literature detailing digestion with LE did not show cleavage at 
the secondary site following purification of (Fab’)2 using Protein A and ion exchange 
chromatography (12). Proteolytic cleavage sites in the hinge region, however, may be 
affected by alterations in the conformation of the protein, i.e., antigen binding, reduction 
of disulfide bonds, or acid pretreatment (17, 19). Select antibodies may show an 
increased susceptibility to proteolytic cleavage, and require optimization of the substrate 
to enzyme ratio, and a more thorough washing procedure to remove residual enzyme, i.e., 
LE. 
A Protein G affinity chromatography purification procedure was developed based 
on known differences in avidity and the number of components in the digestion 
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preparation, i.e., (Fab’)2 and Fc fragments for LE digestion or undigested IgG2a, (Fab’)2, 
and Fab fragments for pepsin digestion (20-22). With LE enzymatic affinity in mind, a 
washing procedure following binding to a protein G affinity column was developed to 
remove residual LE following digestion to prevent further proteolytic cleavage of the 
(Fab’)2 to Fab’ fragment. 
 
2.2.5 Fab’ Dimerization 
In the first experiments, Fab’ fragments derived from the OV-TL16 monoclonal 
antibody were first dimerized using the commercially available (Shearwater/Nektar) 
thiol-specific crosslinker MAL-PEG3400-MAL, a linear PEG polymer with both termini 
functionalized with maleimide moieties. The binding affinity constant of the constructs 
was determined using OVCAR-3 ovarian carcinoma cell lines. The in vitro binding and 
relative rate of uptake by cancer cells was investigated using confocal fluorescence 
microscopy and flow cytometry. Binding constants were determined by Scatchard 
analysis via the binding of 125I-iodinated cells to live OVCAR-3 cells that express the 
CD44/OA3 receptor protein that possesses the epitope for OV-TL16. 
Subsequent experiments used mAbs that recognize P-glycoprotein (UIC2), HER-
2 (ATCC #11602), and EGFR (ATCC #C225) to produce Fab’ fragments for 
dimerization. Commercially available MAL-PEG3400-MAL, and later, a bisvinylsulfone 






RPMI-1640 medium, DMEM medium, Dubelco’s phosphate buffered saline 
(DPBS), insulin, fetal bovine serum, Boc-Val-Leu-Lys-7-amido 4-methyl coumarin, Nα-
tosyl-L-lysyl chloromethyl ketone, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT), and pepsin were purchased from Sigma (St. Louis, MO).  Protein G 
Sepharose 4 Fast Flow column, DEAE cellulose, protein A Sepharose chromatography 
resins, and PD-10 columns were purchased from Pharmacia (Peapack, NJ).  Lysyl 
endopeptidase was purchased from Wako Bioproducts (Richmond, VA). Spectra/Por 2 
dialysis tubing MWCO 12-14 kDa was purchased from Spectrum Laboratories (Rancho 
Dominguez, CA). 4-(Maleimidomethyl)-cyclohexanecarboxylic acid N-
hydroxysuccinimide ester was purchased from Aldrich (Milwaukee, WI).  Bicinchoninic 
acid (BCA) assay was purchased from Pierce (Rockford, IL). All other chemicals were 
obtained commercially as reagent grade products. 
 
2.3 Methods 
2.3.1 Trifunctional Bismalemide PEG Linker 
The trifunctionalized PEG linker proposed for the dimerization of Fab’ fragments 
for the Fab’-PEG-Fab’ targeting complex was synthesized by reacting L-lysine with a 
10% molar excess of the heterobifunctional PEG linker MAL-PEG2000-NHS (2 kDa 
molecular weight PEG end-functionalized with maleimide and N-hydroxysuccinimide 
ester moieties (Shearwater/Nektar). The reactants were first dissolved in a minimal 
volume of PBS, pH 5. While stirring, the pH of the reaction was raised to pH 7.5 over the 
course of 2 h using 0.1 N NaOH. The reaction was then continued for another 8 h. When 
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complete, low MW components were removed by applying to a PD-10 column 
equilibrated with PBS, pH 7.5. The resulting trifunctional linker (MAL-PEG2000-lysine-
PEG2000-MAL) was purified from unreacted PEG linker using SEC (Superdex75). The 
SEC fractions containing the conjugate were combined and then dialyzed against water 
using 6-8 kDa cutoff dialysis tubing (Spectra). The product solution was then frozen and 
the trifunctional PEG conjugate was isolated by freeze-drying. The identity of the 
conjugate was confirmed using SEC retention time. The final yield was approximately 
20%. 
In subsequent syntheses, trifunctional linker made from heterobifunctional linkers 
possessing vinyl sulfone moieties, instead of maleimide, were performed using the same 
protocol. The reaction yield of the dimerized bisvinylsulfone trifunctional linker (VS-
PEG3400-lysine-PEG3400-VS) was 50%. However, SAMSA thiol conjugation assays of the 
thiol reactivity of these conjugates showed that more than 50% of the vinyl sulfone 
functional groups were lost during the procedure. 
 
2.3.2 Maleimide and Vinyl Sulfone Assays 
The content of maleimide and vinyl sulfone functional groups in the bismaleimide 
and bisvinyl sulfone PEG linkers was determined by conjugation with the fluorescent 
marker SAMSA fluorescein [5-((2-(and-3)-S-(acetylmercapto)succinoyl)amino) 
fluorescein] (Fisher). In a small glass tube covered with foil, 1.3 mg of SAMSA 
fluorescein was activated by dissolving in 0.5 ml 0.1 M NaOH. and incubated at room 
temperature for 15 min. This removed the acetyl protecting group. Following activation 
of SAMSA FL, the solution was neutralized with ~3 µL of 6 M HCl and buffered with 
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approximately 0.1 ml of 0.5 M sodium phosphate at pH 7.   
For the conjugation reaction, a 5-fold molar excess of SAMSA-FL was reacted 
with bismal-PEG in phosphate buffer. The PEG conjugate was first dissolved in 0.1 M 
sodium phosphate/1 mM EDTA and then combined with the activated SAMSA-FL 
solution. The reaction proceeded at room temperature for 2.5 h with gentle shaking. The 
unreacted dye was then removed by applying the reaction mixture to a PD-10 column and 
eluting in 0.1 M borate buffer, pH 8.3. The degree of labeling could then be determined 
from the absorbance of the labeled conjugate at 495 nm. The extinction coefficient of 
SAMSA fluorescein is 80,000 cm-1M-1 at 495 nm. 
  
2.3.3 Cell Lines 
The human ovarian carcinoma cell lines OVCAR-3, ES-2 and MDAH 2780 were 
purchased from ATCC (Rockville, MD). Ovarian carcinoma cell lines A2780, A2780/AD 
(doxorubicin resistant), were obtained from Dr. T.C. Hamilton (Fox Chase Cancer 
Center, PA). OVCAR-3 cell lines transfected with the MDR1 genes were a gift from Dr. 
Mikhail Slinkin. All ovarian carcinoma cells lines were cultured in RPMI-40 medium 
containing 10 µg/ml insulin and supplemented with 10% fetal bovine serum. 
The hybridoma cell lines OV-TL16 for anti-OA3 IgG1 mAb, and UIC2 for the 
IgG2a against P-gp (anti-P-gp), and hybridomas for anti-EGFR and anti-HER2 were 
purchased from ATCC (Rockville, MD). Anti-fluorescein IgG2a antibodies from the 
hybridoma cell lines BDC-1 and 4-4-20 were a gift of Dr. James Herron (University of 
Utah) (23). All cells were cultured at 37°C in a humidified atmosphere containing 5% 
CO2 (v/v). 
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2.3.4 Monoclonal Antibody Production 
The hybridoma cells were initially cultured in DMEM medium supplemented 
with 10% fetal bovine serum. The amount of serum in their media was gradually reduced 
over a period of 2 to 3 weeks to adapt them to serum-free hybridoma medium, H-SFM 
(Gibco Life Sciences), prior to either producing ascites in mice or seeding the cells into a 
Cellco Bioreactor system. 
Antibodies obtained from mouse ascites fluid were precipitated in saturated 
ammonium sulfate prior to being dissolved in 0.01 M Na2HPO4, 0.15 M NaCl, 0.01 M 
EDTA pH 7.0 buffer (buffer A).  The protein solution was then filtered through a 0.2 µM 
filter prior to applying it to a Protein G Sepharose 4 Fast Flow column at a flow rate of 1 
ml/min. 
Antibody-containing hybridoma media from the bioreactors were subjected to 
centrifugation at 3500 rpm for 10 min and the supernatant was removed. The hybridoma 
media was filtered sequentially through a glass fiber, 0.45 µm, and 0.2 µm filters prior to 
applying it directly to the protein G affinity chromatography column.  The Protein G 
affinity chromatography column was washed with buffer A until the absorbance at 280 
nm returned to baseline. Purified IgG was eluted using 0.5 M acetate pH 3.0 buffer 
(buffer B). Fractions containing IgG were neutralized with 3M Tris and stored at 4°C. 
Antibody purity was assessed by SDS-PAGE analysis. The specificity of 
fluorescently-labeled antibodies was confirmed by flow cytometry using cell lines that 
possessed the receptor specific to the antibody (24). The specificity of the antifluorescyl 
antibodies was measured against fluorescein directly. 
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2.3.5 (Fab’)2 Production from IgG1 Antibodies 
For OV-TL16 and anti-EGFR antibodies, antibodies were digested with 10% 
pepsin (wt/wt) in 0.1 M citric buffer pH 4.0 at 37°C for 8 h to give (Fab')2. The protein 
was purified using PD-10 columns equilibrated in the particular buffer used to reduce the 
fragment to Fab’. 
 
2.3.6 (Fab’)2 from IgG2a Antibodies Via Lysyl Endopeptidase Digestion  
Buffer A: 0.01 M Na2HPO4, 0.15 M NaCl, 0.01 M EDTA pH 7.0; Buffer B: 0.5 
M acetate pH 3.0 buffer. IgG2a antibodies at a concentration of 2-10 mg/ml were 
incubated with LE for 4 h at 37°C in 50 mM Tris-HCl pH 8.5 (12). The optimal molar 
ratio of anti-Pgp to LE, as determined using titration experiments to obtain complete 
digestion of IgG2a to (Fab’)2 and Fc, without over-digestion was 500:1 (data not shown). 
LE activity was inhibited by excess addition of a stoichometric inhibitor Nα-tosyl-L-lysyl 
chloromethyl ketone (TLCK) (12). The digestion mixture was applied to a protein G 
column equilibrated in buffer A. The UV absorbance was monitored at 280 nm until the 
absorbance returned to baseline. 
The elution of LE was performed by washing the column with 200 mM L-lysine 
in buffer A until the LE activity was negligible. LE activity was measured during elution 
using a fluorogenic assay and the substrate Boc-Val-Leu-Lys-7-amido 4-methyl 
coumarin (BOC-Val-Leu-Lys-AMC) (25, 26). The absence of LE in the eluted Fc and 
(Fab’)2 fractions was confirmed by assaying the elution peaks in buffer B; the samples 
were neutralized by dilution 1:10 (v/v) with 0.2 M Tris-HCl pH 9.0 prior to assay. 
The (Fab’)2 and Fc fragments were eluted from the column by two methods.  The 
 65 
first method involved two step changes in the pH/ionic strength. Once the absorbance 
reached baseline, a solution of buffer A and buffer B, 75:25 (v/v), pH = 4.5, was applied 
to the column until the Fc peak was fully eluted. (Fab’)2 was eluted using a step change to 
100% buffer B. An alternative method was performed with a gradient elution for the Fc 
peak, and elution of the (Fab’)2 peak with a step change to 100% buffer B. The linear 
gradient was changed from 0% to 27% buffer B over a 15 min period to elute the Fc 
fragment, at which point a step change to 100% B elutes the (Fab’)2 fragment.  
Continuation of the gradient following elution of the Fc peak elutes the (Fab’)2 in a broad 
peak consisting of a 5-10-fold higher volume. The (Fab’)2 fragment was eluted in a much 
sharper peak if a step change to 100% buffer B is utilized following elution of the Fc 
peak. The gradient was performed using a FPLC system (Pharmacia) with buffers A and 
B. 
 
2.3.7 Preparation of Fab’ 
For IgG1 antibodies, (Fab’)2 was reduced to Fab' with 20 mM cysteine for 1 h at 
37°C, pH 8. Excess cysteine was removed using a Sephadex G-25 spin column 
(Pharmacia) equilibrated with MES buffer, pH 6.3, to collect Fab’ in crosslinking buffer.  
For IgG2 antibodies, (Fab’)2 from LE digestion was reduced to Fab’ using 1 mM 
β-mercaptoethanol in 20 mM NaH2PO4 pH 8.0 buffer containing 5 mM EDTA at 37°C 
for 1 h.(14, 27) Free β-mercaptoethanol was removed by passing the Fab’ product 
solution twice over a PD-10 column equilibrated in 0.1 M Na2PO4 pH 7.4 buffer 
containing 1 mM EDTA. The purity of the products was confirmed using SDS-PAGE 
(Phastsystem). 
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2.3.8 Preparation and Characterization of PEG-dimerized OV-TL16  
Fab’ was conjugated with MAL-PEG3400-MAL (bismaleimide PEG, MW = 
3,431g/mol, Shearwater) by mixing 30 mg of active Fab’ at a 2.5-molar excess to MAL-
PEG3400-MAL in MES buffer (pH 6.3) at room temperature for 30 h. The PEG linker was 
added in aliquots over a period of 12 h. The progress of the reaction was monitored every 
few hours by SEC (Superdex 200, analytical FPLC column). In the final reaction mixture, 
measured by SEC, peak area indicated yields typically 35-45% Fab’-PEG-Fab’, 50-60% 
Fab’-PEG, with 2-5% free Fab’ remaining. (Figure 2.10) Monosubstituted Fab’-PEG and 
dimerized OV-TL16 Fab’-PEG-Fab’ were separated and purified using 2 rounds of SEC 
(Superdex 75 column, preparative FPLC system). One ml fractions were collected during 
SEC, pooled as shown in Figure 2.11., and product purity was determined by SDS-
PAGE. The identity of the products was assigned by SEC retention time and SDS-PAGE 
migration distance. Fractions containing pure dimerized Fab’-PEG-Fab’ were pooled and 
concentrated using ultrafiltration (Amicon). The final yield after all purifications steps 
was typically 20-40%. The final product was then used for binding kinetic analysis, and 
in vitro cell uptake analysis. 
 
2.3.9 Preparation and Characterization of Bispecific  
(Fab’OV-TL16)-PEG-(Fab’anti-EGFR) 
Bispecific (Fab’OV-TL16)-PEG-(Fab’anti-EGFR) was synthesized using Fab’ fragments 
from OV-TL16 and anti-EGFR antibodies. The final method reacted freshly reduced OV-
TL16 Fab’ with a 5-fold molar excess of VS-PEG5000-VS (bisvinyl sulfone PEG, MW = 
5048 Da, Shearwater/Nektar) in phosphate buffer, pH 8.3, for 3 h. Monosubstituted Fab’-
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PEG was then purified by SEC (Superose 12) to remove the unreacted PEG crosslinker 
and any unreacted Fab’OV-TL16. The isolated fractions pooled, concentrated and then 
exchanged with phosphate buffer, pH 8.7 by ultrafiltration (Amicon). Freshly reduced 
anti-EGFR Fab’ was then added to monosubstituted Fab’-PEG. The reaction solution was 
divided in two equal halves:  in one a 3-fold molar excess of anti-EGFR Fab’ was added, 
in the other, a 2-fold excess was added. In both cases, roughly equivalent amounts of 
bispecific (Fab’OV-TL16)-PEG-(Fab’anti-EGFR) was produced. After two rounds of SEC 
purification, approximately 1 mg of product was obtained. Product identity and purity 
was confirmed by SEC retention time, SDS-PAGE, and by mass spectroscopy (MALDI-
TOF). 
 
2.3.10 Binding Constant Determination 
By the method described previously (1), OV-TL16 Fab’-PEG-Fab’ and OV-TL16 
Ab were radiolabeled with 125I using the Iodo-gen iodination reagent (Pierce). Known 
concentrations of 125I-Fab’-PEG-Fab’ and 125I-OV-TL16 IgG were incubated with 106 
suspended OVCAR-3 cells for 6 h at 4°C. The cells were then pelleted and 
concentrations of bound and free construct/antibody in the pellet and supernatant were 
calculated using a scintillation counter. Scatchard plot analysis was then used to 
determine their binding kinetics. Binding data was plotted using Prism 7 software. 
Isotherm data were used to determine dissociation constants and standard errors using 




2.3.11 Determination of Fab’-PEG-Fab’ Uptake by Confocal Microscopy 
2.3.11.1 Fluorescent Labeling 
 Approximately 1 mg each of homospecific OV-TL16 Fab’-PEG-Fab’ and OV-
TL16 IgG were FITC-labeled using the Alexa Fluor 488 Protein labeling kit (Molecular 
Probes) (28). Approximately 500 µg of Fab’OV-TL16-PEG-Fab’anti-EGFR and 1 mg of anti-
EGFR IgG were fluorescently labeled using Texas Red using the Texas Red Protein 
Labeling kit (Molecular Probes) to produce “(Fab’OV-TL16)-PEG-(Fab’anti-EGFR)–TR” and 
“anti-EGFR-TR”.  
 
2.3.11.2 Uptake of Homospecific OV-TL16 Fab’-PEG-Fab’ 
OVCAR-3 cells seeded on glass coverslips were incubated using RPMI media 
containing 10 µg/ml of FITC-labeled Fab’-PEG-Fab’ or OV-TL16 (37°C). At 1, 4 and 24 
h, slide samples were washed with PBS and fixed with paraformaldehyde. The slides 
were then mounted and examined using laser scanning confocal microscopy (Zeiss) at 
100x magnification. For fluorescence measurements, an excitation wavelength of 488 nm 
was used and a long pass filter cutoff wavelength of 505 nm was used for detection. 
 
2.3.11.3 Uptake of Bispecific (Fab’OV-TL16)-PEG-(Fab’anti-EGFR) 
OVCAR-3 cells mounted on coverslips were incubated in RPMI media containing 
1µg/ml bispecific (Fab’OV-TL16)-PEG-(Fab’anti-EGFR)-TR, OV-TL16-FITC, or anti-EGFR-
TR at 37°C for up to 24 h. At times 1, 3, 5, and 24 h, samples from each incubation series 
were fixed with paraformaldehyde and mounted on slides. The slides were then examined 
by confocal microscopy using fluorescence filters appropriate to each of the labels used. 
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2.4 Results and Discussion 
 
2.4.1 Preparation of (Fab’)2 from IgG2a Antibodies 
The use of IgG2a monoclonal antibodies for this study required the development 
of a new method of (Fab’)2 preparation to provide sufficient quantities for synthetic-scale 
conjugation chemistry. Traditional pepsin digestion of IgG2a subtype antibodies typically 
results in undigested whole IgG2a, and overdigestion, producing free Fab fragments LE 
digestion of the three monoclonal IgG2a antibodies, was shown to produce similar 
cleavage products. The optimal molar ratio of LE to IgG2a was 500:1 for anti-P-gp and 
anti-fluorescyl-IgG2a (BDC1 and 4-4-20). The identity of the two peaks, 100 and 50 
kDa, was confirmed by SDS-PAGE as the (Fab’)2 and Fc fragments, respectively.  
The new method used protein G affinity chromatography after LE proteolytic 
cleavage of IgG2a (12). This allows for purification of (Fab’)2, in a single step, rather 
than the multiple steps previously used, which involved protein A affinity 
chromatography and size exclusion chromatography. This separation procedure took 
advantage of the differing avidities of IgG2a, (Fab’)2, and Fc for Protein G, and allows 
separation and purification of the individual components by use of changes in the 
pH/ionic strength of the chromatographic mobile phase.  
To prevent enzymatic damage to the (Fab’)2 fragment, and to the protein G 
column itself, 200 mM L-lysine in buffer A was required to fully elute LE from the 
column during the washing procedure. To ensure this during method development, 
enzyme activity was monitored using a fluorogenic substrate for LE. The (Fab’)2 was 
stable for at least 8 months, once residual LE activity was eliminated  
Following digestion with LE, isolation of both the Fc and (Fab’)2 fragments from 
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the Protein G column resulted in a highly purified and concentrated preparation, as 
assessed by SDS-PAGE. This procedure for IgG2a allowed for a simpler procedure for 
isolation of the (Fab’)2 fragment, and produced much higher yields compared to (Fab’)2 
purified after pepsin digestion.  
The anti-P-gp antibody proved to be difficult to work with due to its structural and 
colloidal stability. SDS-PAGE analysis of the UIC2 IgG2a and it (Fab’)2 fragments 
frequently showed smeared bands, perhaps indicating heterogeneity due to post-
translational modifications or degradation (Figure 2.10.). The lane with the U1C2 (Fab’)2 
product was typically monodisperse, but doubt still remained about the stability of the 
UIC2 IgG2a. After ensuring that the procedure was not damaging the protein by LE 
overdigestion or other conditions in the procedures, the same protocol was repeated using 
the BDC1 anti-fluorescyl IgG2a. Figure 2.11. shows the resulting SDS-PAGE analysis, 
and whole IgG2a, Fc, and (Fab’)2 proteins are in sharp bands. This was done to ensure 
that the protocol used was applicable for typical IgG2a antibodies and that remaining 
problems with U1C2 Fab’ fragments and with conjugation chemistries were issues 
derived from the choice of anti-P-gp monoclonal antibody.  
 
2.4.2 Dimerization of OV-TL16 Fab’ 
2.4.2.1 Purification and Characterization 
Conjugation reactions of Fab’ with the MAL-PEG-MAL linker typically yielded a 
mixture of 30% Fab’-PEG-Fab’, 50% Fab’-PEG and 20% unconjugated Fab’. As shown 
by the size-exclusion chromatography profile in Figure 2.12., these synthetic yields 
compare favorably to early Fab’ dimerization experiments using low molecular weight 
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linkers, which typically ranged from 5 to 10% (6). Two rounds of purification using 
preparative SEC were required to separate Fab’-PEG from dimerized Fab’-PEG-Fab’ 
(Figure 2.13.). The purity of isolated Fab’-PEG-Fab’ dimer was confirmed using 
analytical SEC (Figure 2.13. C) and by SDS-PAGE (data not shown). In later 
experiments dimerizing OV-TL16 Fab’ using Shearwater’s MAL-PEG-MAL crosslinker, 
yields of Fab’-PEG-Fab’ over 50% were typical. 
 
2.4.2.2 Determination of Binding Constants  
The Scatchard plot dissociation constant determinations of the OV-TL16 Fab’-
PEG-Fab’ construct, as shown in Figure 2.14., indicated an overall binding affinity to 
CD44/OA3 on OVCAR-3 cells of KD=20 nM. This was somewhat lower than that of 
unmodified OV-TL16 antibody (2.0 nM), but significantly higher than that of monomeric 
OV-TL16 Fab’ (83 nM). Furthermore, the Scatchard plot of the construct is biphasic, 
with a low affinity component (30 nM), and a high affinity component (5 nM) that was 
comparable to that of the unmodified antibody (Table 2.1). The biphasic kinetic results 
for the construct may be the result of binding to two different types of surface receptor 
antigens on OVCAR-3, or may represent two modes of construct binding to cell surface 
antigens. This may be an effect of the extended PEG linker since the two Fab’ fragment 
can either bind independently or cooperatively, depending on the relative concentration 
of Fab’ vs. CD44/OA3 antigens on the cells. 
As reported in 2013, Khali et al. created monospecific PEG linked Fab’ fragments 
derived from the commercially available therapeutic mAbs bevacizumab (anti-VEGF) 
and trastuzumab (anti-HER2), as well as the therapeutic Fab fragment ranibizumab (anti-
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VEGF). (29, 30) PEG linkers of 6, 10, and 20 kDa were used for each. Using plasmon 
surface resonance to measure binding kinetics, they found that, although the conjugates 
had lower KD and ka constants, the measured kd values were approximately 5-fold higher 
than the kd values of the unmodified antibody proteins. In vitro assays of the activity of 
the anti-VEGF constructs revealed antiangiogenic activities comparable to or better than 
whole bevacizumab IgG. These results are consistent with the results found for the Fab’-
PEG-Fab’ construct in this study. 
 
2.4.2.3 Uptake of Homospecific OV-TL 16 Fab’-PEG-Fab’ by Live Cells 
In Figure 2.15., the results of the confocal imaging show the binding of the OV-
TL16 Fab’-PEG-Fab’ construct and the OV-TL16 antibody to the plasma membrane via 
cell surface receptors, and showed the presence of each internalized by the cells. The 
distribution of fluorescence showed high concentrations of antibody/construct in the 
lysosomes after incubation times of 1 and 4 h. At t=24 h, most of the fluorescence 
intensity appeared to be distributed throughout the cytosol of the cells. This observation 
can be best explained by initial endocytosis of the antibody/construct followed by release 
of free label into the cytosol as the proteins are degraded in the lysosomal compartment. 
In the images shown, the relative concentration of internalized OV-TL16 Fab’-PEG-Fab’ 
in the cells was significantly greater at 1 h. At 4 h, the apparent concentration of 
internalized antibody appeared approximately the same. Based on fluorescence intensity 
and flow cytometry (data not shown), the relative concentration of surface bound 
antibody was about twice that of Fab’-PEG-Fab’ at all incubation times measured. 
OV-TL16 has been shown to recognize the CD44/OA3 receptor and to be 
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internalized rapidly by OVCAR-3 cells via receptor-mediated endocytosis. These results 
indicated that the chemical modifications used to create the Fab’/PEG construct do not 
interfere with this process and that internalization is actually enhanced somewhat 
compared to the native antibody. 
 
2.4.3 Bispecific Fab’OV-TL16-PEG-Fab’anti-EGFR (preliminary) 
2.4.3.1 Characterization 
After the crosslinking with VS-PEG5000-VS, the identity of the Fab’OV-TL16-PEG-
Fab’anti-EGFR construct was confirmed by SEC retention time, SDS-PAGE, and by 
MALDI-TOF spectroscopy. In MALDI-TOF spectra, the bispecific Fab’-PEG-Fab’ 
construct was indicated by a peak centered around 102 kDa with a double ion peak at 54 
kDa. A small extra peak at 59 kDa is likely the result of a contaminating, doubly 
conjugated Fab’ fragment (Fab’-(PEG)2). Although purified (Fab’OV-TL16)-PEG-(Fab’anti-
EGFR) was obtained and isolated in this experiment, the total yield was very low (3%).  
 
2.4.3.2 Fluorescent Confocal Microscopy 
Comprehensive kinetic and cell uptake experiments were limited due to the 
unavailability of a cell line that expressed both CD44/OA3 and EGFR. Uptake of OV-
TL16 mAb by CD44+ OVCAR-3 showed roughly the same pattern of punctate internal 
distribution and rate of internalization as seen previously for homospecific OV-TL16 
Fab’-PEG-Fab’. Since OVCAR-3 cells do not overexpress EGFR, the intensity of anti-
EGFR-TR seen in the cells was relatively low even at 24 h, although significantly higher 
than the background autofluorescence. The type of intracellular distribution was the same 
type of punctate seen for OV-TL16. In the cells incubated with bispecific (Fab’OV-TL16)-
 74 
PEG-(Fab’anti-EGFR), the distribution of intracellular staining is the same and the 
concentration of conjugate was significantly higher than that seen using anti-EGFR-TR. 
 
2.5 Conclusion 
The goal of this body of work described in this chapter was to investigate the 
utility of PEG dimerized antibody Fab’ fragments for the selective targeting of cancer 
cells. Initial experiment found that OV-TL16 anti-CD44/OA3 Fab’ fragments could be 
dimerized with maleimide-terminating PEGs at high yields and could be readily purified. 
The binding constants measured for OV-TL16 Fab’-PEG-Fab’ was found to be biphasic 
and only moderately lower than that of the modified OV-TL16 IgG1. These conjugates 
were also found to be readily endocytosed by cultured ovarian carcinoma cells at 
concentrations and rates higher than unmodified IgG. Several attempts made to 
synthesize homospecific Fab’-PEG-Fab’ using VS-PEG-VS and OV-TL16 and anti-
EGFR Fab’, however, produced yields that were insufficient for further study. 
Difficulties generating high yields of stable UIC2 anti-P-pg Fab’ fragments 
spurred the development of a novel and efficient method to produce highly purified Fab’ 
fragments from IgG2a subtype antibodies. However, numerous subsequent attempts 
remained unsuccessful in creating stable Fab’-PEG-Fab’ conjugates from the UIC2 
hybridoma antibodies. The isolation of antifluorescein IgG2a type Fab’ fragments from 
BDC1 and 4-4-2 hybridomas revealed that the difficulties with the UIC2 antibodies were 
particularly problematic for that hybridoma’s antibodies. However, aggregation and 
crosslinking side products were a problem with the anti-HER2 and anti-EGFR 
monoclonal antibodies also. 
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Bispecific Fab’-PEG-Fab’ conjugates were successfully produced using vinyl 
sulfone-terminated PEGs using IgG1 subtype mAbs, though at relatively low yields 
(~20%). Full characterization of these conjugates, however, was not feasible (at the time) 
due to the lack of availability of carcinoma cell lines that presented the CD44/OA3 tumor 
marker, while also over-expressing either EGFR or HER-2 receptor proteins. 
The successful site-specific dimerization of OV-TL16 Fab’ fragments showed the 
possible advantages of using chemical conjugation for antibody-based targeting. High 
binding kinetics to cell surface receptors, and high endocytic uptake rates for CD44/OA3 
cells, indicated that the extended linker in the Fab’-PEG-Fab’ construct resulted in 
kinetics at least equivalent to the unmodified OV-TL16 IgG antibody. It can be 
concluded that the chemical reactions to produce Fab’ fragments and the crosslinking 
reactions did not damage the antigen binding activity of the fragments. Difficulty in 
reproducing these results for the other mAbs indicated the need to develop better 
techniques of antibody production, purification and storage, as well as new conjugation 
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Figure 2.1. Depictions of the basic structure of the IgG protein. Lower half 
illustrates the differences in disulfide bridging between IgG1 and IgG2 isotype 
antibodies. (Adapted from Klein JS, Bjorkman PJ (2010) Few and far between: How 




Figure 2.2. General structure of IgG1 antibody. Points of susceptibility in the hinge 
region to pepsin and papain are shown. Image adapted from ThermoFisher instruction 
manual for pepsin and papain. 
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Figure 2.3. General scheme to produce Fab’ fragments from IgG antibodies 
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Figure 2.4. Two types of thiol-specific PEG crosslinkers used in study. Top 
frame:  bismaleimide functionalized PEG crosslinking. Bottom frame:  bisvinyl 
sulfone PEG crosslinking  
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Figure 2.5. General method to dimerize homospecific Fab’ fragments using a 
bismaleimide PEG crosslinker 
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Figure 2.6. General method to dimerize bispecific Fab’ fragments using a 




Figure 2.7. Scheme to produce hemitrifunctional linker for Fab’ dimerization using 


















































Figure 2.9. General structure for proposed HPMA drug conjugates targeted with 
bispecific Fab’-PEG-Fab’  
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Figure 2.10.  SDS-PAGE analysis of: (A) anti-P-gp IgG2a, (B) the digestion mixture 
of anti-P-gp IgG2a, (C) purified Fc fragment, (D) purified anti-P-gp (Fab’)2 fragment, 
(E) molecular weight ladder 
 
Figure 2.11.  SDS-PAGE analysis of: (A) anti-fluorescyl BDC1 IgG2a,  






Figure 2.12. Analytical size exclusion chromatography (SEC Superdex 200) profile  
of OV-TL 16 Fab’ conjugation reaction with MAL-PEG3400-MAL crosslinker 
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Figure 2.13.   Size exclusion chromatography profiles for the purification of dimerized  
OV-TL 16 Fab’-PEG-Fab’. Profiles of the first and second rounds of preparative SEC are 
shown in panes A and B, respectively. Analytical SEC profiles of the indicated pooled 
fractions, “a” and “b”, from the 2nd round of purification are shown in panes C and D, 




A round 1 
Fab’-PEG-Fab’ 
C fraction a 
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Figure 2.14. Scatchard plot analysis of OV-TL16 Fab’-PEG-Fab’ binding kinetics to 




Table 2.1. Summary of results of Scatchard analysis of OV-TL16 IgG, Fab’, and Fab’-




KD,ave (nM) KD,high (nM) KD,low (nM) 
Fab'-PEG-Fab' 20±3 5.4.±0.6 30±2 
IgG 2.0±0.2 N/A N/A 




OV-TL16-FITC IgG1 OV-TL16 Fab’-PEG-Fab’-FITC 
Figure 2.15. Results of confocal microscopy of OVCAR-3 cells incubated with Fab’-








SEMITELECHELIC HPMA COPOLYMERS FUNCTIONALIZED WITH 
TRIPHENYLPHOSPHONIUM AS DRUG CARRIERS  




Semitelechelic HPMA (N-(2-hydroxypropyl)methacrylamide) copolymers 
possessing a single terminal lipophilic triphenylphosphonium (TPP) cation and 
fluorescent labels were synthesized to determine how the attached cation affected cellular 
uptake and intracellular trafficking. In vitro mitochondrial uptake fluorescence quenching 
assays using isolated mouse liver mitochondria indicated that only lower molecular 
weight (<5 kDa) BODIPY® FL-labeled TPP-semitelechelic HPMA copolymers exhibited 
significant organelle localization or uptake. In vitro cellular uptake and intracellular 
trafficking was evaluated using cultured human ovarian carcinoma cells. Cells incubated 
with all types of TPP copolymers used in the study appeared to internalize the polymer 
by endocytosis only and all internalized copolymer was confined to the lysosomal 
                                                 
1 This chapter is adapted with permission from: J. Callahan and J Kopeček. Semitelechelic HPMA 
Copolymers Functionalized with Triphenylphosphonium as Drug Carriers for Membrane Transduction and 




compartment after 24 h. Endocytotic uptake of the TPP-HPMA copolymer conjugates 
was rapid, suggesting that they were internalized by adsorptive endocytosis, rather than 
fluid-phase pinocytosis. Semitelechelic copolymers microinjected into cultured cells 
indicated that the TPP moiety did not significantly localize the polymers to mitochondria. 
 
3.2 Introduction 
Synthetic polymers, such as HPMA copolymers, have been shown in recent years 
to be versatile tools to improve the efficacy of a wide array of conventional low-
molecular weight drugs. When applied to the treatment of cancer, for example, polymeric 
carriers of anticancer drugs have been used to greatly enhance the biocompatibility, 
pharmacokinetics (1), nonimmunogenicity (2), and targetability (3-7) of these agents, 
while reducing their toxicity toward normal cells. 
Because macromolecular therapeutics (polymer-drug conjugates) are not as freely 
diffusible as low molecular weight (LMW) drugs, their transport and biodistribution 
differ markedly from free drugs. Intravascular half-life, for instance, is greatly 
lengthened, particularly for polymer conjugates larger than the glomerular filtration cut-
off. Drug concentrations in tumor tissue are increased due to the EPR (enhanced 
permeability and retention) effect as the result of high rates of leakage from the 
neovasculature of tumor tissue. Typically, cell uptake has been shown to occur via 
endocytosis, whereby high molecular weight molecules are typically trafficked to the 
lysosomal compartment, where nondegradable compounds remain. Drug activity in this 
case typically requires release of the drug from the carrier via hydrolyzable bonds. 
Obstacles that reduce the amount of drug delivered to target cells are created by the rate 
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of cellular internalization and/or lysosomal release. Efficacy is further limited by the 
problem of trafficking of bioactive agents to the subcellular compartment where the 
target’s active site is located. 
Plasma membrane transduction and delivery to the cytosol of synthetic polymers 
and biopolymers (such as nucleic acids) has recently been explored using cationic 
oligopeptides or CPPs (cell penetrating peptides). The CPP Tat peptide from the HIV-1 
Tat protein has been used to deliver HPMA copolymers to the cytosol of cultured cells (8, 
9). Both ANTP peptides from the antennapedia protein and Tat have been used to deliver 
antisense PNAs to the cytosol and nucleus to inhibit gene expression (10, 11).  
Once macromolecules are delivered to the cytosol, several methods have been 
employed to traffic them to specific subcellular compartments such as the nucleus and 
mitochondria. Targeting constructs to affect nuclear and mitochondria targeting of 
synthetic and biological polymers have included nuclear targeting sequence (NLS) (12-
18) and mitochondrial targeting sequence (MLS) (19, 20) peptide, respectively. In both 
cases, the peptide sequences take advantage of the endogenous nuclear or mitochondrial 
import machinery to deliver a conjugated, high-molecular weight cargo. 
Nonpeptidic cationic functional groups have also been used as targeting moieties 
to penetrate the plasma membrane and to traffic conjugates to the mitochondrial 
compartment. These include rhodamine-123 (21, 22), oligoguanidinium (21, 23), and 
triphenylphosphonium (22-27). Notably, the experiments of Murphy et al. used 
terminally functionalized TPP to target antisense PNA into the mitochondria of isolated 
organelles and whole intact cells in vitro (28, 29). It was determined that TPP-PNA 
conjugates as large as 4 kDa were directly transduced through the plasma membrane, 
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trafficked through the cytosol, and passed through the inner and outer membranes of 
mitochondria in high concentrations. 
Here, we have tested whether the lipophilic cationic moiety 
triphenylphosphonium (TPP) can be used to also traffic HPMA copolymer conjugates to 
the mitochondria of target cells. Semitelechelic HPMA polymers were synthesized using 
a thiol chain transfer agent containing TPP, thereby creating low-molecular weight 
polymers possessing single cation fixed on one terminus of the final polymer (TPP-
HPMA) (30). Semitelechelic copolymers were then created using methacroylylated 
monomers containing either fluorescein or BODIPY® FL (4,4-difluoro-5,7-dimethyl-4-
bora-3a,4a-diaza-s-indacene) to act as drug models and to allow for microscopic 
visualization of the polymers (Figure 3.1.). Cell uptake and intracellular trafficking of the 
copolymers was then characterized using cultured human ovarian carcinoma cells. 
Ultimately, the ability to deliver macromolecular carriers to the cytoplasm with 
high efficiency and to control their intracellular trafficking will greatly widen the 
application and improve the efficacy of many drugs. This approach and 
internalization/intracellular trafficking model can be contrasted with the use of the 
polycationic polymer PEI (polyethyleneimine) to transport nucleic acids to the cytoplasm 
and, subsequently, the nucleus (31).  
Mitochondrion malfunction is associated with many aspects of neuron 
degeneration, cancer, and aging (32). Mitochondria-targeting drug carriers could be used 
as effective vectors for anticancer drugs, as well as other drugs, that affect mitochondrion 




3.3.1 Materials  
Chemicals and solvents used were of reagent grade or better unless otherwise 
stated. Before syntheses, 4-bromo-1-butene (Sigma) and thiolacetic acid (Sigma) were 
freshly distilled under N2. Triphenylphosphine (TPP, Sigma) was recrystallized from 
95% ethanol. Diethyl ether was dried over CaCl2 and stored over Na metal. Toluene was 
washed with 1/10 vol. cold concentrated H2SO4, then dried over CaCl2 and stored over 
Na. 
Nontelechelic copolymers of HPMA and methacryloylated fluorescein (MA-
FITC) monomer were used as control and were prepared as described by Minko et al. 
previously (33). These HPMA-FITC copolymers were fractionated using size-exclusion 
chromatography to produce polymers of a narrow polydispersity. 
 
3.3.2 Synthesis of the Chain Transfer Agent 
Thiobutyltriphenylphosphonium Bromide  
Following the protocol by Burns et al., the thiol TBTP was generated by first 
synthesizing acylated TBTP (34). TBTP with a free thiol was generated as needed by 
removing the acyl protecting group using base hydrolysis. (Figure 3.2.) 
 
3.3.2.1 Synthesis of 4-Bromobutylthiolacetate (BBTA)  
The precursor 4-bromobutylthiolacetate, was synthesized by reacting 36 mmol 
(2.8 g) of thiolacetic acid with 18 mmol (2.5 g) of 4-bromo-1-butene with 3.3 mg of 
AIBN (2, 2'-azobis-isobutyronitrile) at 40°C for 60 min under nitrogen (Figure 3.2.). 
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Water was removed from thiolacetic acid by distilling the liquid with phosphorous 
pentoxide. The crude product was extracted into CHCl3, washed 3x with distilled H2O, 
and dried overnight using MgSO4. The solvent was then removed under vacuum and 
BBTA was purified by alumina chromatography using CHCl3 as the mobile phase. The 
identity of BBTA was confirmed by TLC in CHCl3, ESI-MS (electrospray ionization 
mass spectroscopy; m/z = 210.8), and 1H NMR. The yield was 4.0 g (75%). 
 
3.3.2.2 Acylated Thiolbutyltriphenylphosphonium Bromide (aTBTP)  
Acylated thiolbutyltriphenylphosphonium bromide was synthesized by refluxing 
4-bromobutyl thiolacetate (10.1 mmol, 1.5 ml) with triphenylphosphine (10.1 mmol, 2.7 
g) in dry toluene (8 ml) for 2 h under nitrogen (Figure 3.2.). After cooling, the product 
was obtained as a viscous yellow liquid under a layer of toluene and white precipitate. 
The bottom solvent layer was washed with pentane followed by dry diethyl ether and 
dried under vacuum. Product identity and yield was determined using 1H-NMR, ESI MS 
and UV absorption spectra (Lambda 9 Perkin-Elmer spectrophotometer). The yield of 
acyl-protected TBTP was 1.1 g or 22%. 
 
3.3.2.3 Thiobutyltriphenylphosphonium Bromide (TBTP)  
 Thiobutyltriphenylphosphonium bromide, the deprotected mercaptan used as a 
chain-transfer agent (Figure 3.2.), was prepared using a procedure modified from Burns 
et al. (34). Acylated TBTP was first dissolved in 95% ethanol. Then, 0.1 M NaOH was 
added and the solution was bubbled with argon for between 15 and 25 min. The solution 
was then neutralized by the addition of 90 mM HEPES buffer (pH 4.0). The solution 
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containing TBTP thiol was then added directly to the polymerization reactions. 
 
3.3.3 Triphenylphosphonium-BODIPY® FL  
As a control for the BODIPY-labeled HPMA copolymers in the isolated 
mitochondria assay, TBTP was conjugated to BODIPY® FL N-(2-aminoethyl) maleimide 
(Molecular Probes), as shown in Figure 3.3. Activated thiol TBTP was generated from 
acylated TBTP as described above immediately before the conjugation reaction. In a 
glass vial, 5.7 mg (12.1 μmol) of acylated TBTP was first deprotected by base hydrolysis 
and the activated thiol solution was then added to a solution of 4.5 mg (11.0 μmol) 
BODIPY FL N-(2-aminoethyl)maleimide dissolved in 1 ml of 1:1 DMF:H2O and left 
stirring at room temperature overnight. The reaction mixture was then dried by 
rotoevaporation. 
 The TPP-BODIPY conjugate was purified by preparative reverse-phase HPLC, 
using an analytical C18 RP column with UV (220 nm) and fluorescence detection (ex/em 
480/518 nm). The column was run using a linear solvent gradient and solvent system 
consisting of buffer A = acetonitrile with 0.1% TFA, and buffer B = 0.1% TFA. The 
gradient was started at 30%/70% A/B and ended at 80%/20% A/B over 25 min. Fractions 
collected during the main elution absorbance/fluorescence peak were pooled and dried by 
rotoevaporation. A MALDI-TOF MS analysis of the purified product showed a single 
main product with a mass of 765.2, compared to 765 for the M+1 of the expected TPP-




3.3.4 MA-GG-BODIPY® FL Monomer 
Monomer incorporating the BODIPY® FL fluorescent dye was synthesized by 
reacting (11.3 mg, 3.0 nmol) of BODIPY® FL EDA (Molecular Probes) with MA- GG-
ONp(35) (11.8 mg, 3.7 nmol) and a 1.2 molar excess (3.7 nmol) of N,N-
diisopropylethylamine (DIPEA) in DMF (Figure 3.4.). After stirring for 4 h at room 
temperature, the product was purified on an LH-20 column and the fractions containing 
the product were pooled, dried, resuspended in water, and freeze-dried. The final yield of 
the bright orange product was 15.3 mg or 97% theoretical yield. ESI mass spectroscopy 
confirmed the product at mass 517 (M+1, m/z). 1H NMR (400 MHz, d6-DMSO) δ 8.24-
7.84 (m, 4H, -NH-), 7.64-6.29 (m, 4H, Ar-H), 5.74 (s, 1H, - C=CH2), 5.37 (s, 1H, -
C=CH2), 3.76-3.65 (m, 4H, CO-CH2-NH), 3.45-3.10 (m, 8H, -CH2-CH2-), 2.46 (s, 3H, 
Ar-CH3), 2.25 (s, 3H, Ar-CH3), 1.87 (s, 3H, CH3-C=CH2) 
 
3.3.5 Semitelechelic HPMA Polymers: Synthesis and Characterization  
Semitelechelic HPMA polymers possessing triphenylphosphonium as a terminal 
functional group were synthesized by free radical polymerization using TBTP as a chain 
transfer agent. All reactions used AIBN as the initiator. Ratios of initiator, monomers, 
and chain transfer agent used for the polymerization of semitelechelic polymers were 
roughly based on those used by Oupický et al. (36). In general, all polymerization 
reactions were performed with 0.8 M HPMA, 3x10-3 M AIBN and TBTP chain transfer 
agent concentrations ranging from 1x10-3 to 5x10-2 M. If fluorophore containing 
comonomers were included for the synthesis of copolymers, mole%s ranging from 0.5 to 
5.0 were used, as stated below. 
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Reactions were typically performed at a scale of 1 ml. Before each reaction, the 
protecting acyl group of the chain transfer agent TBTP was removed to produce the free 
thiol, as described above.(34, 37) Methanol was used to dissolve all other reactants of the 
polymerization. After mixing, the reactant solution was bubbled with argon and sealed in 
a glass ampule. Polymerization reactions were done at 50°C for 24 h. When complete, the 
solutions were diluted 10x with distilled water and then dialyzed extensively against 
water using tubing with a molecular weight cut-off (MWCO) of 1 kDa for polymers 
ranging below 5 kDa, and a MWCO of 2 kDa for polymers ranging above 5 kDa. The 
samples were then freeze-dried to isolate the finished solid product. 
 
3.3.6 Octanol : H2O Partition Coefficient Determinations 
Approximately 1 mg of fluorescently-labeled HPMA copolymer was first 
dissolved in 500 μl of PBS (pH 7.4) in a 1.7 ml tube. An equal volume (500 μl) of 1-
octanol was aliquotted to the tube and the sealed tube was mixed by shaking for at least 1 
h. The tubes were then centrifuged at high speed for 1 min. The octanol layer was then 
removed and the concentration in each fraction was determined by fluorescent 
spectrophometry (ex/em = 480/518 nm; in/out slit widths = 10 nm). For this, standard 
curves of each polymer were created using both octanol-saturated PBS and PBS-saturated 
octanol. 
 
3.3.7 Size-exclusion Chromatography  
Size-exclusion chromatography (SEC) was used to determine the molecular 
weight distribution of the polymers. All samples were run on a Pharmacia FPLC System 
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equipped with UV and differential refractive index detectors (ÄKTA, Pharmacia) using 
either a Superdex 75 or Superose 6 HR10/30 analytical column in PBS (pH 7.3) 
calibrated with polyHPMA standards of a narrow polydispersity (Mw/Mn <1.1). 
 
3.3.8 Mass Spectrometry  
MALDI TOF mass spectra were determined using a Voyager-DETM STR 
Biospectrometry Workstation (Perseptive Biosystems, Framingham, MA). Polymer 
samples were spotted for analysis using a dried-droplet method. For each sample, ~1 mg 
of polymer sample was first dissolved in 400 μl of 50:50 water:acetonitrile/0.1% TFA 
solution. Fresh saturated solution of matrix material in the solvent system of 50:50 
water:acetonitrile and 0.1% TFA solution was prepared by thoroughly mixing the matrix 
powder of either HABA (2,4-hydroxy-3,5-dimethoxyphenyl)acrylic acid) or sinapinic 
acid with 1 ml of solvent in a 1.7 ml tube, and then centrifuged to pellet the undissolved 
matrix. Then 5.0 μl of the supernatant matrix solution in a small plastic tube was taken 
and mixed thoroughly for a few seconds in a vortex mixer with the 5.0 μl of polymer 
sample. A 0.5-2 μl droplet of the resulting mixture was placed on the mass spectrometer’s 
sample stage then the droplet was dried at room temperature. 
 
3.3.9 TPP-HPMA-FITC Copolymers  
Preliminary polymerizations were performed to characterize fluorescently labeled 
TPP-HPMA polymers. Initial copolymerizations used 0.5 mole% (4 mM) 
methacryloylated fluorescein (MA-FITC) monomer (38). In general, two different 
conditions were used consisting of either 7.5 or 12.5 mM TBTP chain transfer agent and 
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the same comonomer concentrations described for TPP-HPMA polymers above. During 
dialysis, the samples were centrifuged to remove precipitate that formed due to the high 
concentrations of MA-FITC and TBTP in the aqueous solution. 
The molecular weights of the polymers were characterized by SEC using an 
analytical Superose 6 HR10/30 FPLC column. Due to the high polydispersity of the TPP-
HPMA-FITC copolymers, they were further fractionated using a preparative Superdex 75 
(HR16/60) column by FPLC. Fractions from the SEC column were subsequently pooled 
into 6 separate cohorts. These were then dialyzed extensively against water and freeze 
dried. The molecular weight distribution of each polymer fraction was then analyzed 
using SEC (Superose 6 HR10/30)) and MALDI-TOF MS. 
 
3.3.10 TPP-HPMA-BODIPY® FL Copolymers 
Semitelechelic polymers incorporating BODIPY monomer were synthesized 
using MA-GG-BODIPY® FL monomer and TBTP as a chain transfer agent and the 
general conditions described above. Copolymers with higher molecular weights (between 
8 to 12 kDa) were produced using a TBTP concentration of 10 mM and a 0.1 mole% 
MA-GG-BODIPY® FL comonomer feed concentration. Low molecular weight 
copolymers were generated using either 0.5 mole% (4 mM) MA-GG-BODIPY® FL with 
40 mM TBTP, or 1.0 mole% (8 mM) MA-GG-BODIPY® FL with 10 mM TBTP. Due to 
the low polydispersity of the BODIPY® FL-labeled polymers, no further purification or 




3.3.11 Polymers for Uptake and Localization Experiments  
The semitelechelic polymers, synthesized to characterize mitochondrial and 
cellular uptake, were designed to test a range of parameters considered important to the 
mechanism of action of the cationic TPP moiety. In studies using TPP to enhance the 
uptake and localization of PNA the criteria cited to ensure activity were a molecular 
weight less than 4 kDa and a noncharged and relatively nonpolar macromolecular 
conjugate. For this reason, the semitelechelic polymers were synthesized of several types 
to investigate the physical requirements for activity. By varying the concentration of 
CTA used in polymerization, two classes of molecular weight distribution were created: a 
lower molecular weight class from 2-5 kDa, and a higher molecular weight class of 8-12 
kDa. For both classes, semitelechelic copolymers were synthesized using fluorescent 
monomers possessing either fluorescein or BODIPY® FL. A summary of the polymers 
used in uptake and microinjection studies is shown in Table 3.1. 
 
3.3.12 Uptake of TPP-HPMAs by Isolated Mitochondria  
Uptake of the labeled polymers was measured by a fluorescence quenching assay 
using isolated mitochondria. Mouse liver mitochondria were suspended in solutions 
containing fluorescently labeled polymers, and quenching after the activation of 
mitochondrial electropotential was used to determine polymer uptake (39).  
Free mitochondria were isolated from freshly removed mouse liver. For each 
series of experiments, the organ was washed with ~10 ml of isolation buffer (10 mM 
sucrose, 200 mM mannitol, 5 mM HEPES, 1 mM EGTA, 1 mg/ml BSA – pH 7.4). The 
liver was then homogenized using an Ultraturrax homogenizer with an S25N186 shearing 
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head. The liver was homogenized at low speed (8000 rpm) until tissue was dispersed and 
then at high speed (9500 rpm) two times for 15 sec. 
To remove crude tissue debris, the homogenate was centrifuged at low speed (800 
x g) for 10 min. The supernatant was then aliquotted into new tubes and centrifuged at 
high speed (10,000 x g) for 10 min. The pellets were then washed with fresh isolation 
buffer and recentrifuged for 10 min. The pellets were then suspended in ~1 ml of cold 
mitochondria uptake assay buffer (70 mM sucrose, 230 mM mannitol, 3 mM HEPES, 5 
mM KH2PO4, 0.5μM rotenone – pH 7.4). The yield of mitochondria was calculated by 
total protein content using a standard microplate/Coomassie Blue assay. 
An LS-55 luminescence spectrometer (Perkin-Elmer) was used to monitor the 
fluorescence of 2.5 ml sample solutions over time in a stirred sample cell warmed to 
37°C. Polymer concentrations used were typically between 0.1 – 1 μg/ml. Solutions of ~1 
μM MitoTrackerTM CM-H2TMRos (Molecular Probes) and ~10 μg/ml TPP-BODIPY® 
FL were used as controls. Solutions testing unconjugated, free FITC, BODIPY® FL 
EDA, and non-telechelic HPMA-FITC (MW=10 kDa) were also run as controls. To test 
for the effect of bulk polymer on probe fluorescence, solutions containing 10 μg/ml TPP- 
BODIPY® FL and 10 μg/ml unlabeled pHPMA were run also. 
For each incubation and fluorescence measurement, 0.5 mg of mouse liver 
mitochondria in 100 μl of uptake buffer was aliquotted to the glass cuvette. Shortly after, 
100 μl of succinate solution buffered in 5 mM HEPES (pH 7.4) was added to activate the 
mitochondria to a final concentration of 5 mM. Finally, after 1-4 min, the decoupler 
FCCP was aliquotted in 100 μl to a concentration of 0.4 μM (40). 
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3.3.13 Whole Cell Incubation  
Live cell, polymer uptake studies using scanning laser confocal fluorescence 
microscopy (Olympus Flowview with krypton/argon excitation lasers) were performed 
using OVCAR-3 and MDAH2774 ovarian carcinoma cells (ATCC) to determine if 
polymer was internalized and localized to mitochondria. Cells were cultured in media 
supplemented with 10% fetal bovine serum (HyClone Laboratories, Logan, UT) and 10 
μg/ml insulin (HyClone) and 12.5 mM HEPES buffer (pH 7.4) under a humidified 
atmosphere at 37°C. OVCAR-3 cells were grown in RPMI media, and MDAH2774 
ovarian carcinoma cells were grown in Leibovitz L-15 media (Sigma). 
One day prior to each study, 50,000 to 100,000 cells were seeded on no. 1.5 glass-
bottom 14 mm microwell dishes (MatTek Corp., Ashland, MA). For incubations, 2 ml of 
fresh media containing micromolar concentrations of TPP-HPMA polymer was added 
and the cell incubated for up to 24 h. Polymer concentrations were varied from 1 to 10 
μM. However, 2 μM was used in most experiments. To visualize mitochondria, 100 mM 
MitoTrackerTM Orange CM-H2TMRos was added to the media at least 1 h before 
microscopy. In some experiments, MitoTrackerTM was added after the cells had 
incubated with polymer. Before microscopy, the incubation media was replaced with 
fresh media and the cells were observed without ambient polymer to reduce background 
fluorescence. For microscopy, images were collected by combining dual-channel 
fluorescent and transmitted light using z-series slices in 0.2 μm steps. Image data were 





Polymer localization from the cytosol was determined using microinjection. 
Fluorescently-labeled 0.5 mg/ml polymer/PBS solutions were directly introduced into the 
cytosol of plated MDAH2774 cells. Injections were performed using 0.5 μm glass 
needles equipped on an Eppendorf Transjector 5346 pressure injector and fixed to an 
Eppendorf 5171 micromanipulator arm. Pressures used varied from 50 to 200 HPa and 
extra care was taken to inject solutions as far from the cell nuclei as possible to avoid 
traumatizing the cell structure during injection. After injection, the media was replaced 
with fresh media containing 100 nM of MitoTrackerTM. The cells were then observed 
periodically for up to 24 h using laser scanning fluorescence confocal microscopy, as 
described above, to determine copolymer localization. 
 
3.4 Results 
3.4.1 Synthesis and Characterization of Semitelechelic  
TPP-HPMA Copolymers  
In Figure 3.5., the average molecular weights of pHPMAs as a function of CTA 
concentration are summarized. The average molecular weights for two MA-FITC 
copolymers are also shown. There was a strong correlation between CTA concentration 
and the resulting polymer molecular weights.  
When the data of these results are fitted into the Mayo equation (Equation 3.1.) 
(41): 
1/DPn(end ) =1/DPn,o + Cs[S]/[M]                           (Equation 3.1)  
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where: DPn(end) and DPn,0 are the number average degrees of polymerization with and 
without the chain-transfer agent S, respectively, [M] is the monomer concentration, and 
Cs is the chain-transfer constant. If all polymers synthesized using the CTA TBTP are 
semitelechelic, and using the number average molecular weights derived from the SEC 
data, the calculated Cs value was determined to be 0.84. Compared to previous data for 
other thiols used as CTAs, this result indicated that TBTP had a high efficiency of chain-
transfer in the polymerization reaction (42). 
UV-vis spectra of the semitelechelic polymers were determined using 1 mg/ml 
polymer sample solutions in water. The UV-vis spectra of the polymer samples indicated 
the incorporation of the TPP moiety based on its absorption maximum at 262 nm. 
MALDI-TOF mass spectra indicated that approximately 100% of the polymer chains 
possessing a single TPP moiety.  Number average molecular weights of the polymer 
preparations were calculated using a molar absorptivity of ε262nm = 1650 M-1 cm-1. 
MALDI-TOF analyses of all preparations of semitelechelic TPP-HPMA showed a 
single series of molecular weights corresponding with the increments of increasing 
degrees of polymerization. As shown in Figure 3.6., the peak series corresponded well 
algebraically with m/z = 143.1 x n(HPMA) + 349.1 (TBTP), where n is the degree of 
polymerization. For copolymers incorporating MA-FITC, the MALDI spectra typically 
showed two series of peaks: one corresponding to TPP1-(HPMA)n and another consistent 
with the empirical formula: m/z = 143.1 x n (HPMA) + 349.1 (TBTP) + 532 (MA-FITC). 
In Figure 3.7., the MALDI spectrum of SEC-fractionated semitelechelic copolymer 
synthesized using a 1% MA- FITC:HPMA mole ratio is shown. Here, only one peak 
series is evident and the masses correspond to semitelechelic copolymer where every 
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polymer possesses exactly one TBTP moiety and one MA-FITC monomer. The MALDI-
TOF MS of semitelechelic copolymer synthesized with a 1% MA-GG- 
BODIPY®FL:HPMA feed mole ratio and 10 mM TBTP. (Figure 3.8.) Here, there are two 
series of peaks: one corresponding to TPP(1) - (HPMA)n and another consistent with the 
empirical formula: m/z = 143.1n (HPMA) + 349.1 (TBTP) + 517.4 (MA-GG-BODIPY® 
FL) SEC and MALDI-TOF MS analyses of the synthesized copolymers confirmed that 
all labeled polymer chains possessed exactly one TPP moiety and exactly one 
fluorophore pendant group.  
Polymers were produced with narrow molecular weight distributions, which were 
predictably determined by the concentration of chain-transfer agent in the polymerization 
reaction. Overall, the TPP-HPMA copolymers produced for experimentation were 
synthesized within two molecular weight distributions: a lower molecular weight range of 
2-4 kDa, and a higher molecular weight range of 8-16 kDa. When semitelechelic 
copolymers were produced using methacryloylated fluorescein monomer (MA-FITC), the 
average molecular weight of the polymer was found to be somewhat higher than 
predicted from the curve for semitelechelic TPP-HPMA, based on the concentration of 
chain-transfer agent. Before fractionation, the polydispersity of the FITC-labeled 
polymers was significantly higher than those determined for other semitelechelic 
polymers (μ=1.4-1.8). The molecular weights of copolymers using the BODIPY® FL 
monomer MA-GG-BODIPY® FL were significantly lower than that predicted by the 
CTA concentration. In general, typical yields of TPP-HPMA were 25%, TPP-HPMA- 
FITC 10%, and TPP-HPMA-BODIPY® FL only 1%. 
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3.4.2 Partition Coefficients  
The relative hydrophobicities of native pHPMA and semitelechelic TPP-HPMAs 
were found to range in values near those reported for PNAs.(43) The octanol:water 
partition coefficients determined for FITC-labeled and BODIPY® FL-labeled TPP-
HPMA copolymers were found to be not significantly different from each other based on 
fluorophore type or molecular weight. The coefficients for TPP-HPMA copolymers all 
ranged from 3x10-3 to 1.5x10-2. The coefficients for nonsemitelechelic control HPMA-
FITC polymers all were found to be approximately 5x10-2. These results can be compared 
to the coefficient for PNAs, which has been determined to be between 1x10-2 and 2x10-2. 
 
3.4.3 Fluorescence Quenching Analyses with Isolated Mitochondria 
Quenching studies using free mitochondria were performed with MitoTrackerTM 
CM-H2TMRos and TPP-BODIPY® FL as positive controls for the assay. Shown in 
Figure 3.9. are typical examples of the timeline profiles obtained using TPP-BODIPY® 
FL control probe (Figure 3.9. A), and the copolymer TPP-HPMA-BODIPY® FL (Figure 
3.9. B). In these examples, specific uptake/adsorption of the fluorescently labeled 
compounds is indicated by the quenching of fluorescence following the addition of 
succinate (S) and reactivation of mitochondrial membrane potential. Reversal of 
membrane potential and fluorophore uptake occurred after the addition of the inhibitor 
FCCP (F). The linear decrease of the fluorescent intensity before the addition of 
mitochondria, and increase seen after the addition of the succinate solution, are likely due 
to photobleaching of the fluorophores. For all probes and labeled copolymers, quenching 
occurred immediately after succinate addition and deflection of the fluorescence profile 
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reached equilibrium within 60 s. For each profile, the addition of the inhibitor was 
followed by a mirror image deflection profile that reached equilibrium in the same time 
frame as quenching. After correcting for appropriate dilution effects from the added 
activator and inhibitor solutions (3% – 4%), the magnitude of dequenching was 
calculated to be approximately of the same magnitude as quenching in each profile as a 
percentage of total fluorescent intensity. Profiles from the low molecular weight 
MitoTrackerTM and TPP-BODIPY® FL probes all showed smooth exponential 
transitions to equilibrium fluorescence after each step addition of solutions containing 
mitochondria, succinate, and FCCP. Using polymer solutions, however, these transitions 
were sometimes characterized by large fluctuations in intensity before reaching 
equilibrium. The profile for TPP-HPMA-BODIPY® FL-3kDa (Figure 3.9. B) displays 
one example.  
Using the control TPP-BODIPY® FL probe, the average percentage of 
quenching/de-quenching was found to be about +/- 4% (Figure 3.9. A). Of the copolymer 
samples, only the profile of TPP-HPMA- BODIPY® FL-3 kDa possessed significant 
deflections from mitochondrial activation and inhibition, which were +/- 2% (Figure 3.9. 
B). The profile of the higher molecular weight copolymer TPP-HPMA- BODIPY® FL-12 
kDa appeared to also have a quenching/de-quenching deflection. However, it was not 
significant (<1%). The profile of control HPMA-FITC-12 kDa possessed small decreases 
in fluorescent intensity consistent with dilution effects. None of the FITC-labeled 
semitelechelic TPP-HMPA-FITC copolymers had deflections significantly different from 
that of control HPMA-FITC. The presence of unlabeled polyHPMA-10 kDa in the assay 
had no significant effect on the profile of the TPP-BODIPY® FL probe (data not shown).  
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3.4.4 Cell Uptake and Localization Studies  
Typical results from incubating cultured cells with fluorescently labeled polymers 
are shown in Figure 3.10. MDAH2774 cells incubated with TPP-HPMA copolymers in 
media showed only punctuate fluorescent staining for all types of polymers, regardless of 
time of incubation, cell type, or polymer concentration, fluorophore or molecular weight. 
No significant colocalization of polymer (green channel) with MitoTrackerTM (red 
channel) was observed for any of the polymer samples. In general, the semitelechelic 
TPP-HPMA copolymers showed a much more rapid degree of internalization compared 
to nonsemitelechelic HPMA-FITC control polymers. After 1 h, the amount of TPP-
HPMA-BODIPY® FL internalized was roughly equivalent to that seen after 24 h using 
nontelechelic FITC-labeled control polymer. After 1 h the amount of internalized TPP-
HPMA-FITC was significantly lower than that of TPP-HPMA-BODIPY® FL. No 
differences in the results occurred whether polymer or MitoTrackerTM was applied first 
to the cells. 
MDAH2774 ovarian carcinoma cells microinjected with TPP-HPMA copolymer 
showed only diffuse fluorescent staining throughout the cytosol and nucleus for all
sample types (Figures 3.11. A and 3.11. B). This was true for all types of polymer, 
regardless of time of incubation, fluorophore used, or molecular weight. In control 
injections, the diffusion of 10 kDa HPMA-FITC (Figure 3.11. C) was observed to not be 
significantly different than that seen using TPP-HPMA-FITC or TPP-HPMA-BODIPY® 
FL, and all appeared to enter the nuclei of the cells rapidly (< 15 min). No differences in 
the amount of label between the cytosol or nucleus was noticeable after approximately 30 
min. When injecting 170 kDa HPMA-FITC, the polymer was largely excluded from the 
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nucleus for up to 8 h after injection (Figure 3.11. D). No differences in the results 
occurred whether polymer or MitoTrackerTM was applied first to the cells.  
 
3.5 Discussion 
3.5.1 Polymer Synthesis and Characterization  
In characterizing the semitelechelic polymers in this study, there are several 
points and caveats that should be made. In general, all the MALDI-TOF MS analyses of 
the polymers indicated that a large majority of the polymerization products were 
semitelechelic and possessed exactly one TPP moiety per chain. In polymerizations using 
comonomers possessing a fluorophore, the product typically indicated that most common 
species incorporated no fluorophore while species possessing one fluorophore were a 
minority product. In evaluating the distribution of molecular weights, it should be noted 
that MALDI spectra have several biases due to the varying efficiencies of ionization of 
the different molecules that alter the results (44, 45). First, the polymers are polydisperse 
and the sensitivity of MALDI signals attenuates rapidly with increased molecular weight. 
For this reason, the molecular weight distribution of polymers derived from MALDI is 
heavily biased toward polymers with lower degrees of polymerization. This is especially 
true of polymers whose MWs range below 1 kDa as the ionizability of polymers grows 
exponentially higher as the degree of polymerization went below n=10. Conversely, it is 
difficult to collect MALDI signals for synthetic polymers with molecular weights greater 
than 15 kDa. In general, “reasonable” molecular weight distributions from MALDI 
analyses were only possible when the total ranges were between approximately 2 kDa 
and 12 kDa. 
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It is also possible that MALDI analysis overestimated the percentage of 
semitelechelic polymers compared to nontelechelic pHPMA. The addition of a single 
TPP moiety to the polymer greatly increases its efficiency of ionization compared to 
native pHPMA. If there was an order of magnitude difference in ionizability, it is 
possible that the assumed yield of semitelechelic polymer has been greatly overestimated 
in some of the calculations (44, 45). 
These caveats aside, the MALDI-TOF MS spectra for TPP-HPMA were shown to 
be significantly more uniformly semitelechelic in contrast to previously synthesized 
semitelechelic polymers using thiol CTAs.(42) Previous analyses indicated that a 
significant portion of the polymers were terminated with AIBN adducts. This increased 
efficiency seen here may be the result of using lower concentrations of AIBN initiator 
and higher concentrations of CTA in the polymerizations (36). 
The drawback of the concentration ratios used to produce this series of polymers, 
however, was low polymer yield. Typical yields of TPP-HPMA were 25%, TPP-HPMA-
FITC 10%, and TPP-HPMA- BODIPY® FL only 1%. The very low yield of BODIPY 
copolymers, however, can be largely attributed to the radical scavenger activity of 
BODIPY (46). Fortunately, very little material was required to complete the studies 
described here. 
 
3.5.2 Biological Activity 
 The use of lipophilic cations to target mitochondria is based on its physical 
properties. Trafficking to the mitochondria is a function of the attraction of the 
delocalized positive charge to the large electronegative transmembrane potential of the 
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mitochondria. Membrane transduction can occur since the lipophilic cation disrupts the 
membrane structure allowing the molecule to diffuse through the barrier, drawn by the 
transmembrane potential. In the case of the macromolecule PNA, it can be assumed that 
membrane destabilization is sufficient to drive the insertion of the linear conjugate 
through the lipid bilayer. Since PNA is a neutral molecule and relatively hydrophobic, the 
energy barrier required to move the rest of the molecule through the membrane would be 
low enough to be driven by the electrostatic interaction created by the cation. Here, we 
have tested this hypothesis with synthetic copolymers of HPMA.  
The scenario for this hypothesized transmembrane transport mechanism suggested 
that the mitochondriotropic cation should be fixed to one terminus of a linear 
macromolecule. This was achieved for HPMA copolymers using a triphenylphosphonium 
alkyl thiol as a chain transfer agent. Radical chain polymerization with TBTP resulted in 
semitelechelic polymers that possessed single terminal TPP moiety on the polymer 
backbone. The other presumed physical requirements for mitochondrial targeting with 
lipophilic cations qualified that the conjugate possess a molecular weight less than 4 kDa 
and be otherwise electrically neutral and relatively nonpolar.  
In this study, batches of TPP-HPMA copolymers were synthesized above and 
below 4 kDa by altering the concentration of CTA used in the polymerization. The 
requirement for conjugate neutrality was investigated using two different fluorophores in 
comonomers: fluorescein, which possesses a negative charge at physiological pH, and the 
lipophilic dye BODIPY® FL, which is uncharged. Using these probes, ionization state 
was investigated as a requirement for membrane transduction. The uptake studies using 
free isolated mitochondria indicated that TPP-modified HPMA polymers could be 
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trafficked to mitochondria in solution, but also showed that this partitioning was sensitive 
to the physical properties of the conjugate. In this qualitative analysis, only semitelechelic 
TPP-HPMA-BODIPY® FL with an average molecular weight below 5 kDa showed 
significant localization to mitochondria after the activation of membrane potential. 
Higher molecular weight BODIPY® FL copolymers above 10 kDa showed little if any 
localization and none of the FITC-labeled polymer yielded significant localization. 
Apparently, the TPP cation is only able to direct the movement of electrically neutral and 
very low molecular weight conjugates.  
The fluorescence quenching results are not definitive, however, as they represent 
only a qualitative analysis of mitochondrial uptake. Fluorophore quenching can only 
indicate local concentration and does not yield information as to whether the probe is 
uptaken into the membranes of mitochondria or only absorbed to their surface. The 
significance of the degree of quenching of fluorophores conjugated to polymers is also 
questionable since the structure of the polymer around the fluorophore can have 
unpredictable effects on quenching/de-quenching. This issue may be responsible for the 
complex fluctuations of fluorescent intensity seen in the quenching profiles for the 
copolymers. Because of these uncertainties, localization studies using live cells should be 
considered more definitive on the effects of TPP conjugate.  
The results of the cell incubation studies clearly showed that TPP-HPMA 
copolymers were not uptaken by the cells in the same manner as TPP-PNA. All 
internalization occurred by endocytosis and no evidence of endosomal release was noted 
after 24 h. Interestingly, different relative rates of internalization were noted for the 
different classes of copolymers. Compared to the nontelechelic HPMA-FITC polymer 
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control, the TPP semitelechelic polymers appeared to internalize significantly more 
quickly. This may simply be a function of their positive charge producing higher binding 
affinity to the plasma membrane. It is possible that the TPP moiety enhanced the amount 
of adsorption of the polymers and, thereby, greatly increased the rate of adsorptive 
endocytosis. Also, the BODIPY® FL-labeled polymers were internalized more rapidly 
than the FITC polymers. It can be hypothesized that the lack of negative charges on the 
BODIPY® FL polymers was the source of this difference.  
The lack of plasma membrane penetration may simply be a consequence of some 
unknown physical requirement that is possessed by PNA, but is lacking in the HPMA 
copolymers. Membrane transduction may require some parameters of chemical make-up 
or molecular shape that have yet to be described. Another possibility is that TPP does not 
actually act to affect direct plasma membrane transduction by PNA, but rather enhances 
the uptake mechanism that occurs for unmodified PNA. Recent work describing the 
uptake of naked PNA has suggested that internalization occurs mainly by fluid-phase 
endocytosis followed by endosomal/lysosomal release to the cytosol (19). The role of 
TPP on the mechanism of cellular uptake of TPP-PNA may, therefore, be analogous to 
that proposed more recently for cell penetrating peptides, such as TAT, in high molecular 
weight conjugates (47). It is possible that TPP increases the rate by instead enhancing the 
rate of adsorptive endocytosis by increasing plasma membrane binding. TPP may also 
greatly increase the rate of endosomal release by disrupting vesicle structure after 
endocytosis. A combination of these effects is also possible.  
More surprising were the results after polymer microinjection into the cytosol. 
None of the TPP polymers exhibited colocalization with mitochondria. Regardless of 
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molecular weight distributions or fluorophore type, all types of semitelechelic polymer 
were found to diffuse evenly throughout the cytosol and nuclei of the cells and to remain 
in that state after 24 h. These results are consistent, with respect to polymer distribution 
and time scale, with previous work where HPMA copolymers were microinjected into 
Hep G2 cells (48). Similar to the results described here, FITC-labeled HPMA copolymers 
with molecular weights of 23-25 kDa were found to enter the nuclei within 15 min of 
microinjection. However, in this study it was found that the copolymers partitioned 
largely into the nuclear compartment after 60 min. Here, the amount of LMW (< 20 kDa) 
control HPMA-FITC and TPP-HPMA copolymers of weights in the cytosol and nucleus 
remained roughly equivalent for up to 24 h. Meanwhile, the high molecular weight (170 
kDa) HPMA-FITC control copolymer remained completely excluded from the nuclei. 
The similar results for semitelechelic and nontelechelic polymers demonstrated that the 
presence of the cationic TPP moiety had no significant effect on nuclear entry or nuclear 
accumulation of the copolymers.  
One possibility for the absence of mitochondrial localization is that the movement 
restriction of HPMA polymers is much lower than that of PNA in cytoplasm. In the 
former case, the energetics of the electrostatic attraction of the TPP cation to the 
mitochondrial transmembrane potential may be insufficient to affect the free diffusion of 
the synthetic polymer in cytoplasm. Since PNA is a nucleic acid analog, its diffusion in 
cytoplasm may be restricted and guided by interactions with other nucleic acids and 
various proteins that are present in the cytosol. The formation of hybrid RNA:PNA 
duplexes, for example, may influence the intracellular fate of PNA in a manner not 
available to synthetic polymers in the cytosol (49). It may be significant that the 
 119 
localization of TPP-HPMA copolymers was dependent on the type of fluorophore used. 
TPP-HPMA copolymers labeled with BODIPY® FL adsorbed readily to isolated 
mitochondria in vitro, whereas FITC-labeled copolymers showed insignificant 
adsorption. It is possible that the presence of the single negative charge on FITC was 
enough to significantly counteract the electrostatic force between the mitochondria and 
the TPP-copolymers. This suggests that driving force created by the lipophilic cation may 





1. Seymour LW, Duncan R, Strohalm J, & Kopeček J (1987) Effect of molecular 
weight (Mw) of N-(2-hydroxypropyl)methacrylamide copolymers on body 
distribution and rate of excretion after subcutaneous, intraperitoneal, and 
intravenous administration to rats. Journal of Biomedical Materials Research 
21(11):1341-1358. 
2. R̆íhová B, Ulbrich K, Kopeček J, & Mancal P (1983) Immunogenicity of N-(2-
hydroxypropyl) methacrylamide copolymers--potential hapten or drug carriers. 
Folia Microbiologica 28(3):217-227. 
3. Kopeček J (1991) Targetable polymeric anticancer drugs. Temporal control of 
drug activity. Annals of the New York Academy of Sciences 618:335-344. 
4. Lu ZR, Gao SQ, Kopečková P, & Kopeček J (2000) Synthesis of bioadhesive 
lectin-HPMA copolymer-cyclosporin conjugates. Bioconjugate Chemistry 
11(1):3-7. 
5. Omelyanenko V, Kopečková P, Gentry C, & Kopeček J (1998) Targetable HPMA 
copolymer-adriamycin conjugates. Recognition, internalization, and subcellular 
fate. Journal of Controlled Release 53(1-3):25-37. 
6. Omelyanenko V, Gentry C, Kopečková P, & Kopeček J (1998) HPMA 
copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in 
epithelial ovarian carcinoma cells in vitro. International Journal of Cancer 
75(4):600-608. 
7. Xu JP, Ji J, Chen WD, & Shen JC (2005) Novel biomimetic polymersomes as 
polymer therapeutics for drug delivery. Journal of Controlled Release 
107(3):502-512. 
8. Nori A, Jensen KD, Tijerina M, Kopečková P, & Kopeček J (2003) Tat-
conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to 
human ovarian carcinoma cells. Bioconjugate Chemistry 14(1):44-50. 
9. Jensen KD, Nori A, Tijerina M, Kopečková P, & Kopeček J (2003) Cytoplasmic 
delivery and nuclear targeting of synthetic macromolecules. Journal of Controlled 
Release 87(1-3):89-105. 
10. Astriab-Fisher A, Sergueev D, Fisher M, Shaw BR, & Juliano RL (2002) 
Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-
penetrating peptides: Effects on cellular uptake, binding to target sequences, and 
biologic actions. Pharmaceutical Research 19(6):744-754. 
11. Astriab-Fisher A, Sergueev DS, Fisher M, Shaw BR, & Juliano RL (2000) 
Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide 




12. Aronov O, et al. (2004) Nuclear localization signal-targeted poly(ethylene glycol) 
conjugates as potential carriers and nuclear localizing agents for carboplatin 
analogues. Bioconjugate Chemistry 15(4):814-823. 
13. Braun K, et al. (2002) A biological transporter for the delivery of peptide nucleic 
acids (PNAs) to the nuclear compartment of living cells. Journal of Molecular 
Biology 318(2):237-243. 
14. Frederickson R (1999) PNA-NLS delivers. Nature Biotechnology 17(8):739. 
15. Kaihatsu K, Huffman KE, & Corey DR (2004) Intracellular uptake and inhibition 
of gene expression by PNAs and PNA-peptide conjugates. Biochemistry 
43(45):14340-14347. 
16. Nori A, Jensen KD, Tijerina M, Kopečková P, & Kopeček J (2003) Subcellular 
trafficking of HPMA copolymer-Tat conjugates in human ovarian carcinoma 
cells. Journal of Controlled Release 91(1-2):53-59. 
17. van der Aa M, et al. (2005) Covalent attachment of an NLS-peptide to linear dna 
does not enhance transfection efficiency of cationic polymer based gene delivery 
systems. Journal of Controlled Release 101(1-3):395-397. 
18. van der Aa MA, et al. (2005) An NLS peptide covalently linked to linear DNA 
does not enhance transfection efficiency of cationic polymer based gene delivery 
systems. The Journal of Gene Medicine 7(2):208-217. 
19. Chinnery PF, et al. (1999) Peptide nucleic acid delivery to human mitochondria. 
Gene Therapy 6(12):1919-1928. 
20. Szeto HH, Schiller PW, Zhao K, & Luo G (2005) Fluorescent dyes alter 
intracellular targeting and function of cell-penetrating tetrapeptides. FASEB 
Journal : Official publication of the Federation of American Societies for 
Experimental Biology 19(1):118-120. 
21. Teicher BA, Holden SA, Jacobs JL, Abrams MJ, & Jones AG (1986) Intracellular 
distribution of a platinum-rhodamine 123 complex in cis-platinum sensitive and 
resistant human squamous carcinoma cell lines. Biochemical Pharmacology 
35(19):3365-3369. 
22. Teicher BA, Varshney A, Khandekar V, & Herman TS (1991) Effect of hypoxia 
and acidosis on the cytotoxicity of six metal(ligand)4(rhodamine-123)2 
complexes at normal and hyperthermic temperatures. International Journal of 
Hyperthermia : The Official Journal of European Society for Hyperthermic 
Oncology, North American Hyperthermia Group 7(6):857-868. 
23. Fernandez-Carneado J, et al. (2005) Highly efficient, nonpeptidic 
oligoguanidinium vectors that selectively internalize into mitochondria. Journal 




24. Smith RA, Porteous CM, Coulter CV, & Murphy MP (1999) Selective targeting 
of an antioxidant to mitochondria. European Journal of Biochemistry 263(3):709-
716. 
25. Coulter CV, Kelso GF, Lin TK, Smith RA, & Murphy MP (2000) 
Mitochondrially targeted antioxidants and thiol reagents. Free Radical Biology & 
Medicine 28(10):1547-1554. 
26. Kelso GF, et al. (2002) Prevention of mitochondrial oxidative damage using 
targeted antioxidants. Annals of the New York Academy of Sciences 959:263-274. 
27. Smith RA, Kelso GF, James AM, & Murphy MP (2004) Targeting coenzyme Q 
derivatives to mitochondria. Methods in Enzymology 382:45-67. 
28. Filipovska A, Eccles MR, Smith RA, & Murphy MP (2004) Delivery of antisense 
peptide nucleic acids (PNAs) to the cytosol by disulphide conjugation to a 
lipophilic cation. FEBS Letters 556(1-3):180-186. 
29. Muratovska A, et al. (2001) Targeting peptide nucleic acid (PNA) oligomers to 
mitochondria within cells by conjugation to lipophilic cations: Implications for 
mitochondrial DNA replication, expression and disease. Nucleic Acids Research 
29(9):1852-1863. 
30. Kamei S & Kopeček J (1995) Prolonged blood circulation in rats of nanospheres 
surface-modified with semitelechelic poly[N-(2-hydroxypropyl)methacrylamide]. 
Pharmaceutical Research 12(5):663-668. 
31. Erbacher P, et al. (2004) Genuine DNA/polyethylenimine (PEI) complexes 
improve transfection properties and cell survival. Journal of Drug Targeting 
12(4):223-236. 
32. Singh KK (2004) Mitochondrial dysfunction is a common phenotype in aging and 
cancer. Annals of the New York Academy of Sciences 1019:260-264. 
33. Minko T, Kopečková P, & Kopeček J (2000) Efficacy of the chemotherapeutic 
action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian 
carcinoma. International Journal of Cancer 86(1):108-117. 
34. Burns RJ, Smith RA, & Murphy MP (1995) Synthesis and characterization of 
thiobutyltriphenylphosphonium bromide, a novel thiol reagent targeted to the 
mitochondrial matrix. Archives of Biochemistry and Biophysics 322(1):60-68. 
35. Rejmanová P, Labský J, & Kopeček J (1977) Aminolyses of monomeric and 
polymeric 4-nitrophenyl esters of N-methacryloylamino acids. Die 





36. Oupický D, Koňák Č, & Ulbrich K (1999) DNA complexes with block and graft 
copolymers of N-(2-hydroxypropyl)methacrylamide and 2-
(trimethylammonio)ethyl methacrylate. Journal of Biomaterials Science, Polymer 
Edition 10(5):573-590. 
37. Burns RJ & Murphy MP (1997) Labeling of mitochondrial proteins in living cells 
by the thiol probe thiobutyltriphenylphosphonium bromide. Archives of 
Biochemistry and Biophysics 339(1):33-39. 
38. Omelyanenko V, Kopečková P, Gentry C, Shiah JG, & Kopeček J (1996) HPMA 
copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. Influence of the 
method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells 
in vitro. Journal of Drug Targeting 3(5):357-373. 
39. Torchilin VP, Khaw BA, & Weissig V (2002) Intracellular targets for DNA 
delivery: Nuclei and mitochondria. Somatic Cell and Molecular Genetics 27(1-
6):49-64. 
40. Davey GP, Tipton KF, & Murphy MP (1993) Use of an electrode selective for 1-
methyl-4-phenylpyridinium (MPP+) to measure its uptake and accumulation by 
mitochondria. Journal of Neural Transmission. Supplementum 40:47-55. 
41. Heitz W (1989) Telechelics by radical polymerization reactions (CRC Press, 
Boca Raton, FL). 
42. Lu ZR, Kopečková P, Wu Z, & Kopeček J (1998) Functionalized semitelechelic 
poly[N-(2-hydroxypropyl)methacrylamide] for protein modification. 
Bioconjugate Chemistry 9(6):793-804. 
43. Ardhammar M, Norden B, Nielsen PE, Malmstrom BG, & Wittung-Stafshede P 
(1999) In vitro membrane penetration of modified peptide nucleic acid (PNA). 
Journal of Biomolecular Structure and Dynamics 17(1):33-40. 
44. Chen H & He M (2005) Quantitation of synthetic polymers using an internal 
standard by matrix-assisted laser desprption/ionization time-of-flight mass 
spectroscopy. American Society for Mass Spectrometry 16:100-106. 
45. Zhang L-K, Rempel D, Pramanik BN, & Gross ML (2005) Accurate mass 
measurements by fourier transform mass spectrometry. Mass Spectrometry 
Reviews 24:286-309. 
46. Makrigiorgos GM (1997) Detection of lipid peroxidation on erythrocytes using 
the excimer-forming property of a lipophilic BODIPY fluorescent dye. Journal of 
Biochemical and Biophysical Methods 35(1):23-35. 
47. Brooks H, Lebleu B, & Vives E (2005) Tat peptide-mediated cellular delivery: 




48. Jensen KD, Kopečková P, Bridge JH, & Kopeček J (2001) The cytoplasmic 
escape and nuclear accumulation of endocytosed and microinjected HPMA 
copolymers and a basic kinetic study in Hep G2 cells. AAPS PharmSci 3(4):E32. 
49. Abibi A, Protozanova E, Demidov VV, & Frank-Kamenetskii MD (2004) 
Specific versus nonspecific binding of cationic PNAs to duplex DNA. 







Figure 3.1. Synthetic scheme for TPP-functionalized semitelechelic HPMA 











Figure 3.3. Synthesis of the control fluorescent probe TPP-BODIPY® FL by the 
conjugation of TBTP and BODIPY® FL N-(2-aminoethyl) maleimide 
 
Figure 3.4. Synthetic scheme for the comonomer MA-GG-BODIPY® FL by the 





Table 3.1 Summary of polymers used for mitochondrial uptake, cell incubation and 
microinjection studies 
Figure 3.5. Summary of semitelechelic TPP-HPMA molecular weight vs. feed 
chain-transfer agent concentration to monomer concentration ratio. ()  The results 






Figure 3.6. Typical MALDI-TOF mass spectrum of semitelechelic TPP-HPMA 
copolymer 







Figure 3.8. Typical MALDI-TOF mass spectrum of semitelechelic 
TPP-HPMA/MA-GG-BODIPY® FL copolymer 
 
Figure 3.9. Timeline profiles of fluorescence quenching by mitochondria. Solution of 
TPP-BODIPY FL® control probe (A). Solution of semitelechelic copolymer TPP-
HPMA-BODIPY FL® - 3 kDa (B). Points are indicated for the addition of 





Figure 3.10. Confocal laser scanning fluorescent microscopy (40x mag.) of 
MDAH2774 ovarian carcinoma cells after incubation with fluorescently-labeled 
polymers.  The red channel is Mitotracker Orange and the green channel is either 
FITC or BODIPY® FL. (A) Control polymer HPMA-FITC after 24 h incubation.  (B-
E): Semitelechelic TPP-HPMAs after 6 h incubations; (B) TPP-HPMA-FITC-4 kDa; 
(C) TPP-HPMA-FITC-12 kDa; (D) TPP-HPMA-BODIPY® FL-3 kDa; E: TPP-




TPP-HPMA-FITC-4 kDa TPP-HPMA-BODIPY® FL-3 kDa 






Figure 3.11  Confocal laser scanning fluorescent microscopy of MDAH2774 cells 
after microinjection with fluorescently-labeled polymers.  The red channel is 
Mitotracker Orange and the green channel is either FITC or BODIPY® FL.  A: 
Injection with TPP-HPMA-FITC-4 kDa and 24 h incubation at 37 °C.  B: Injection 
with TPP-HPMA-BODIPY® FL-3 kDa and 24 h incubation. C: Injection with HPMA-
FITC-10 kDa control and 20 min incubation. D: Injection with HPMA-FITC-170 kDa 




INTRACELLULAR TRAFFICKING AND SUBCELLULAR 





The basic physicochemical properties that determine the distribution and fate of 
synthetic macromolecules in living cells were characterized using fluorescently labeled 
HPMA (N-(2-hydroxypropyl)methacrylamide) copolymers. Twelve different classes of 
water-soluble copolymers were created by incorporating eight different functionalized 
comonomers. These comonomers possessed functional groups with positive or negative 
charges, or contained short hydrophobic peptides. The copolymers were fractionated to 
create parallel “ladders” consisting of 10 fractions of narrow polydispersity with molecular 
weights ranging from 10 to 200 kDa. Polymer samples were added to the growth media of 
live cells and the resulting endocytosis and trafficking of the polymers was characterized 
and quantitated. All polymers were trafficked to the lysosomal compartment, but the 
kinetics and endocytotic pathway favored varied greatly due to comonomer chemical type 
                                                 
1 This chapter is adapted with permission from: J. Callahan, P. Kopečková and J Kopeček. Intracellular 
Trafficking and Subcellular Distribution of a Large Array of HPMA Copolymers. Biomacromolecules. 
2009 Jul 13; 10(7): 1704–1714. Copyright © 2009 American Chemical Society 
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and the molecular weight of the copolymers. The intracellular distribution of polymers 
introduced directly into the cytoplasm was characterized for copolymer solutions 
microinjected into cultured ovarian carcinoma cells. Even the highest molecular weight 
HPMA copolymers were shown to quickly and evenly diffuse throughout the cytoplasm 
and remain excluded from membrane-bound organelles, regardless of composition. The 
exceptions were the strongly cationic copolymers, which demonstrated a pronounced 
localization to microtubules. For all copolymers, nuclear entry was consistent with passive 
transport through the nuclear pore complex (NPC). Nuclear uptake was shown to be largely 
dictated by the molecular weight of the copolymers. However, detailed kinetic analyses 
showed that nuclear import rates were moderately, but significantly, affected by differences 
in comonomer composition. HPMA copolymers containing amide-terminated 
phenylalanine-glycine (FG) sequences, analogous to those found in the NPC channel 
protein, demonstrated a potential to regulate import to the nuclear compartment. Kinetic 
analyses showed that 15 kDa copolymers containing GGFG, but not those containing 
GGLFG, peptide pendant groups altered the size-exclusion characteristics of NPC-
mediated nuclear import.  
 
4.2 Introduction 
Water-soluble, synthetic polymers have been successfully used in a variety of 
applications to enhance the delivery and efficacy of therapeutic drugs, nucleic acids, 
peptides, and proteins. For example, polymeric anticancer drug carriers have been used to 
greatly enhance the biocompatibility (1, 2), pharmacokinetics (3, 4), nonimmunogenicity 
(2, 5), and cell targetability (6-10) of chemotherapeutic agents, while reducing their toxicity 
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toward normal tissues.  
Typically, cell uptake of synthetic macromolecules occurs via endocytosis, 
whereby high molecular weight molecules are routed to the lysosomal compartment. 
Pharmaceutical activity necessitates the subsequent release of the active agent from the 
endocytotic vesicles. For polymer–low molecular weight drug conjugates, release of the 
drug from the polymeric carrier can be accomplished using hydrolyzable bonds. The 
delivery of intact macromolecules directly to the cytosol of target cells has been 
accomplished by a variety of methods that destabilize lipid membranes (11).  
Once macromolecules are delivered to the cytosol, several methods may be 
employed to traffic them to specific subcellular compartments, such as the nucleus and 
mitochondria, to enhance their therapeutic efficacy. Nuclear and mitochondrial localization 
of macromolecules has been mediated by targeting peptides (12-15) or the lipophilic 
triphenylphosphonium (TPP) cation (16-18).  
However, macromolecules (without subcellular targeting moieties) are typically 
excluded from entering membrane-limited organelles, such as mitochondria, lysosomes, 
the endoplasmic reticulum, in a nonspecific manner. The exception to this is the nucleus 
whose membrane possesses channels that allow the passive uptake of intermediate-sized 
macromolecules. The NPC (nuclear pore complex) of the nuclear envelope is composed of 
about 30 different nucleoporin proteins and is the conduit for both nuclear import and 
export of macromolecules, such as proteins and nucleic acids. In active transport, cargo as 
large as 40 nm possessing NLS (nuclear localization sequence) or NES (nuclear export 
sequence) signaling peptides are guided through the channel after binding to NTR (nuclear 
transport receptor) proteins (19). For smaller macromolecules below 10 nm, however, 
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NPCs have been shown to act as nonspecific pores that allow exchange between the 
nucleus and cytoplasm by diffusion (20). As a conduit for nonbiological macromolecules, 
the NPCs have been shown to transmit PEG-coated gold colloid particles 4–7 nm in 
diameter (21). In contrast, 27 and 39 nm PEG-gold particles and 25 nm quantum dot 
particles conjugated with NLS peptide sequences have been shown to require the active 
nuclear import mechanism for uptake by the nucleus (19, 21, 22). 
Dynamic structural modeling of several of the nucleoporins in the core of the NPC 
has been used in an attempt to explain the dual size selection of active versus passive 
nuclear transport selection (23). The structure of several nucleoporins notably possesses 
natively unfolded domains containing hydrophobic FG (phenylalanylglycine) domains, 
consisting of FG, GLFG, and FXFG peptide repeats. Several different models have been 
debated to account for the dynamics of NPC transport. Ribbeck et al. have proposed that 
the FG domains form a polymer brush conformation in the NPC channel that excludes 
larger solutes by entropic hydrophobic repulsion (24, 25). Frey et al. have suggested that 
nucleoporins form an unstructured hydrogel mesh in the core of the NPC channel through 
reversible cross-links of FG peptide repeats that they possess (26, 27). Nuclear transport 
receptors have been shown to possess a number of hydrophobic regions that specifically 
bind to nucleoporins in their FG repeat regions and have been proposed to disassociate 
interchain cross-links. The pore proteins, thereby, form a 3-dimensional mesh with a simple 
molecular weight permeability cutoff when cross-linked. In this model of active transport, 
NTRs can open the nucleoporin mesh by “melting” the hydrogel structure and guide large 
macromolecules in or out of the nuclear compartment (28). Alternately, Melčák et al. 
proposed that the interface between the α-helical regions of nucleoporins selectively slide 
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circumferentially to dilate the NPC pore opening after NTR binding (29). More recently, 
several models of Nup structure have been proposed to account for transport in and out of 
the nucleus. This includes a diblock copolymer brush model (DCBM) that models FG nups 
as diblock polymers that form an unstructured “forest” of short and extended nup proteins 
that account for the different transport properties of the NPC (30). All these models 
emphasize the role of FG crosslinking in nup functionality, but the models envision the 
roles of the unstructured nucleoporin proteins in different configurations (31). 
Nonetheless, relatively little is known about the chemical and physical forces that 
direct localization of macromolecules once in the cytosol. To help ascertain this basic 
understanding, we took advantage of a well-characterized and synthetically flexible 
polymer system to create an array of macromolecules with widely divergent chemical 
characteristics. Fluorescently labeled N-(2-hydroxypropyl)methacrylamide (HPMA) 
copolymers with a reproducible range of well-defined molecular weights were made using 
comonomers with a variety of charges and hydrophilicities in an attempt to reveal the 
physicochemical properties that guide the intracellular transport and distribution of 
synthetic macromolecules. The copolymers were fractionated into a series of polymers of 
narrow polydispersity and microinjected into the cytosol of cultured human ovarian 
carcinoma cells. Their fate was observed using fluorescence microscopy and other imaging 
methods. A variety of subcellular markers were simultaneously used to identify subcellular 
compartments within the cells to determine colocalization. Specific issues investigated 
included diffusion in the cytoplasm, relative rates of nuclear entry, binding to intracellular 
membranes and other structures, and sequestration by subcellular compartments.  
Finally, HPMA copolymers containing FG (Phe-Gly) motifs were generated as an 
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attempt to modulate the kinetics of nuclear uptake of macromolecules. Their structure was 
based on recent theories describing the function of proteins of the NPC (nuclear pore 
complex) in the nuclear membrane that have been shown to regulate nuclear import and 
export of macromolecules.  
 
4.3 Experimental Methods 
4.3.1 Monomers  
All chemicals and solvents used were of reagent grade or better unless otherwise 
stated. MAA (methacrylic acid), DEMA (2-(N,N-dimethylamino)ethyl methacrylate), and 
SEMA (2-sulfoethyl methacrylate) were purchased from PolySciences, Inc. HPMA (N-(2- 
hydroxypropyl)methacrylamide) (32) and MA-FITC (N-methacrylolyaminopropyl 
fluorescein thiourea) (33) were prepared as previously described. MATC (N-
methacryloyloxyethyl trimethylammonium chloride) was prepared as described before by 
quaternization of DEMA with gaseous methylchloride in acetone (34). The peptide 
monomers N-methacryloylglycylglycine (MA-GG), N-methacryloylglycylphenylalanine 
(MA-GF), and N-methacryloylglycylphenylalanylleucylglycine (MA-GFLG) were 
prepared as described previously (35).  
The amide-terminated monomers MA-GGFG-NH2 (N-
methacryloylglycylglycylphenylalanylglycine amide) and MA-GGLFG-NH2 (N-
methacryloylglycylglycylleucylphenylalanylglycine amide) were synthesized using 
standard Fmoc solid-phase peptide chemistry. On Rink Amide MBHA resin 
(Novabiochem), glycine and phenylalanine or glycine, phenylalanine, and leucine were 
sequentially attached. While still conjugated to the resin, the peptides were coupled to N-
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methacryloylglycylglycine peptide (MA-GG). The completed monomers were then 
released using a TFA solution and precipitated in diethyl ether. The dried monomers were 
purified using RP-HPLC, and their mass verified using MALDI-TOF MS. The molecular 
masses for the two main ion peaks measured for MA-GGFG-NH2 were 404.2 and 426.2, 
corresponding to calculated values 404.4 (M·H+) and 426.4 (M·Na+). The molecular mass 
of the main ion peak measured for MA-GGLFG-NH2 was 539.3 versus a calculated value 
of 539.5 (M·Na+). 
 
4.3.2 Polymer Chemistry  
All copolymers used in this study were generated by radical chain polymerization 
using 0.60 wt % AIBN as the initiator. The feed mole ratios of all 12 copolymerizations 
and copolymer compositions are shown in Tables 4.1. and 4.2. The structure of monomers 
and copolymers is depicted in Figures 4.1. and 4.2. (For the sake of clarity, all polymers 
were named based on the concentration of feed comonomer rather than final content in the 
copolymers.) Methanol was used as the bulk solvent for all reactants of the polymerization 
in a total reaction volume of 5ml. To slightly lower the average molecular weight of each 
of the resulting copolymers, 0.078 wt % mercaptopropionic acid was added as a chain 
transfer agent. Before mixing with the other components of the polymerization reaction, 
some of the monomers were first dissolved in other solvents to ensure complete dissolution. 
The liquid monomer SEMA was diluted 1:10 with water to ensure miscibility with 
methanol during the polymerization reaction. The peptide monomers MA-GFLG, MA-GF, 
MA-GGFG-NH2, and MA-GGLFG-NH2 were dissolved in a minimum volume of DMSO 
(~2μL/mg) before addition to the reaction solution. The alkaline monomers DEMA and 
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MATC were dissolved in 0.05 N HClaq to a monomer concentration of 250 mg/ml to 
acidify the final reaction solution.  
After mixing, the polymerization solutions were bubbled with argon, sealed in a 
glass ampule, and then heated to 50°C for 24 h. When complete, the reactions were dried 
under vacuum and then redissolved in a minimum volume of methanol. The polymers were 
then separated from the unreacted monomers on an LH-20 column with methanol as the 
mobile phase. The eluted fractions containing the FITC-labeled product were then dried 
under vacuum, redissolved in a minimum amount of distilled water, and then freeze-dried 
to isolate the finished solid product. The final yields of all copolymers were between 75–
85%.  
 
4.3.3 Texas Red-labeled HPMA Copolymer  
HPMA copolymers labeled with Texas Red (Table 4.2.) were synthesized in a two-
step process, as previously described.(36) First, a copolymer of HPMA with N-(3- 
aminopropyl)methacrylamide (molar ratio 98:2) was synthesized by radical 
copolymerization. The copolymer contained 1.9 mol% of amine side chains; Mw = 80000. 
In the second step, Texas Red was attached by the reaction of Texas Red succinimidyl ester 
(Molecular Probes) with amine groups of the copolymer. The purified product contained 
1.6 mol% Texas Red, containing side chains as determined spectrophotometrically (ε593 nm 





4.3.4 Copolymer Characterization  
For all FITC-labeled copolymers, the content of MA-FITC monomer was 
determined by spectrometry using the absorbance at 495 nm (ε495 nm = 80000 M−1cm−1) 
in 0.1 M borate buffer (pH 9). The content of peptide monomer in the six peptide-
containing copolymers was determined by HPLC amino acid analysis (AAA) using 
phenylalanine as a reference. For this, 2–3 mg of peptide-containing copolymer was 
hydrolyzed in 0.2 ml of 6N HCl in a sealed glass ampule at 115°C for 16 h. The hydrolyzate 
was dried over NaOH pellets in vacuo and then dissolved in 0.5 ml of distilled H2O. Before 
separation on a reverse phase Microsorb MV C18 column, the amino acids in the sample 
were derivatized with o-phthaldialdehyde (OPA). HPLC used a 10–90% gradient elution 
where solvent A was 0.05 M sodium acetate in 0.25% acetonitrile pH 6.0 and solvent B 
was 0.05 M sodium acetate in 70% acetonitrile. The HPLC fluorescence detector used the 
excitation at 229 nm and emission at 450 nm. The content of charged MAA, SEMA, and 
DEMA comonomers was determined using an automated TIM854 pH titration workstation 
(Titralab, Radiometer Analytical, Lyon, France) with a combined minitype electrode and 
either 0.05N NaOH or 0.05N HCl as a titration standard solution. Content of MATC was 
determined by potentiometric titration of chloride ions using a combined silver type 
electrode and 0.05 M AgNO3 titration standard solution. The comonomer content and 
characterization of the copolymers are summarized in Tables 4.1. and 4.2. 
 Size-exclusion chromatography (SEC) was used to determine the molecular weight 
distribution of the polymers. All samples were run on an FPLC system (GE Healthcare) 
equipped with UV and differential refractive index detectors using a Superose 6 HR10/30 
analytical column in PBS (pH 7.3) calibrated with pHPMA standards of a narrow 
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polydispersity (Mw/Mn < 1.2). To ensure accurate molecular weight calculations, polymer 
size was also calculated using dynamic light scattering in tandem with SEC. For this, dn/dc 
measurements were determined for each polymer with a DSP interferometric refractometer 
(OPTILAB, Wyatt Technology, Santa Barbara, CA) using standard polymer/PBS 
solutions. Molecular weight determinations were made using laser light scattering data 
(MINIDAWN, Wyatt Technology) and calculated using chromatographic software 
(ASTRA, Wyatt Technology).  
 
4.3.5 Copolymer Fractionation  
All 12 copolymers were further fractionated into a standard molecular weight 
“ladder” series using a preparative Superose 6 HR16/60 FPLC column. For each 
separation, 50 mg of polymer was loaded on to the column using PBS as the eluent and a 
flow rate of 1 ml/min. Fractions were collected using the same schedule for all copolymers, 
whereby 10 fractions of 5 ml each were taken during the 50 min window of polymer elution 
from the column. At least two 50 mg fractionations were performed for each copolymer. 
The corresponding fractions for each separation (labeled F1–F10 for fractions 1–10) were 
pooled, dialyzed extensively against water, and freeze-dried. The molecular weight 
distributions of the resulting polymer fractions were then characterized using a Superose 6 
analytical SEC column. A summary of the molecular weight analyses for the fractions used 
in subsequent experiments is shown in Tables 4.1. and 4.2. Analyses of the content of 
comonomer for several randomly selected copolymer fractions were analyzed using pH 
titrations, AAA and AgCl titration to ensure that the mole fractions of the fractionated 
polymers were similar to the starting unfractionated polymers.  
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4.3.6 Cell Culture  
MDAH2774 ovarian carcinoma cells (ATCC) were cultured in Lebowitz’s L-15 
media supplemented with 10% fetal bovine serum (HyClone Laboratories, Logan, UT) 
with 10 μg/ml insulin (HyClone) and 12.5 mM HEPES buffer (pH 7.4) under a humidified 
atmosphere at 37°C. All uptake experiments were performed in the presence of 10% FBS. 
For static imaging studies, cells were seeded in No. 1.5 glass-bottom 14 mm 
microwell dishes (MatTek Corp., Ashland, MA). For time-lapse experiments, cells were 
seeded on 0.17 mm Delta T temperature-controlled microwell dishes (Bioptechs, Inc., 
Butler, PA).  
In colocalization studies, fluorescent subcellular markers were used. For these, 
media containing the markers was added approximately 1 h before initial imaging, and 
fresh media was added to the microwell dishes immediately before imaging. To identify 
mitochondria, 100mM MitoTracker Orange CM-H2TMRos (Molecular Probes) was 
added. To identify lysosomes, 50mM LysoTracker Red (Molecular Probes) was used.  
 
4.3.7 Live Cell Imaging  
Live cell polymer uptake studies were conducted using scanning laser confocal 
fluorescence microscopy (Olympus Flowview with krypton/argon excitation lasers). For 
static microscopy, images were collected by combining dual-channel fluorescent and 
transmitted light using z-series slices in 0.2 μm steps. Image data were processed using 




4.3.8 Incubation of MDAH Cells with Copolymers  
Dissolved in Media  
As a control to determine the baseline mode of polymer internalization, MDAH 
ovarian carcinoma cells (ATCC) were incubated with each of the polymers in their 
incubation media. A single molecular weight fraction (fraction 9, all ranging in average 
molecular weights between 12–17 kDa) of each polymer type was used in a systematic 
study of uptake. Plated cells were incubated for 24 h in growth media containing 0.5 mg/ml 
polymer. Before imaging the media was replaced with fresh media. The cells were then 
imaged using confocal laser scanning microscopy (see Figure 4.2.).  
More detailed uptake studies using the large polymer array were subsequently 
performed on C4-2 prostate carcinoma cells. (see Chapter 5) (37). 
 
4.3.9 Microinjection 
Fluorescently labeled 1.0 mg/ml polymer/PBS solutions were directly injected into 
the cytosol of plated MDAH2774 cells using 0.5 μm glass needles equipped on an 
Eppendorf Transjector 5346 pressure injector and fixed to an Eppendorf 5171 
micromanipulator arm. Pressures used varied from 80 to 120 hPa and care was taken to 
inject solutions as far from the cell nuclei as possible to avoid causing physical trauma to 
the cells.  
 
4.3.10 Intracellular Distribution of Copolymer Fractions  
Following microinjection, MDAH2774 cells were observed periodically (every 10 
or 15 min) for up to 48 h using laser scanning fluorescence confocal microscopy. For 
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detailed comparisons of the effect of molecular weight, every fraction from polymers 5% 
MAA-P, 5% GFLG-P, and 20% DEMA-P was used. The distribution of all types of 
polymers that were completely excluded from nuclei was characterized by injecting 
MDAH2774 cells with every F4 polymer, which all possessed molecular weights greater 
than 75 kDa. Cells were microinjected and then incubated at 37°C for 24 h. At 1 h before 
imaging, either LysoTracker Red or MitoTracker Orange (Molecular Probes) was added to 
the media. Immediately before imaging, the media was replaced with fresh media.  
 
4.3.11 Rates of Nuclear Entry/Time Lapse Imaging  
F7 (fraction 7) polymers of a uniform molecular weight (Mw = 36 ± 6 kDa) of 5% 
comonomer polymers were selected. To quantify the rate of nuclear entry, time-lapse 
imaging was performed on MDAH2774 cells after microinjection. Each movie was started 
10–15 min after polymer microinjection. Each frame of the movies represents 15 min (or 
10 min in the case of polymers MAA-P, MATC-P, and GFLG-P) and they were collected 
until there was an apparent equilibrium between the nuclear vs. cytosolic concentrations. 
Laser power was set low (2–5%) to minimize bleaching during imaging. The image series 
used for measurement was of one confocal plane taken approximately midway through the 
nuclei or 2–4 μm above the coverslip surface. For quantification analysis, the image series 
was coded and the fluorescent image intensity data were collected by a blinded second 
party. Cells in the image series were numbered and tracked separately during the movie to 
account for cell migration and changes in cell shape. For each polymer, 5–9 cells in the 
series in the imaging frame were used in the analysis. Polymer concentrations in the nuclei 
and cytosol were measured by the image intensity of a 2 μm radii circular region in the 
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nuclei and the perinuclear cytosol of each cell. The regions used for measurement were 
manually moved during the series to account for cell movement. Nuclear entry time courses 
of each cell measured for each polymer were averaged and then curve-fitted by regression 
analysis using Equation 3.1 on SigmaPlot software to a three-parameter rising exponential 
function of the form:  
𝑅𝑅𝑛𝑛 𝑐𝑐⁄ + 𝑅𝑅0 + 𝑅𝑅𝑒𝑒𝑒𝑒  × (1 − 𝑒𝑒−𝑘𝑘𝑘𝑘)                               (Equation 4.1) 
where Rn/c is the ratio of the nuclear versus cytosol polymer concentration, R0 is the fitted 
initial N/C ratio (to account for background fluorescence in measured values), Req is the 
equilibrium concentration of polymer in the nucleus versus cytosol, and k (min−1) is the 
rate constant of nuclear uptake. 
To evaluate statistically significant differences, the nuclear entry rate constants for 
all test polymers were compared to the rate constant calculated from control pHPMA-FITC 
using the two-tailed Student’s t test. Differences in mean values were considered 
significant for P-values less than 0.05.  
 
4.3.12 Fluorescence Recovery After Photobleaching (FRAP)  
FRAP was performed on MDAH2774 cells after cytosolic microinjection of 
copolymers. In each study, polymer was injected 1–2 h before the bleaching experiment. 
Imaging was performed on a FV1000 Olympus confocal microscope with an independent 
light path and galvo SIM scanner (simultaneous image microscopy) image scanning 
system. An ~2 μm diameter spot was bleached for each microinjected cell using a 405 nm 
diode laser as the light source. Images before, during, and after bleaching were taken every 
~0.6 s for several min. In some series, the bleaching laser was turned on continuously to 
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determine whether any copolymer was retained by components of the cell (i.e., FLIP, 
fluorescence loss in photobleaching).  
 
4.3.13 Coinjection of FG Peptide Copolymers and Nuclear  
Exclusion Markers  
The FG containing polymers were generated to determine whether the peptide 
pendant groups affected the kinetics of nuclear entry via the NPC. For this, the FITC-
labeled, fractionated copolymers were coinjected into MDAH2774 cells with fractionated 
Texas Red-labeled pHPMA (TR-P) as a marker for nuclear exclusion and uptake. For each 
coinjection, PBS solutions of 1mg/ml FITC test polymer and 1mg/ml TR-P marker 
polymer were injected into a field of cells. In separate regions of the same coverslip, the 
cells were injected with 1mg/ml solutions of either test polymer (green) or TR-P marker 
polymer (red) alone, to act as controls. Time-lapse confocal z-series imaging of the injected 
live cells was immediately initiated after injection. Images were collected using 488 nm 
and 543 nm lasers in sequence using the same settings for all three regions of injected cells.  
 
4.4 Results and Discussion 
4.4.1 Design and Characterization of an HPMA Copolymer Array  
A large array of HPMA copolymers was synthesized by radical polymerization 
(Tables 4.1. and 4.2.). Eight different methacryloyl-functionalized comonomers were 
employed to confer different pendant functional groups to the resulting linear polymers 
(Figure 4.3.). For each copolymer, 1 mol% of MA-FITC (N-methacrylolyaminopropyl 
fluorescein thiourea) was incorporated for convenient visualization. Monomers with four 
 148 
different types of charged groups were used: MAA (methacrylic acid), a weak acid; SEMA 
(2-sulfoethyl methacrylate), a strong acid; DEMA (N,N-dimethylaminoethyl 
methacrylate), a weak base; and MATC (N-methacryloyloxyethyl trimethylammonium 
chloride), a strong base. Four peptide-containing monomers were used to create relatively 
hydrophobic copolymers: N- methacryloylglycylphenylalanine (MA-GF), N- 
methacryloylglycylphenylalanylleucylglycine (MA-GFLG), N- 
methacryloylglycylglycylphenylalanylglycineamide (MA-GGFG-NH2), and N- 
methacryloylglycylglycylleucylphenylalanylglycineamide (MA-GGLFG-NH2). 
Fractionation using SEC provided 10 molecular weight fractions (F1–F10) each with a 
narrow polydispersity. The content of the comonomers in the resulting copolymers was 
typically 75–85% of the mol % of the feed concentration; however, for the sake of clarity, 
the feed comonomer concentrations were used for the nomenclature of the copolymers. For 
example, “5% GFLG-P” refers to the peptide copolymer resulting from the 
copolymerization of 5 mol% MA-GFLG, 94% HPMA, and 1% MA-FITC. SEC- 
fractionated copolymers were further designated by fractionation order and decreasing 
molecular weight. For example, the suffix in “5% GFLG-P-F7” refers to the seventh SEC 
fraction of copolymer 5% GFLG-P (Tables 4.1. and 4.2.).  
The molecular weight profiles of the array copolymers from high (F4), midrange 
(F7), and low (F9) molecular weight fractions from the array copolymers used in later 
experiments were characterized by SEC. The middle range of fractions from F5 to F9 
formed a molecular weight “ladder” of standard copolymer hydrodynamic sizes, as the 
differences in average molecular weight for fractions 5–9 from all the polymers had 
standard deviations less than ±6%. To illustrate, the average structure, and the SEC profiles 
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for the fractions collected from copolymer 5% MATC-P and 5% MAA-P are shown in 
Figures 4.4. and 4.5., respectively.  
In summary, a two-dimensional array of HPMA copolymers was generated with 12 
distinct chemical characteristics in one dimension, and a discrete sequence of five parallel 
molecular weights (10–80 kDa) in the other dimension.  
 
4.4.2 Endocytosis and Subcellular Trafficking of Polymers from Media  
Initial uptake studies showed that all copolymers when incubated with MDAH2774 
ovarian carcinoma cells were internalized by endocytosis (Figure 4.5.). Punctate staining 
of all cells after incubation with all the polymers was consistent with lysosomal 
compartmentalization. It was also evident that the relative amount of polymer uptaken by 
the cationic polymers was consistent with adsorptive endocytosis and thereby showed the 
greatest amount of uptake. For no polymer was there evidence of any endosomal/lysosomal 
of polymer escape after 24 h. 
 
4.4.3 Cytosolic Microinjection of HPMA Copolymers  
The subcellular distribution of HPMA copolymers was characterized by pressure 
microinjecting copolymer solutions directly into the cytosol of cultured cells. For each 
species of copolymer, diffusion occurred rapidly throughout the cytosol after 
microinjection and had reached equilibrium within a few minutes required to collect 
images. The copolymers appeared to be excluded from all membrane-limited subcellular 
compartments, even after 24 h. The only notable shifts in intracellular distribution were 
observable in rates of nuclear entry. Here, differences were largely, but not entirely, a 
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function of molecular weight rather than the identity or initial concentration of comonomer. 
The lowest molecular weight polymers injected (i.e., the “F9” and “F10” fractions), with 
masses less than 25 kDa, immediately diffused throughout the nucleus after cytosolic 
injection (row a of Figure 4.6.). In contrast, the highest molecular weight polymers (>60–
80 kDa; up to fraction “F5”) remained completely excluded from the nuclei, even after 24 
h. (row b of Figure 4.6.).  Polymer fractions in the intermediate molecular weights between 
25–50 kDa entered the nuclear compartment in time frames that ranged from 15 min to 12 
h. Subsequent experiments were designed to explore in detail the differences between 
polymers with respect to initial subcellular distribution and fate.  
 
4.3.4 Short-term Intracellular Distribution  
To evaluate polymer diffusion through the cytoplasm, FRAP (fluorescence 
recovery after photobleaching) experiments were performed on selected polymer samples 
using high-speed time-lapse imaging. When 2 μm regions of cytoplasm were bleached 
using a short burst from the laser, the diffusion of the surrounding polymer into the 
bleached area was very rapid and equilibrium was reestablished in less than 3 sec for all 
polymers types (Figure 4.7.).  
Subsequent FLIP (fluorescence loss in photobleaching) experiments where laser 
bleaching was used for several minutes showed that all the polymers in the cell freely 
diffused to the bleached region within a few minutes. The only exception to this trend was 
observed when using copolymers possessing intermediate molecular weights (25–50 kDa) 
able to enter the nucleus but slowly over a period of hours. In these microinjected cells, the 
polymers disappeared from the cytoplasm within 2–3 min, but the copolymer in the nuclei 
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was retained and remained visible. Continued bleaching produced a very gradual decrease 
of polymer in the nuclei as the polymer slowly diffused out of the nuclear compartment 
and into the cytosol where it could quickly diffuse through the bleached region. The rapid 
and homogeneous diffusion of HPMA copolymers as large as 100 kDa throughout the 
cytoplasm is in good agreement with previous studies of the diffusion of biological 
macromolecules such as dextran and Ficoll (38-40). On the contrary, theories on the 
hydrogel nature of the cytoplasm seem not to hold based on these results (41).  
The FLIP experiments using intermediate molecular weight (25–50 kDa) 
copolymers also confirmed that the only barriers to the free diffusion of most of the 
polymers were subcellular membrane structures. Furthermore, all the results, with respect 
to nuclear uptake and export, were consistent with simple size-limited unassisted diffusion 
through the nuclear pore complex (42, 43). Transport in and out of the nuclear compartment 
was thus symmetrical and consistent with the known properties of passive NPC transport, 
as opposed to active import or the result of disruption of the nuclear envelope.  
 
4.3.5 Long-term Intracellular Distribution  
The systematic analysis of the long-term fate of the copolymers used fractions with 
molecular weight averages greater than 80 kDa to avoid potential toxicity. This issue was 
illustrated in a time-lapse imaging of cells injected with the strongly cationic copolymer 
20% MATC–P-F7, which showed the cells collapse and die immediately after the 
copolymer began to enter the nucleus of each cell, 1-3 h after microinjection.  
Use of the organelle markers for mitochondria and lysosomes showed no 
colocalization using polymers of any of the 10 types studied here, even 24 h after 
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microinjection (data not shown). Further, the only cells that showed significant 
distributional nonhomogeneity in the cytoplasm were the highly cationic types, particularly 
20% MATC-P. As shown in Figure 4.8, this polymer clearly localized to microtubules, as 
confirmed by colocalization with antitubulin antibodies. Much weaker microtubule 
localization was also noted for polymers 5% MATC-P and 20% DEMA-P. In each of these 
experiments, fluorescent staining of microtubules was a slow process and required several 
hours to become observable. Microtubule binding is consistent with the known cation-
binding properties of tubulin proteins (44, 45).  
Nuclear entry of copolymers was largely dictated by molecular weight rather than 
chemical composition. Copolymers with intermediate molecular weights between 25–50 
kDa entered the nuclei, but slowly, over the course of 15 min to 24 h. The hydrodynamic 
diameters of charged HPMA copolymers in this mass range have been shown to be between 
2–4 nm in free aqueous solution (34), a range consistent with passive diffusion through the 
NPC. Systematic time-lapse imaging was then performed on each type of copolymer using 
size fractions near the cutoff for entry. By using polymers near the nuclear uptake size 
limit, differences in the rate of nuclear uptake due to chemical composition might be 
characterized.  
 
4.3.6 Kinetics of Nuclear Entry of Copolymers  
The use of well-characterized synthetic macromolecules with well-controlled 
molecular size permitted to better characterize the passive transport characteristics of the 
NPC. Macromolecular size and shape of HPMA copolymers could be held constant while 
the chemical functional groups were altered. Because all the copolymers were charged and 
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relatively hydrophilic, they were all assumed to possess a similar extended, random coil 
structure in solution, given the presence of counterions. Small changes in import kinetics 
could be detected and attributed to surface chemical interactions apart from the dimensions 
of the macromolecules. To this end, time-lapse imaging of MDAH2774 cells after cytosolic 
injection was performed using all of the intermediate-sized F7 fractions of the 5% 
copolymers (Mw = 36 ± 6 kDa) in the polymer array. This copolymer size range has been 
shown in preliminary studies to enter the nucleus in a time range of 1–6 h, a window 
convenient for reproducible image analyses. Samples from the time-lapse imaging are 
shown in Figure 4.9. for copolymer 5% GFLG-P-F7. 
For comparison, fractionated pHPMA was used as a control. Imaging of the cells 
injected with control (neutral) homopolymers was taken rapidly (3 min/frame) to create a 
baseline with a minimized experimental error. Cells microinjected with HPMA copolymers 
were imaged using longer time intervals (10 or 15 min/frame). The time-lapse movies of 
the cells after microinjection of each of the six types of polymer revealed a large amount 
of both qualitative and quantitative data. 
 
4.3.6.1 Observational Summary of Time-lapse Movies after 
Microinjection of Copolymers 
• 5% SEMA-P (Strongly acidic): Entry of the polymer into the nuclear is relatively 
quick, although not completely uniform. Maximum nuclear concentration is reached 
in 60 to 90 min. Rounding of the cells after injection suggests some toxicity to the 
cells. 
• 5% MAA-P (Weakly acidic): Entry of the polymer into the nucleus is relatively 
 154 
quick, although the concentration in the nuclei never surpasses higher than half the 
starting concentration in the cytosol. The maximum nuclear concentration is reached 
in less than 30 min. Loss of adhesion and rounding of the cells after injection suggests 
some toxicity to the cells. 
• 5% DEMA-P (Weakly basic): Entry of the polymer into the nuclei is quick and very 
uniform. The maximum nuclear concentration is reached in less than 60 min for all 
cells. The cells remain well attached and spread during the time course indicating that 
the polymer is not significantly toxic. 
• 5% and 20% MATC-P (Strongly Basic): In each case, entry of the polymer into 
the nucleus was immediately followed by collapse of the nuclei and the whole cell. 
Nuclear entry appears to be dose-dependent as the cells with the lightest fluorescence 
exclude the polymer from their nuclei throughout the time of observation and never 
round or collapse. It may be hypothesized that the nuclear membrane is impermeable 
to the cationic polymer at low concentration, but destabilizes the membrane at higher 
concentrations allowing the polymer to quickly enter after that point. Nuclear entry 
is typically observable after 60 min for both comonomer concentrations. The polymer 
is toxic to the cell once in the nucleus at high enough concentration, perhaps due to 
condensation of genomic DNA. 
• 5% GF-P (Peptide polymer): Entry of the polymer into the nuclei was slow and not 
very uniform. The maximum nuclear concentration is reached doesn’t appear to be 
reached within 3-4 h and quantitation is complicated by the rounding of the cells 
during the time course. These results are most similar to those found using the 5% 
MAA polymer. 
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• 5% GFLG-P (Hydrophobic peptide polymer): Entry of the polymer into the nuclei 
is slow and uniform. The maximum nuclear concentration doesn’t appear to be 
reached within the 4 h of the time course. The cells remain attached and spread during 
the time course indicating that the polymer is not disruptive to the cell’s structure. 
There appears to be some localization of the polymer to the perinuclear space and the 
nuclear membrane.  This localization was not seen with higher molecular weight 
GFLG polymer so it cannot be identified as a specific localization to a subcellular 
compartment. 
 
4.3.6.2 Nuclear Uptake Kinetics 
In all cases, copolymer entry into the nucleus was consistent with first-order 
kinetics and the data were fit to rising exponential functions (Figure 4.10.). P values for 
calculated equilibrium N/ C (nuclear/cytoplasmic) ratios (Req) and import rate constants 
(k) were typically 0.001 or less. For all polymer types the final equilibrium ratios of nuclear 
versus cytoplasmic concentrations were less than unity, and ranged between 0.4 and 0.9. 
Since the polymers possessed some polydispersity and the average Mw varied between 
polymer types, one possibility was that these differences in equilibrium concentration 
reflected a fixed molecular cutoff for polymer entry; however, there was no statistical 
correlation between polymer molecular weight distribution (SEC) and the equilibrium 
nuclear to cytosol concentration ratio (data not shown).  
Overall, the calculated nuclear import rate constants and equilibrium nuclear 
concentration ratios were significantly different between some copolymer types. The 
calculated import rate constant (k) for the control pHPMA polymer was 0.0454 min−1, 
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corresponding to a relatively rapid time (1–2 h) for uptake. The only two copolymers with 
statistically equivalent import rates were the two weakly charged copolymers 5% MAA-P 
and 5% DEMA-P, with similar rate constants. Forming another distinct group, the two 
strongly ionic copolymers and the hydrophobic 5% GF-P copolymer had import times 
which were significantly longer than the control pHPMA, between 2–3 h. Interestingly, the 
hydrophobic 5% GFLG-P peptide copolymer had the longest import requiring 4–5 h to 
reach equilibrium. In general, the kinetics of uptake of the different copolymers were found 
to be moderately, but significantly affected by their respective chemical characteristics. 
The weakly charged hydrophilic copolymers were found to possess uptake kinetics little 
different from the pHPMA control. 
It can be concluded that the kinetics of nuclear entry of copolymers with different 
chemical compositions became distinguishable as the molecular weight of the polymers 
approached the size limit for passive diffusion through the NPC. It is possible that the 
hydration layer effects of the proteins and copolymers may have played a general role in 
transport rates. The “uncharged” pHPMA control polymer and weakly ionic copolymers 
had the fastest transport rates, and decreased charge in the hydrophobic environment of the 
pore may account for more free movement. The two strongly ionic copolymers had 
permanent charges, and repulsion from these charges may have created a barrier to 
transport by reducing partition into the hydrophobic NPC pore environment. It is also 
possible that the different copolymers may preferentially associate with proteins or other 
biological agents in the cell that may have greatly changed their hydrodynamic size or their 
relative affinity for the nucleoporins (Nups), the proteins that compose the internal 
structure of the NPC channel. Alternately, the slower transport rates for the peptide 
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copolymers may reflect a higher interaction between the polymers and Nups, where the 
higher hydrophobicity of the peptide copolymers produced a higher partition ratio into the 
nuclear channel, but a slower release rate from the interior side of the pore. The low release 
equilibrium into the nucleoplasm may have presented the rate-limiting step for nuclear 
entry of the peptide copolymers. Overall, nuclear import may have been optimized for the 
copolymers with minimal capacity for interaction with biological macromolecules.  
 
4.3.6.1 Nuclear Entry by FP Peptide Copolymers 
The results of nuclear import kinetics using copolymers with GF and GFLG 
peptides, GF-P and GFLG-P, were of interest to recent work in modeling the dynamics of 
the structure of Nups to explain the dual size selection of active versus passive nuclear 
transport selection by the NPC. The structure of Nups is most notable due to the role 
natively unfolded domains play in controlling NPC transport kinetics (24-29, 46, 47). 
These unfolded domains are referred to as FG-regions due to their characteristic 
hydrophobic repeat peptide sequences containing FG, frequently including GLFG, and 
FXFG. It was by happenstance that two of the HPMA copolymers used in the initial cohort 
of samples in this study possessed similar (though inverted) peptide sequences, GF and 
GFLG. Furthermore, the average half-life of nuclear entry of the peptide copolymers (but 
not the molecular weight cutoff) was significantly higher, particularly for the GFLG 
copolymer. The overall pattern of the rate of nuclear entry was possibly merely a function 
of the relative hydrophobicity of these polymers. However, the slower import kinetics of 
the GFLG tetrapeptide copolymer were also suggestive that this polymer may be able to 
interact with proteins in the NPC channel in a specific manner that may resemble Nups or 
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the activity of the Nups- binding proteins responsible for active transport through the NPC 
(karyopherins). Subsequent experiments with an array of peptide-containing copolymers 
were designed to explore this possibility further.  
 
4.3.7 Nuclear Transport Modulation with FG-peptide Copolymers  
The 5% GGLFG-P and 5% GGFG-P (Table 4.2.) were selected to evaluate the 
potential of HPMA copolymers with FG motifs to modulate the kinetics of nuclear uptake. 
In these copolymers the FG sequence matched the correct sequence directionality of Nups 
and a spacer between the FG motif and the polymer backbone increased the accessibility 
for protein binding. Moreover, the peptide side chains were terminated with amides to 
remove the negative charge that would be directly adjacent to the putative binding sites.  
In Figure 4.11. the calculated nuclear uptake half-lives and equilibrium 
nuclear/cytosol ratios, respectively, are shown for “F7” fractions of both copolymers after 
microinjection into the cytosol of MDAH2774 cells. The kinetic results showed that both 
copolymers displayed extended uptake half-lives similar to those measured for the 5% 
GFLG-P-F7 copolymer. In contrast, only the 5% GGFG-P-F7 copolymer yielded an 
equilibrium nuclear concentration significantly higher than that derived for control 
pHPMA. These results suggested that the rate of polymer transport through the NPC was 
affected by the overall hydrophobicity/hydrophilicity of the copolymers rather than by 
specific peptide interactions with nucleoporin proteins. The higher equilibrium nuclear 
concentration of the 5% GGFG-P-F7 copolymer, however, raised the possibility that this 
copolymer affected an increase in the molecular weight cutoff for diffusion through the 
NPC.  
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4.3.8 Polymer Coinjections  
Because the peptide copolymers are presumed to interact directly with the 
nucleoporin cross-linking domains, general effects on NPC transport were evaluated using 
fractionated pHPMA labeled with Texas Red (TR-P) as nuclear exclusion marker (Table 
4.2.).  
For time-lapse imaging, FITC-labeled peptide copolymers were injected 
simultaneously into MDAH2774 cells with TR-P. As controls, separate regions of cells 
were injected with either the test or marker copolymers alone. When this approach was 
used, small changes in the kinetics of transport through the NPC affected by the peptide 
copolymers could be measured separately from the uptake kinetics of the peptide polymer 
itself. This precision in the experimental design and use of several types of controls were 
included to overcome several potential sources of experimental error. Pressure 
microinjection of high concentrations of the HPMA copolymers introduces several factors 
that may have interfered with the quantization of intracellular polymer concentrations over 
time. The injected cell’s responses to the physical trauma of injection and the dispersal of 
copolymers may include direct damage to the nuclear membrane, mitosis in the cell, or 
other stresses that induce apoptosis or necrotic death. These can affect the structure of the 
nuclear envelope and obscure measurements of NPC-mediated nuclear uptake. For these 
reasons, data were collected from many separate cells and were used only from cells that 
remained morphologically stable and intact (alive) for the duration of time-lapse imaging. 
Cells that had very high initial concentrations or sudden increases in nuclear copolymer 
concentrations were excluded from data analysis.  
Presuming that the FG peptide copolymers affect Nup cross-links and that this 
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interaction had a measurable effect on NPC transport, these changes were hypothesized to 
have several possible manifestations. One was that the copolymers might form their own 
cross-links with the Nups. If stably cross-linked, the polymers may have had the effect of 
blocking the NPC pore or tightening a putative hydrogel mesh structure. This may express 
itself as slowing the rate of pore transport or lowering the molecular weight cutoff of the 
channel. Alternately, the copolymers may have disrupted the Nup FG-domain cross-links 
or alter the dynamics of cross-linking. Given the hydrogel model of Nup structure (24, 26, 
27), a phase transition in the pore structure may be affected similarly to the hypothesized 
mechanisms of active nuclear uptake by importin proteins. These changes may be 
expressed by increased uptake kinetics or a large increase in the size of macromolecules 
able to transit the NPC. Because it is known that the larger copolymers contained an 
increasing number of FG-peptides per polymer chain, different sizes of copolymer were 
anticipated to have different effects on transport, depending on the model of Nup structure.  
Coinjections with the TR-P-F6 (Mw = 45 kDa) marker polymer were performed to 
better evaluate whether the test copolymers increased the molecular weight cutoff of NPC 
transport. Because of its molecular weight distribution, TR-P-F6 was largely excluded from 
passive nuclear uptake for up to 12 h. Preliminary coinjections determined that noticeable 
increases in nuclear uptake only occurred when the lowest molecular weight fractions (F9) 
from each peptide copolymer were used. In addition, differences in marker polymer uptake 
only occurred when the peptide copolymer concentration was higher than a given 
threshold. For microinjections using 5% GGFG-P-F9 and 5% GGLFG-P-F9, it was found 
that polymer concentrations greater than 1 mg/ml were required given microinjection 
volumes less than 5–10% of the total cell volume, or an intracellular copolymer 
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concentration greater than 50–100 μg/ml. 
In the final series of coinjection experiments, 5% GGFG–P-F9 (Mw = 15 kDa) and 
5% GGLFG-P-F9 (Mw = 14 kDa) were each coinjected with TR-P-F6 marker polymer into 
MDAH2774 cells and then imaged for 8–12 h. Differences in the rate of nuclear uptake of 
the marker polymer were directly derived from a comparison of the coinjected cells and 
cells injected with the TR-P marker polymer alone. As shown in Figure 4.11., coinjection 
with 5% GGFG-P-F9 (but not 5% GGLFG-P) significantly increased the import rate 
constant and total equilibrium nuclear concentration of TR-P-F6 marker pHPMA 
compared to marker polymer alone. These results showed that the incorporation of the FG 
peptide motif onto HPMA copolymers had a small but measurable effect on the molecular 
size of solutes able to diffuse into the nuclei of nondividing cells. Although time to reach 
equilibrium was not increased significantly, the initial rate of uptake increased more than 
3-fold, and the apparent molecular weight cutoff of the NPC channel was effectively 
increased by 20–30%.  
The subtle variations in the kinetics of the different chemical types of copolymers 
near the molecular weight cutoff of passive nuclear uptake correlate well with the expected 
differences in binding to the hydrophobic domains of Nups. This observation is consistent 
with the repulsive exclusion models of NPC gating and passive transport (48, 49). It is also 
consistent with models of partitioning into the hydrophobic interior of the pore (50). 
However, more consensus between all of the competing models of NPC transport is 
required to fully interpret the meaning of these differences in transport (51-53). None of 
the FG-peptide copolymers dramatically increased the rate or the molecular weight limit 
of nuclear import in a manner that would suggest a complete phase transition of a putative 
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reversible Nup hydrogel. The importance of this is difficult to evaluate since the 
copolymers did not possess Nup binding sites analogous to those found on karyopherin 
proteins. Without a direct determination of the binding affinity between the copolymers 
and the Nups, it is difficult to evaluate the implications of unaltered uptake dynamics. The 
most striking result, however, was the shift in the molecular weight cutoff of nuclear uptake 
affected by low molecular copolymers containing GGFG peptides. This shift in NPC 
dynamics was significant, but was only seen using GGFG peptide and not with the GGLFG 
peptide polymer. It can be speculated why there was an observed difference in effects 
between the two peptides. One possibility is that the GGFG moieties weakly bound to FG-
domain cross-links in a way that altered the dynamics of a putative Nup hydrogel structure, 
whereas GGLFG peptides would be expected to bind more strongly and not allow a rapid 
transfer of cross- links. These issues would be best resolved in future studies using 
copolymers created with more carefully controlled copolymer substitutions. For example, 
uniform low molecular weight polymers with exactly one, two, or more peptide groups 
would be useful to determine if the effects observed here were influenced by single vs. 
multimer binding to Nups. An essential preliminary to further this work would be to 
characterize the exact binding properties of a test polymer with Nup proteins in vitro before 
evaluating their effects in living cells.  
 
4.4 Conclusions 
HPMA copolymers were chosen for this series of experiments that exhibited a very 
wide range of chemical characteristics. This effectively served as a “copolymer library” to 
survey the basic interactions between synthetic polymers and living cells. All polymer 
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species were shown to be naturally uptaken by cells via endocytosis and are all ultimately 
trafficked to the lysosomal compartment.  
HPMA copolymers directly microinjected into the cytosol of live cells proved to 
have very little interaction with any macromolecular component in the cell and were 
specifically excluded from all membrane-limited subcellular compartments, with 
exception of the nucleus. All copolymers rapidly and evenly diffused throughout the 
cytoplasmic compartment following microinjection, and the smallest copolymer fractions 
also rapidly diffused into the nucleus. After 24 h, most polymers freely diffused throughout 
the cell and remained at relatively equivalent concentrations where not membrane-limited, 
though variations were noted during time-lapse confocal live imaging. The exception to 
passive intracellular diffusion was the strongly cationic copolymer containing 20% MATC, 
a quaternary amine. This copolymer was found to exclusively localize to microtubules over 
a period of 2–12 h.  
Nuclear entry from the cytoplasm was dictated by size-limited passive diffusion 
through the NPC. However, small but significant differences in rates of nuclear import 
were observed for polymers with sizes near the molecular weight exclusion limit as a 
function of the charge and hydrophobicity of the copolymers. HPMA copolymers 
containing peptides with Nup cross-linking sequences were found to exert a significant and 
specific, though modest, effect on the kinetics of NPC transport. It was found that low 
molecular copolymers possessing GGFG pendant groups (but not GGLFG peptides) 
increased the molecular weight threshold for passive uptake through the NPC channel. This 
was observed for the 5% GGFG copolymer itself and with coinjected polymer acting as a 
nuclear exclusion marker. It was hypothesized that interactions with the GGFG copolymer 
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may have altered the dynamics of Nup cross-linking in the NPC channel rather than 
affecting any general conformational transition in the proteins’ structure. However, since 
the structure and function of Nup proteins in the nuclear pore is still an active area of debate 
(54), it is difficult to conclude whether the kinetics of FG-containing polymers were likely 
affecting FG-crosslinks due to the presence of their peptide pendant groups. However, 
more recent research has revealed that the Nup98 protein has a critical role in the exclusion 
of macromolecules through the NPC. Further, the Nup98 protein possesses terminal GLFG 
repeats whose interactions are critical for their function (55). As the structure/function 
relationships of Nup proteins are better modeled, the effect of the peptide copolymers used 
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Figure 4.1. General synthetic scheme for HPMA copolymers 
Figure 4.2. Structures of the monomers used to create the array of copolymers 
 171 
  
Table 4.1. Characterization of microinjected HPMA copolymers.  




Figure 4.3. Example of the structure of an array HPMA copolymer. 
5% MATC-P:  HPMA, MATC, MA-FITC copolymer 
Figure 4.4. Size-exclusion chromatography profiles for fractionated 5% MAA-P 
with average Mw indicated for each fraction 
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  Figure 4.5. Confocal images of MDAH2774 after 24 h incubation with 
0.5 mg/ml F9 fractions of HPMA copolymers. Examples shown are (a) 20% 
DEMA-P, (b) 20% MAA-P and (c) 5% GFLG-P 
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Figure 4.6. Typical images from confocal laser scanning fluorescent 
microscopy (40× mag.) of live MDAH2774 ovarian carcinoma cells after 
microinjection with FITC-labeled polymers. The transmitted images are on the 
left. On the right, images represent fluorescent FITC-labeled copolymer. (a) 
20% MATC-P-F8 (Mw = 23 kDa) 15 min after microinjection. Polymers under 
25 kDa immediately dispersed in cytoplasm and nucleoplasm, but were 
excluded from other membrane-limited organelles. (b) 5% SEMA-P-F4 (Mw = 
125 kDa) 24 h after microinjection. Polymers over 75 kDa remain excluded 
from the nuclei and all membrane-limited organelles. All polymers except for 
20% MATC-P remained evenly dispersed throughout the cytoplasm and 
excluded from subcellular structures, as demonstrated in this example 
 175 
  
Figure 4.7.  Example of time-lapse imaging from FRAP. Here, 
MDAH2774 cells were microinjected with copolymer 5% MAA-P-F4 (Mw 
= 96 kDa) 2 h before the experiment. Area was bleached as indicated and 
cytosolic copolymer rediffused and restored equilibrium concentration 
within 3 s. The free diffusion in the cytoplasm of relatively high molecular 
weight copolymers was demonstrated 
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Figure 4.8. Typical images of fixed MDAH2774 cells after microinjection with 
strongly cationic copolymer 20% MATC-P-F4 (Mw = 103 kDa), thereby 
demonstrating its localization on microtubules. Cells were microinjected with 
copolymer 24 h before fixation with 3% paraformaldehyde. Microtubules were 
labeled using E7 antitubulin primary antibody, which was visualized using a goat 
antimouse 555-Alexafluor secondary antibody. The transmitted image is shown in 
(a). The green channel (b) is from the FITC-labeled copolymer and the red channel 
(c) shows microtubule staining. Overlay fluorescent image (d) demonstrated 
microtubule colocalization with the copolymer although some inhibition of the 
antitubulin antibody was evident when injected cells were compared with 
noninjected cells  
 177 
  
Figure 4.9. Time series of a single z-slice of MDAH2774 ovarian carcinoma 
cells microinjected with 5% GFLG-P-F7 (Mw = 34 kDa; hydrophobic peptide) as 
a 1 mg/ml polymer solution in PBS. Green indicates HPMA copolymer and entry 
into the nuclei is shown over time 
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Figure 4.10. Nuclear uptake kinetics for copolymer injected cells (a) Nuclear 
uptake rate constants k (min−1) for 5% copolymers. (b) Equilibrium 
nuclear/cytosol polymer concentrations (Req) for each copolymer type. (N = 5–9 




Figure 4.11. Summary of the nuclear uptake kinetics of co-microinjected TR-P-
F6. Inset graph on the left shows the nuclear uptake rate constants k (min−1) and inset 
graph on the right shows the equilibrium nuclear/cytosol polymer concentrations 












5.1 Bispecific Fab’ Conjugates for the Targeting of HPMA Copolymers 
Despite a great deal of method development, no PEG dimerized Fab’ constructs 
were synthesized suitable for conjugation to HPMA-drug conjugates. Only homospecific 
OV-TL16 (Fab’)-PEG dimerization constructs were successfully made in yields that could 
be well characterized. All attempts to crosslink the UIC2 anti-P-gp, anti-EGFR, and HER-
2 antibodies resulted in low yields due to protein degradation, chain disassociation, and the 
production of PEG side products. The refinement of Fab’ production from IgG2a 
antibodies was successful for Fab’ conjugation directly to activated HPMA copolymers 
(1), however, the UIC2 mAb proved to be too unstable for dimerization using PEG 
crosslinkers. Indeed, purified UIC2 (Fab’)2 fragments were found to significantly degrade 
and aggregated in storage at 4°C after just a few days. Some issues were by resolved the 
use of gentler reaction conditions by switching from bismaleimide to bisvinyl sulfone 
crosslinkers; however, this was not enough to produce sufficient yields for subsequent 
conjugation reactions. 
In retrospect, it is not surprising that we encountered trouble with the stability of 
the UIC2 (Fab’)2 fragment. Indeed, in the field of therapeutic antibodies, finding methods 





active area of development for mAbs and genetic engineered antibody constructs. It is now 
a well-known problem in antibody purification that high protein concentrations are prone 
to loss of material due to protein unfolding/denaturation, self-aggregation, intermolecular 
crosslinking, and colloidal stability (2). 
“Stability engineering” of antibodies is a very active area of current research (3). 
This has been prompted by the greatly expanded industry of antibody products as 
therapeutics and the large number of production problems associated with purified 
antibodies and antibody products (4). Much of the work to modify antibody products is due 
to the difficultly of optimizing the structure, colloidal stability, binding constant, and 
effector functions of the proteins simultaneously. The genetic constructs are modified in 
many ways, with the most common being isotype switching where the constant domains 
of different isotypes of antibodies are swapped out (5). 
For therapeutic and targeting purposes, Fab fragments from monoclonal IgG 
antibodies continue to be used extensively. The use of Fab’ from reduced (Fab’)2 fragments 
has fallen out of favor due ongoing problems with low yields, disulfide scrambling and 
protein stability. Problems with Fab’ fragments for use in synthetic chemistry have been 
associated with linker cyclization, protein aggregation and disulfide instability in the 
constant domains. One approach that has been successful in resolving the major problems 
with the use of Fab’ fragments has the development of thiol-specific bridging moieties. 
These are bifunctional crosslinkers that effectively replace the disulfide bond with dithiol 
bonds connected by a short carbon spacer 
As shown in Figure 5.1., these include dihalomaleimides and dithiolmaleimides (6, 





crosslinkers, these linkers can be attached in situ in a single reaction step and have much 
higher yields (11). The resulting crosslinking spacers are also much more stable than 
previous reaction products. 
 
5.1.1 PEG Dimerized Fab’ Fragments 
Using PEG as a linker between two Fab fragments has continued to be developed 
and investigated as a potential stand-alone therapeutic. For example, Khali et al. have 
developed an efficient method of creating PEG dimerized Fab fragments, rather than Fab’ 
fragments. The term “antibody mimetics” has been coined to describe their structure and 
function (12). 
For a series of mAbs, the protein is digested with papain to produce free Fab 
fragments. These are then crosslinked using a PEG-di(monosulfone), a bis-thiol-specific 
conjugation dimerizer. Conjugation is accomplished by a sequence of addition–elimination 
reactions that has the net effect of inserting thiol ether bonds and a 3-carbon methylene 
bridge in the place of the terminal cysteine bridge of the Fab fragments. Due to the 
accessibility of the terminal disulfide bonds of the Fab fragment, this produces a very 
efficient, site-specific conjugation chemistry. The resulting conjugate is stabilized by 
replacing the cysteine disulfide bond at once in situ with a covalent spacer. This has been 
demonstrated to not only dimerize the Fab fragments via a PEG linker, but the resulting 
thiol ether bonds are more stable than the original disulfide bond. The PEG linkers used 
have ranged from 6-20 kDa. For later work, 20 kDa was chosen to duplicate the topography 
and hydrodynamic volume of unmodified whole IgG proteins as much as possible. This 





unmodified IgG antibody proteins by preventing disassociation of the Fab light chain (13-
15). 
The binding kinetics of two of the Fab-PEG-Fab constructs was determined using 
surface plasma resonance. Constructs using the commercially available mAbs 
Bevacizumab (anti-VEGF-A) and Trastuzumab (anti-HER2/neu) were made. In both cases, 
the binding constants of the Fab-PEG-Fab construct were somewhat lower than the 
unmodified mAbs, but in both cases the ka constants were lower but the kd constants were 
much higher. These results are consistent with the binding constants measured for the 
homospecific OV-TL16 Fab’-PEG-Fab’ studied here. 
The same research group has created monospecific PEG linked IgG1 anti-TNF-α 
conjugate that is currently being used in animal testing for the treatment of uveitis, a non-
infectious inflammatory disease of the eye (12). Their PEG dimerized Fab fragment 
(termed “FpFinfliximab”) was created using Fab’ fragments derived from the commercially 
available therapeutic mAb Infliximab, which is clinically approved for the treatment of 
inflammatory conditions such as rheumatoid arthritis, and is used off-label to treat uveitis. 
This application was chosen as it had previously been indicated that the Fc receptors in the 
eye cause the Infliximab mAb to be rapidly cleared.(16-19) In EAU (experimental 
autoimmune uveoretinitis) mice, it was found that FpFinfliximab and Infliximab were equally 
effective in reducing the infiltration of CD45+ cells after a single injection before the peak 








5.1.2 Drug-free Therapeutic Polymers 
More recent developments in macromolecular conjugates have incorporated the 
concept of oligomerization of cell receptors and Fab’ targeting, and taken it in a novel 
direction to create a new class of drug-free therapeutics. Rather than dimerizing recognition 
motifs directly on the carrier, new systems have been successfully developed that use 
complementary paired conjugates that are able to induce conjugation and activation of cell 
surface receptor proteins in situ after binding to the cell surface. These use pairs of either 
antiparallel coiled-coils peptide sequences or complementary oligonucleotides 
In these systems, a Fab’ fragment is coupled to one sequence of the pair, and 
multiple copies of the complementary sequence are conjugated to an HPMA copolymer. 
The Fab’ conjugate is applied first to prime the cells with one of the complementary pairs. 
Next, the polymer with the other complementary sequence is applied. Binding to the 
copolymer via the complementary pairs induces the interactions and activation of the 
targeted receptor protein. This approach has been successfully used to induce apoptosis in 
CD20+ lymphoma cells. 
This approach was used with anti-parallel coiled-coil peptide sequences and anti-
CD20 Fab’ fragments to create recognition pairs able to activate CD20 receptor proteins 
on lymphoma cells. When this system was used on Raji B cells, high levels of apoptosis 
were observed in vitro, and long-term survivors were observed in vivo in a lymphoma mice 
model (20, 21). A similar approach, using complementary morpholino nucleic acid analog 
oligomers as complementary recognition pairs, was shown to be even more effective. In 






5.1.3 Bispecific Targeting for Cancer 
Cancer treatments employing the general concept of bispecific targeting has 
expanded greatly since the time of this work. Using bispecific antibody constructs is now 
one of the most promising strategies for the treatment of cancer. Table 5.1. displays a 
selected list of bispecific antibody constructs that are undergoing clinical testing or have 
been approved for clinical use (23). All of the bispecific or multispecific antibody 
constructs that have reached clinical testing are the result of molecular biological 
techniques that engineered antibody domains.  
 
5.2 Mitochondrial Targeting Using TPP 
In retrospect, the inability of TPP-HPMA to achieve mitochondrial localization or 
plasma membrane transduction is not surprising given polymer molecular weights over 3 
kDa. Only one paper in 2011 has reported the successful use of a single TPP moiety to 
traffic a PNA or any other macromolecule over 3 kDa, since the original 2001 paper by 
Murphy et al. (24). TPP is still used to target drugs to mitochondria; however, it has been 
found that uptake and localization of larger molecules requires multiple TPP moieties. The 
conjugates containing a single TPP moiety have used been used successfully to target small 
molecules, such as doxorubicin (25), MitoC, a derivative of ascorbic acid (26), and 1,8-
naphthalimide, a fluorescent probe (27). 
Large molecules and delivery of large payloads of LMW drugs have been 
successfully developed using TPP localization, but these have used nanoparticles that 
possess many TPP moieties on their surface. Polymeric micelles, liposomes and dendritic 





are incorporated in the resulting complexes. They are termed “second generation” carriers 
for the targeting of mitochondria and are being developed as potential treatments for a 
range of diseases (28). For example, liposomes incorporating stearyltriphenylphosphonium 
bromide (STPP) were shown to localize encapsulated paclitaxel to mitochondria in 
OVCAR-3 cells (29). The liposome were prepared from mixed lipids consisting of lecithin 
(PC), cholesterol (Chol), and STPP at a molar ratio of PC:Chol:STPP = 65:15:2.  
Mitochondriotropic dendrimers were created with branched poly(amidoamine) 
(PAMAM), PEI (poly(ethyleneimine)), and with oligolysine copolymers incorporating 
monomers functionalized with TPP (30-33). These were synthesized to possess surface 
termini functionalized with many triphenylphosphonium moieties. These have the potential 
to be an effective drug delivery system by encapsulating drugs or other bioactive molecules 
in their core or by conjugation on their surface.  
After the results described here using semitelechelic TPP-HPMA, the lipophilic 
cation was used to increase the efficacy of a traditional lysosomotropic HPMA-drug 
copolymers. Cuchelkar et al. constructed HPMA copolymers containing monomers with 
TPP coupled to the photosensitizer drug Mce6 (mesochlorin e6), both linked by a 
degradable spacer to the copolymer backbone (34). TPP and Mce6 were coupled via a 6-
carbon spacer which was itself linked to the pendant group of a comonomer by a disulfide 
bond. An analogous copolymer was synthesized with BODIPY FL in place of Mce6 to 
track the location of the conjugate. When this copolymer was incubated with ovarian 
carcinoma cells, it was shown to be initially trafficked to lysosomes. After several hours, 
TPP-BODIPY FL was observed to be released from lysosomes and localized to 





functionalized Mce6 was only somewhat more effective at inhibiting the growth of ovarian 
carcinoma cells compared to HPMA-Mec6 conjugate without TPP. It was also observed 
that the relative cytotoxicity of the TPP conjugate plateaued over time, and after 12 h, TPP 
targeted Mce6 was only slightly more cytotoxic than HPMA-Mce6 conjugates without TPP. 
 
5.2.1 Conclusions on Mitochondrial Targeting with TPP 
Targeting mitochondria remains a promising approach for the treatment of cancer 
and other diseases. However, the work here and the work of others has revealed some of 
the obstacles of using carriers targeting using lipophilic cations. This method of localizing 
to mitochondria is generally effective; however, the organelle has a complex structure with 
an inner and outer membrane and carriers do not necessarily partition into the needed area. 
It is also difficult to selectively release free drug in mitochondria as there are no effective 
enzymes or other obvious physio-chemical conditions that could be used for drug release. 
Others have found that TPP-conjugated carriers and TPP-drug conjugates are inactivated 
due to high binding to the inner mitochondria membrane (35, 36). Using cations also 
appears to be self-limiting since the binding of lipophilic cations progressively lowers the 
electronegativity of the mitochondria over time (37). This effect may explain the loss of 
cytotoxicity seen over time during growth inhibition studies. This may also be the source 
of nonspecific cytotoxicity that has been reported for some TPP-drug conjugates, 








5.3. Large Polymer Array 
 The large polymer array was designed to observe polymer-cell interactions in a 
systematic way that had never been explored before. When new, engineered materials are 
exposed to cells in vitro or in vivo, they often behave in unexpected ways. Cell binding, 
cell uptake, intracellular trafficking and distribution occur in unexpected ways. Comparing 
structurally parallel, but chemically diverse, HPMA copolymers provided us with an 




 After the experiments in Chapter 4, Lui et al. (39) used the same array of polymers 
to characterize their uptake and trafficking by endocytosis in more detail. To observe cell 
internalization, array polymers were added to the media of cultured C4-2 prostate 
carcinoma cells. Uptake concentrations were measured by flow cytometry, and endocytosis 
was characterized using confocal microscopy. A series of inhibitors were used to determine 
differences in the endocytotic pathways used by the different array copolymers. 
 
5.3.1.1 Uptake Measurements by Flow Cytometry 
The C4-2 cells were seeded in 12-well plates at a density of 2.5 × 105 cells per well 
and incubated in medium for 1 day (37°C, 5% CO2). Then cells were incubated with 
copolymers at 37°C for the indicated time periods. The concentration of copolymers used 
                                                 
1 Parts of the following sections were adapted with permission from: J. Liu, H. Bauer, J. Callahan, P. 
Kopečková, H. Pan, J. Kopeček Endocytic uptake of a large array of HPMA copolymers: Elucidation into 
the dependence on the physicochemical characteristics. Journal of Controlled Release, 2010. 143(1): p. 71-





was 0.1 mg/ml in this type of study. After incubation, medium was removed. Cells were 
harvested and washed with PBS three times followed immediately by flow cytometry 
analysis. For each, 1.0 × 104 cells were processed and the mean fluorescence intensity was 
recorded for each sample. 
Mean fluorescence intensity of each sample was converted into amount of 
copolymer taken up by the cells using flow cytometry and fluorescence plate reader. The 
fluorescence intensity of copolymers in cells was obtained from both flow cytometry 
analysis and fluorescence plate reader measurement. Meanwhile, the amount of FITC (ng) 
in the same sample was measured using the fluorescence plate reader. Hence, based on the 
content of FITC in each copolymer, the amount of copolymer in cells was derived. 
 
5.3.1.2 Inhibition of Uptake Via Endocytic Pathways by Selective Inhibitors  
Cells were preincubated in medium containing a selective chemical inhibitor of 
endocytic pathways for 30 min. Next, polymers were added in the presence of the inhibitor. 
Then cells were further incubated for fixed periods of time and harvested for flow 
cytometry. The inhibitors used, their concentrations, and pathways they inhibit are shown 
in Table 5.2. 
 
5.3.1.3 Uptake of Polymers by C4-2 Cells  
Subsequent, more detailed, analysis of the internalization of the array polymers 
using C4-2 cells revealed the differences in the endocytic pathways the copolymers 
followed. Fluid phase endocytosis is observed when membrane vesicles entrapping fluid 





perinuclear areas. Adsorptive endocytosis occurs when surrounding solutes associate with 
plasma membrane. In our studies, internalization of copolymers by cells was observed and 
captured under confocal microscope. For neutral pHPMA (P-FITC) and copolymers 
possessing weakly negatively charged groups (20% MAA-P), no internalization was 
detectable within 30 min incubation (Figure 5.1. A and E). The visible perinuclear 
localization of these copolymers was noticed after incubation for 4 h (Figure 5.1. B and F) 
and was more significant after prolonged incubation (Figure 5.1. C and G). For copolymers 
possessing strongly negatively charged groups (20% SEMA-P), perinuclear localization of 
copolymers only appeared after 12 h of incubation with cells (Figure 5.1. K). Unlike neutral 
or negatively charged copolymers, the copolymers possessing strongly positively charged 
groups (20% MATC-P) were seen to quickly (within 10 min) associate with the whole 
plasma membrane after exposure to cells (Fig. 5.1. Q), displaying characteristic adsorptive 
endocytosis. Subsequently, the membrane-associated pattern gradually disappeared and 
was replaced by an intracellular pattern, indicating that these membrane-associated 
copolymers were endocytosed into cells (Figure 5.1. S). The copolymers possessing 
weakly positively charged groups (20% DEMA-P) behaved similarly but less dramatically 
(Figure 5.1. M-O). In addition, P-FITC and HPMA copolymers containing different 
functional groups were found to colocalize with dextran 10 kDa, a fluid phase endocytosis 
marker (Figure 5.1. D, H, L, P and T). Hence, HPMA copolymers containing different 
charged groups were internalized into cells through different types of endocytosis. The 
neutral homopolymer and negatively charged copolymers were internalized into cells via 






5.3.1.4. The Rate of Endocytic Uptake of HPMA Copolymers  
Flow cytometry was used to quantify the endocytic uptake of copolymers 
possessing charged groups (Figure 5.2.) Mean fluorescence intensity of each sample was 
obtained and converted into amount of copolymer taken up by the cells. Positively charged 
copolymers, 20% MATC-P and 20% DEMA-P, were taken up much more efficiently than 
pHPMA (P-FITC) or copolymers containing negatively charged groups, 20% MAA-P and 
20% SEMA-P. The uptake of copolymers containing negatively charged groups, 20% 
MAA-P and 20% SEMA-P, decreased when compared to P-FITC. Maximum uptake 
occurred with the strongly positively charged copolymer, 20% MATC-P, whereas least 
uptake took place with the strongly negatively charged copolymer, 20% SEMA-P; 5% 
MATC-P and 5% DEMA-P did not show significant increase in uptake, and 5% SEMA-P 
and 5% MAA-P did not show significant decrease of uptake compared to pHPMA (P-
FITC), probably due to a low content of charged groups. Thus, the rate of uptake of HPMA 
copolymers was determined by the structure and content of the charged groups. 
 
5.3.1.5 Effect of Molecular Weight on the Uptake of Charged Copolymers 
 The effect of molecular weight on the uptake of copolymers was evaluated by flow 
cytometry analysis. Copolymer fractions were incubated with cells and the uptake was 
measured. For pHPMA (P-FITC fractions) and negatively charged copolymers (20% 
MAA-P fractions), it was shown that the lower the molecular weight, the higher the uptake 
(Figure 5.4.). While there is little difference in the rate of uptake for small 20% DEMA 
copolymers, there was notable inflection point for copolymers larger than fraction F6 (MW 





positively charged copolymers (20% DEMA-P fractions) decreased with decreasing 
molecular weight. These results suggest that uptake of HPMA copolymer containing 
charged groups is molecular weight dependent, but that the charge or charge density has a 
greater impact on endocytosis. 
 
5.3.1.6  Summary of Results: Endocytosis of Array Copolymers 
All copolymers, regardless of composition, charge or molecular weight, were 
internalized by endocytosis and all were ultimately trafficked to lysosomes, where they 
remained. Even the most strongly cationic HPMA copolymer used (20% MATC-P) was 
not observed to be capable of endosomal/lysosomal escape. Obvious differences in the 
rates and concentration of polymer internalized were noted, but the differences could all 
be (unsurprisingly) attributed to charge differences. Uptake was largely dictated by non-
specific adsorption to the outer plasma membranes of the cells, yielding adsorptive 
endocytosis. Strongly positively charged polymers bound avidly, neutral and hydrophobic 
polymers bound weakly, and strongly negative polymers were repelled from the plasma 
membrane. This simple effect was reflected in differences in the preferred pathway of 
uptake: positively charged copolymers were shown to use micropinocytosis, as well as 
clathrin-mediated and dynamin-dependent endocytosis, weakly negatively charged 
copolymers employed the same pathways but to a lesser degree, whereas the strongly 
negatively charged copolymers were almost entirely uptaken by micropinocytosis. 
 These general results were all expected; however, the rates of adsorptive 
endocytosis for the strongly negative copolymers were also shown to be strongly dependent 





positively charged comonomer (20% MATC-P and 20% DEMA-P) were internalized at 
concentrations 10x-20x higher than the pHPMA control polymer, the 5% MATC-P and 
5% DEMA-P copolymers were absorbed at rates only slightly higher than the control. 
Further, high molecular weight 20% DEMA-P copolymer fractions higher than 50 kDa are 
endocytosed to high concentrations, while 20% DEMA-P fractions lower than 50 kDa were 
internalized at concentrations no different than the control pHPMA. These results revealed 
inflection points where cell surface adsorption occurs; critical charge densities or zeta 
potentials that dictate whether adsorptive endocytosis of a nanoparticle will be the 
dominant uptake pathway.  
Since adsorptive endocytosis is nonspecific, is it usually avoided in the design of 
drug delivery carriers. These results have helped inform others in the design of their 
constructs. Many drug delivery systems are meant to use a specific endocytic pathway and 
these results are frequently cited as an explanation for their choice of design (40-44). 
 
5.3.2 Microinjection 
 Array polymers were also microinjected into the cytosol of MDAH2773 ovarian 
carcinoma cells. The distribution of the copolymers the cells was observed by time-lapse 
confocal microscopy and difference in kinetics of nuclear entry were calculated. Given the 
diverse chemical makeup of polymers, it was surprising how similarly all the polymers 
distributed throughout the cells. All copolymers initially diffused throughout the cytosol 
freely, rapidly and evenly. Low molecular weight fractions of the copolymer (MW = 11-
15 kDa) immediately diffused throughout the cytosol and nucleus, while the largest 





next 24 h, only very subtle differences in their overall distributions were seen, which is 
remarkable considering how diverse their chemical makeup was. After several hours of 
observation, the only copolymers that didn’t remain freely diffusable were the copolymers 
containing quaternary cations (MATC) which avidly bound to the microtubules in the 
cytosol. Furthermore, spot photobleaching (FRAP) of the copolymers in the cells 
confirmed that pHMPA remains freely diffused throughout the cell after 24 h. Sustained 
photobleaching showed that no copolymer was retained within any intercellular 
compartment or structure, including the nucleus. Weakly cationic copolymers were 
expected to preferably bind to organelle membranes or the inner lumen of the plasma 
membrane, but this was not observed. 
 
5.3.2.1 Nuclear Entry 
The subtle variations in the kinetics of the different chemical types of copolymers 
near the molecular weight cutoff of passive nuclear entry is consistent with the repulsive 
exclusion models of NPC gating and passive transport (45, 46). Again, given the broad 
range chemical characteristics of the different copolymers what was most striking was how 
similar all of them behaved. The only type that displayed significantly higher entry kinetics 
and a higher equilibrium nuclear concentration were the weakly basic MATC copolymers. 
For proteins, passive diffusion was considered to be limited in the 30-60 kDa, though more 
recently, it has been proposed that there is a “firm threshold” of 40 kDa for passive 
diffusion through the NPC (47), which is in good agreement with the results found for 
HPMA copolymers. 





interactions with the unstructured Nup proteins in the NPC. However, the differences in 
their entry kinetics remain difficult to interpret. At the time of this study, a simple” Nup 
hydrogel” model had been hypothesized to interpret the structure and function of the NPC. 
Nup proteins containing FG-repeats line the channel of the pore are unstructured (like 
synthetic polymers) and it is known from mutation studies that the hydrophobic 
interactions between FG-rich regions of the proteins are critical for NPC gating. In the past 
10 years, however, competing models of nuclear have been proposed (Figure 5.5.) and the 
precise role of the Nup proteins remains an active topic of debate. Until a consensus on 
NPC function develops, the possible interplay between HPMA FG-peptide copolymers and 
gating into the nucleus will be difficult to interpret. 
 
5.3.3 Other Work Citing Array Copolymers 
 All the observations and results using the large array represented preliminary 
survey of polymer-cell interactions and intracellular distribution due to charge and/or 
hydrophilicity/hydrophobicity, but they have proven useful for other groups developing 
various therapeutic nanoparticles. A review of non-PEG polymers used for therapeutic 
nanomedicines summarized the results for the array polymer study at length (48). 
For example, recent work has used detailed computer modeling to describe the 
uptake and intracellular trafficking of gold nanoparticles used as radio-sensitizers for the 
treatment for cancer. Dobay et al. (2012) used the kinetics values determined in the 
polymer array study for the nuclear entry of 2-4 nm HPMA copolymers to approximate the 





used to predict the concentration of gold nanoparticles in proximity of DNA in the nucleus 
to optimize dosing schedules before radiation treatments. 
Zhong et al. (2016) developed an HPMA-drug conjugate for direct cytoplasmic 
delivery and nuclear targeting by incorporating a cationic MT (microtubule) targeting 
peptide sequence (50). They described their conjugate entering the cytosol using a non-
endocytic microtubule pathway and accumulating in the nucleus. They referenced our array 
polymers, noting that awareness of nonspecific binding of polycationic HPMA copolymers 
to microtubules was important to the design of the conjugate. 
 
5.4 Final Observations 
Since this dissertation is being submitted 10 years after the work described was 
completed, an opportunity is presented to see the advances in our understanding of biology 
and our innovations in nanomedicines in a larger perspective.  
For a polymer chemist developing nanomedicines, our increased knowledge of 
natural protein functions is a bit ironic when presented with the models that describe 
transport in and out of the nucleus through the NPC. All hypothesized simulations of the 
functioning of the unstructured Nup proteins use physio-chemical principles that had been 
developed long ago to describe the structure and function of synthetic polymers. The Nup 
proteins are now often referred to as “block copolymers” and the modelling of their 
structural transformations as hydrogels, or brush/comb conformations are directly 
borrowed from polymer physics. Indeed, the past decade has revealed that intrinsically 
disordered proteins (IDPs) and intrinsically disordered protein domains (IDR) account for 





in a variety of cellular functions (51). In addition to transport through the nuclear pore, they 
have regulatory functions, a central role in the ordered assembly of macromolecular 
machines such as the ribosome, in organization of chromatin, in assembly and disassembly 
of microfilaments and microtubules, in binding and transport of small molecules, in the 
functioning of protein and RNA chaperones, and as flexible “entropic” linkers that separate 
functional protein domains (52-54). All along, Nature has been using the same properties 
of “synthetic’ polymers that had originally been thought to be uniquely man-made. 
From the other side, engineered materials for medical applications have become 
better and better refined to mimic biological structure and function. For example, one of 
the advantages of synthetic materials is that they resist enzymatic or chemical degradation 
in living systems. However, once their function has been completed, lack of polymer 
degradability can have toxic long-term consequences in vivo (55). For this reason, second-
generation, biodegradable HPMA block copolymers have been developed that incorporate 
enzymatically degradable sequences in their backbone structure. These use a combination 
of RAFT (reverse addition-fragmentation chain transfer) polymerization and click 
reactions (alkyne-azide or thiol-ene) to add enzyme-degradable GFLG peptide sequences 
to the backbone of HPMA copolymer-drug conjugates (56). This approach has successfully 
been used to produce drug carriers for doxorubicin, paclitaxel, gemcitabine, and epirubicin 
for the treatment of ovarian cancer (57-60), and as a carrier for prostaglandin E1 for the 
treatment musculoskeletal disease (61). 
The future development of nanomedicines will continue to be a promising approach 
to the treatment of many diseases as the human ability to manipulate the molecular 





nanotechnology, imaging, proteomics, and genomics will inform us to new biological 
approaches, provide new tools to this technology, and produce an endless supply of new 
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Inhibitor Concentration Endocytic pathway 
Chlorpromazine 10 µM Clathrin mediated endocytosis 
Filipin 2.5 µg/ml Caveolae mediated endocytosis Mevinolin 10 µM 
Dynasore 80 µM Dynamin dependent endocytosis 
Amiloride 10 µM 
Macropinocytosis Wortmannin 1 µM 
LY 294002 10 µM 
Table 5.1. Selected list of bispecific antibody constructs that are undergoing 
clinical testing or have been approved for clinical use. (Adapted from Kontermann, 
RE & Brinkmann U (2015) Bispecific antibodies. Drug Discovery Today  
20(7):838-847 






Figure 5.2. Endocytosis and quantification of uptake of HPMA copolymers. 






Figure 5.3. Quantification of uptake of copolymers by flow cytometry. 
Cells were incubated with F6 of copolymers for 12 h. The data shown are 
averages (±SD) of four separate experiments. 
Figure 5.4. Molecular weight dependence of uptake of HPMA copolymers. 
Cells were incubated with medium containing 0.1 mg/ml of different fractions 
of P-FITC, 20%DEMA-P or 20%MAA-P for 12 h. After incubation, cells were 
harvested for flow cytometry analysis. The data shown are averages (±SD) of 






Figure 5.5. Illustration of NPC models (. Each NPC depicted spans the double lipid bilayer 
nuclear envelope, oriented such that the tops of the pores face the cytoplasm, while the 
bottoms of the pores face the nucleus. (A) FG nups form a hydrogel, which transport-factors 
and their cargo complexes transit by binding with FG motifs and temporarily disrupting 
cross-links in the FG nup meshwork.(62) (B) FG nups are collapsed and lie along the wall 
of the NPC, creating a surface to which transport-factors bind and diffuse along in a 
dimensionally reduced manner.(63) (C) FG nups form a polymer brush that binds transport 
factors (possibly collapsing in their presence) but excludes unwanted molecules that do not 
interact with the FG nups.(46) ((D) The di-block copolymer brush gate (DCBG) model 
individual FG nups can have collapsed coil gel-like regions and extended coil brushlike 
domains, resulting in a microphase separation of these domains within the NPC.”(64) 
(Figure reproduced with permission from Ando D et al. (2014) Nuclear pore complex 
protein sequences determine overall copolymer brush structure and function. Biophysical 
Journal 106(9):1997-2007. Copyright © 2014 Biophysical Society. Elsevier Inc) 
